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ABSTRACT 
Adenovirus (ADV) can cause significant morbidity and mortality in children following 
allogeneic haemtopoietic stem cell transplantation (HSCT) when immunity is 
compromised.  HSCT can offer a cure for many haematological diseases, primary 
immunodeficiencies, and inborn errors of metabolism. However not all transplant 
recipients have fully matched sibling donors and alternative donor sources have to be 
sought. In HLA-matched or mismatched unrelated donor setting, conditioning regimens 
will often include serotherapy such as Alemtuzumab (monoclonal anti-CD52 antibody) 
or thymoglobulin (polyclonal rabbit thymocyte globulin [ATG]) to remove donor 
alloreactive T cells  that can cause acute Graft versus Host Disease (GVHD).  During 
the post-transplant period of reduced T-cell immunity when reconstitution of donor-
derived immune system is slow and the use of immunosuppressive agents is 
necessary, transplant recipients are vulnerable to viral reactivations and/or infections 
with CMV, EBV, or ADV (Hiwarkar et al., 2012) and other viruses. 
 
Whilst antivirals such as Ribavirin and Cidofovir are available for the treatment of ADV, 
they are associated with toxicity and have variable efficacy.  It has been demonstrated 
that reconstitution of virus-specific immunity is essential to control viral infection after 
allo-HSCT (Feuchtinger et al., 2005a; Heemskerk et al., 2005). Over the past 2 
decades, adoptive transfer of donor-derived virus specific T cells has been explored 
extensively as an alternative method to prevent and treat ADV and other viral infections 
post-HSCT.  This thesis examines recent pre-clinical and clinical studies on T-cell 
Immunotherapy for ADV and presents data from a phase1/2 first-in-man trial of using 
donor-derived ADV CTLs in high-risk paediatric HSCT patients (ASPIRE trial).  
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Introduction 
Adenovirus (ADV) causes mild illnesses in immunocompetent hosts and 
infections are usually benign and short-lived. The virus is endemic in paediatric 
populations, with 80% of children between the ages of 1 and 5 years having 
antibody to one or more serotypes. They most commonly manifest as upper 
respiratory tract infections, ranging from pharyngitis to pneumonia, particularly 
with serotypes 1, 2, 5 and 6 (Baldwin et al., 2000; Hale et al., 1999).  Infections 
can also result in gastroenteritis (mainly with the non-cultivable serotypes 40 
and 41), cystitis, myocarditis, and keratoconjunctivits.  The virus is responsible 
for 5-11% of cases of viral pneumonia and bronchiolitis in infants and children; 
and illness typically lasts less than 2 weeks, but the virus remains latent in 
lymphoid or renal disease (Hale et al., 1999; Munoz et al., 1998).  Once infected 
adenovirus persists within lymphoreticular tissue including tonsils, adenoids, and 
intestines; and viral shedding can persist for months or years in healthy children. 
However, in the immunocompromised hosts, for example, children in the post-
haematopoietic stem cell transplant setting, ADV can cause significant morbidity 
and mortality.  Haematopoietic stem cell transplantation (HSCT) can offer a cure 
for many haematological diseases, primary immunodefiencies, and inborn errors 
of metabolism. Not all transplant recipients have fully matched sibling donors 
and alternative donor sources have to be sought. In HLA-matched or 
mismatched unrelated donor setting, conditioning regimens will often include 
serotherapy such as Alemtuzumab (monoclonal anti-CD52 antibody) or 
thymoglobulin (polyclonal rabbit thymocyte globulin [ATG]) to remove 
alloreactive T cells in the recipient that can cause acute Graft versus Host 
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Disease (GVHD).  During the post-transplant period of reduced T-cell immunity 
when reconstitution of donor-derived immune system is slow and the use of 
immunosuppressive agents is necessary, transplant recipients are vulnerable to 
viral reactivations and/or infections.  
Whilst antivirals such as Ribavirin and Cidofovir are available for the treatment 
of ADV, they are associated with toxicity and have variable efficacy.  Over the 
past decade or so, adoptive transfer of donor-derived virus specific T cells has 
been explored extensively as an alternative method to prevent and treat ADV 
and other viral infections post-HSCT.  This review examines recent pre-clinical 
and clinical studies on T-cell Immunotherapy for ADV and provides a strategy for 
monitoring and management of ADV in children after allo-HSCT. 
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1.1 ADENOVIRUS 
1.1.1 Classification and Structure 
Adenoviruses (ADV) were first isolated in 1953 from human adenoid tissues 
obtained during adenoidectomy (Rowe et al., 1953).  They are non-enveloped, 
double stranded DNA viruses that range in size from 65 to 80nm in diameter 
(Walls et al., 2003). To date, over 60 ADV serotypes have been identified based 
on their specific neutralizing abilities, and can be further classified into seven 
subgroups, A-G, on the basis of their haemagglutination properties, their 
oncogenic potential in rodents and DNA homology or GC content of their DNA 
(Table 1.1) (Heim, 2011; Kojaoghlanian et al., 2003; Lion et al., 2003; Robinson 
et al., 2013).  The virion is composed of 252 capsomers: 240 hexons and 12 
pentons arranged in an icosahedral shape; and a nucleoprotein core that 
contains the DNA viral genome and internal proteins.  The linear, double 
stranded DNA genome is 34-36 kb in size and encodes for more than 30 
structural and non-structural proteins (Kojaoghlanian et al., 2003; Robinson et 
al., 2013). The genome has a terminal protein (TP) attached covalently to the 5’ 
termini, which have inverted terminal repeats (ITRs). The virus DNA is intimately 
associated with the basic protein VII. Another protein, V, is packaged with this 
DNA-protein complex and appears to provide a structural link to the capsid 
(Russell, 2000). Each penton in the capsid comprises a base and a rod-like 
outward fibre projection of variable length depending on serotypes (Hierholzer, 
1992; Walls et al., 2003).  The hexon contains group-specific antigenic 
determinants in addition to subgroup-specific determinants and type-specific 
neutralising epitopes (Hierholzer, 1992) (Figure 1.1). 
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Table 1.1 Classification of human adenoviruses and their sites of infection 
 
 
 
Figure 1.1 Structure of Adenovirus 
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1.1.2 Tropism and replication cycle of Adenovirus 
Tissue tropism of ADV differs among the different serotypes but generally 
corresponds to the subgroups (Table 1.1).  Subgroups C, E and some B viruses 
typically infect the respiratory tract, other B serotypes infect the urinary tract 
(B11, B34, B35); serotypes from subgroups A and F target the gastrointestinal 
tract and serotypes from species D the eyes (Kojaoghlanian et al., 2003; 
Lenaerts et al., 2008). All the human ADV subgroups, except for B, use the 
coxsackie-adenovirus receptor (CAR) for entry into cells via interaction with the 
fibre knobs (Kojaoghlanian et al., 2003).  CAR is a plasma membrane protein of 
46 kDa belonging to the immunoglobulin superfamily. It plays a role in 
maintaining the integrity of tight junctions in polarized epithelial cells and is 
normally sequestered on the basolateral surface of these cells. It contains 
extracellular, transmembrane, and cytoplasmic domains, with the extracellular 
domain being sufficient for attachment (Russell, 2000; Walters et al., 2002; 
Wiethoff and Nemerow, 2015). It is expressed in heart, brain, pancreas, intestine 
and at low levels in liver and lung (Fechner et al., 1999; Wolfrum and Greber, 
2013). Other receptors include the histocompatibility class I molecule (for 
subgroup C viruses), sialoglycoprotein receptors (for Ad37 in subgroup D) and 
desmoglein-2 (DSG-2) (Wiethoff and Nemerow, 2015) (Russell, 2000).  ADV-B 
subgroup and ADV-37 (subgroup D) bind to blood and epithelial cells via the 
membrane cofactor CD46 (a complement regulatory protein family member) via 
their fibre knobs which recognize the extracellular domain of CD46 (Wolfrum 
and Greber, 2013). 
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The adenovirus infection cycle is divided into an early (E) and late (L) phase.  
The early phase (6-8h) covers the entry of the virus into the host cell and the 
passage of the virus genome to the nucleus, followed by the selective 
transcription and translation of the early genes. The phase starts with high-
affinity binding of the virus to cell receptors via the knob portion of the fibre. 
Entry into cells is then mediated by binding of the virus penton base to cell 
surface integrins (αvβ3 and αvβ5) (Lenaerts et al., 2008; Russell, 2000).  
Following endosomal acidification, conformational changes occur in the ADV 
capsid that ultimately provokes endosomal lysis and input of virions into the 
cytoplasm.  ADV genome is transferred into the nucleus when the partially 
dismantled capsid is translocated to the nucleopore complex (Lenaerts et al., 
2008). The early phase ends with activation of the early viral transcription units 
(E1A, E1B, E2A, E2B, E3 and E4) that facilitate replication of the virus DNA and 
the resultant transcription and translation of the late genes; eventually leading to 
the assembly in the nucleus of the structural proteins and virus maturation in the 
late phase of infection (Lenaerts et al., 2008; Russell, 2000). 
 
 
1.1.3 Adaptive Immunity against ADV 
1.1.3.1 Humoral immunity against ADV 
Hexon, fiber and to a lesser extent penton have been shown to be the major 
targets for ADV neutralising antibodies (Nab) (Gahery-Segard et al., 1998; 
Sumida et al., 2004; Sumida et al., 2005; Toogood et al., 1992).  Hexon-specific 
Nab titers are 4- to 10- fold higher than fiber-specific Nab titers in humans 
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(Sumida et al., 2005).  ADV fiber induces neutralising antibodies, which function 
by aggregating virus particles and thereby inhibiting absorption.  Hexon and 
penton induce antibodies which inhibit low pH induced conformational changes 
in the virus (Toogood et al., 1992).  
 
After HSCT, subjects who developed ADV viraemia but subsequently 
cleared the infection have humoral immune responses after a period of several 
weeks to months after viral clearance, with titers of serotype-specific neutralising 
antibodies increasing by 8-16 fold. Interestingly in some cases, pre-existing, 
high titers of ADV-specific Nabs in serum did not prevent progression to 
viraemia (Heemskerk et al., 2005).   
 
Until recently, antibodies were thought to mediate anti-viral effects in the 
extracellular environment (Murphy et al., 2008). However, it has now been 
shown that ADV specific antibodies can also be carried into cells in association 
with virion particles (Mallery et al., 2010) and once in the cytosol, antibody-
coated virus particles are targeted via the Fc region by the cytosolic 
immunoglobulin receptor TRIM21 (Tripartite motif-containing 21) (McEwan et al., 
2013).  This process leads to antibody-dependent intracellular neutralisation as 
well as activation of the innate immune pathways leading to production of 
proinflammatory cytokines (Watkinson et al., 2013).  Whilst humoral immunity 
clearly plays a critical role in anti-ADV immunity, administration of 
immunoglobulin therapy has not been shown to be effective in preventing ADV 
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reactivation or of proven benefit of management of established viraemia or 
organ specific infection (Legrand et al., 2001; Ljungman, 2004). 
 
 
1.1.3.2 Cell-mediated Immunity against ADV 
Cellular immunity towards adenoviruses has been extensively studied over the 
past two decades. In humans the response is predominantly in CD4+ T cells 
specific for capsid derived antigens (Flomenberg et al., 1995; Heemskerk et al., 
2003; Olive et al., 2002).  These ADV-specific CD4 T cells have been shown to 
be of CD45RO memory phenotype with expression of Th1 cytokines such as 
IFN-γ, Il-2, and TNF-α (Hutnick et al., 2010; Sester et al., 2002).  CD8+ T cell 
cytotoxic responses against ADV have also been identified (Flomenberg et al., 
1996; Smith et al., 1996; Tang et al., 2006) with both viral structural proteins and 
regulatory proteins, such as E1A (early region 1A) predicted as targets 
(Flomenberg et al., 1995).  In generated ADV-specific T-cell (CTL) lines, 
cytotoxic activity has been documented to be MHC class I restricted and 
mediated by CD8+ T cells (Flomenberg et al., 1996; Smith et al., 1996).  In 
contrast to ADV-specific CD4+ T cells, CD8+ T cells were found to express 
effector-like combinations of IFN-γ, MIP1α and perforin activity (Hutnick et al., 
2010).  Using peptide-MHC tetramer staining and intracellular cytokine staining 
following stimulation with ADV hexon peptide pool, low frequencies of ADV 
hexon-specific CD8+ and CD4+ have been detected in peripheral blood from 
38% and 81% of healthy adults, respectively (Zandvliet et al., 2010).  
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The cellular immune response to adenovirus is cross-reactive across serotypes, 
both in CD4+ and CD8+ T cells, confirming the presence of conserved antigens 
(Flomenberg et al., 1995; Heemskerk et al., 2003; Leen et al., 2004b; Olive et 
al., 2002; Smith et al., 1996; Smith et al., 1998).  Peripheral blood mononuclear 
cells (PBMCs) taken from a group of eight healthy subjects with no serologic 
evidence of prior exposure to the uncommon group B Ad35, showed specific 
proliferative responses to both Ad2- and Ad35-infected cell lysates (all subjects 
had Ad2-specific neutralising antibody).  The responder T cells were CD4+ T 
cells (Flomenberg et al., 1995).  Similarly Smith and colleagues showed that 
CTL lines (consisting of both CD4+ and CD8+ cells) generated against Ad5 
(subgroup C) readily killed fibroblasts infected with Ad11 (subgroup B) (Smith et 
al., 1996); as well as to viruses from 3 other subgroups (Ad4 subgroup E, Ad18, 
subgroup A, Ad26 subgroup D) (Smith et al., 1998). The recognition pattern of 
different ADV serotypes has been investigated at the clonal level.  Eleven 
independent T-cell clones from four different donors were tested for cross-
reactivity against ADV belonging to subgroup C (Ad1, Ad5, Ad6), subgroup B 
(Ad3, Ad7, Ad11, Ad34, Ad35) and subgroup A (Ad12, Ad18, Ad31).  These 
clones contained IFN-γ producing CD4+ T cells and five of the eleven clones 
recognised ADV from all three subgroups tested.  Using blocking antibodies to 
HLA-DR and HLA-DP, the Ad5-specific clones have been shown to use either 
HLA-DR or HLA-DP as restriction element for antigen recognition (Heemskerk et 
al., 2003). 
 21 
 
1.1.4 Dominant Adenovirus-derived T cell Epitopes (Table 1.2) 
Recently a number of immunodominant CD4+ and CD8+ epitopes of ADV hexon 
have been defined ((Joshi et al., 2009; Leen et al., 2008; Leen et al., 2004b; 
Olive et al., 2002; Tang et al., 2004; Tang et al., 2006; Veltrop-Duits et al., 
2006).  Olive and colleagues identified the first human T-cell epitope from ADV, 
located in the major capsid protein hexon (Olive et al., 2002).  Four viral protein 
sequences were screened for the HLA-A2 binding motif using PBMCs from 
HLA-A2-positive and HLA-A2-negative healthy donors.  A 15-mer peptide, 
H910-924, was identified as the optimal CD4+ T-cell epitope with majority (9/12) 
of donors exhibiting memory/effector CD4+ T-cell responses to this peptide in 
IFN-γ ELISPOT assay (Olive et al., 2002).  This epitope is located near the C-
terminus within a β-pleated sheet ‘viral jellyroll’ structure that helps form the 
base of the hexon molecule.  The HLA class II molecule DP4 (the most common 
class II allele with antigenic frequency of 75% in general population) has been 
identified as the restricting allele (Tang et al., 2004). 
 
Heemskerk’s group generated ADV-specific CD4+ T cell clones against ADV5 
and determined the HLA restriction, protein, and peptide specificity of these 
clones.  Most of these clones exhibited a broad cross-reactivity pattern towards 
serotypes from subgroups A, B and C; recognising peptides derived from 
structural viral proteins and appeared to have a Th1-like phenotype based on 
secreted cytokines. Two clones recognised II64, which contains a conserved 
epitope II910-924 that was described by Olive’s group above (Heemskerk et al., 
2006).  Since then further class II restricted epitopes have been identified, all 
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derived from the conserved region of the hexon protein (Leen et al., 2008; 
Veltrop-Duits et al., 2006). 
 
Five CD8+ T cell clones isolated from adenovirus-specific CTL lines have had 
epitopes identified in the conserved regions of the capsid protein hexon. Four of 
these epitopes restricted by HLA-A*1, HLA-A*2, and HLA-B*7 were processed 
and presented in a species cross-reactive manner, while the remaining epitope, 
recognised in the context of HLA-A*24, was specific for viruses within subgroups 
C and D (Leen et al., 2004b).  A further 12 class I restricted hexon epitopes 
have been identified since (Leen et al., 2008; Tang et al., 2006; Zandvliet et al., 
2010).  In addition five CD8+ T-cell epitopes (HLA-A24 TYF, HLA-B35 MPN, 
HLA-B35 LPG, HLA-B35/53 IPY, and HLA-A2 YVL) have been found to overlap 
directly with CD4+ T-cell epitopes (aa 31 to 55, FAR; aa 321 to 335, PNP; aa 56 
to 590, FFA; aa 691 to 715, LGS; and aa 906 to 930, EVD) (Leen et al., 2008). 
 
Although the ADV capsid protein hexon has been found to be the dominant T-
cell target, CTLs targeting early viral proteins (early region 2 proteins DNA 
polymerase [Pol] and DNA-binding protein [DBP]) have also been identified 
(Joshi et al., 2009) (Table 1.3).  Pol-epitope-specific T cells were detected at 
similar or higher frequencies than hexon and DBP in three of three HSCT 
recipients recovering from invasive ADV disease.  In particular, Pol contains T-
cell epitopes that were well conserved among different serotypes (Joshi et al., 
2009). 
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Table 1.2 HLA restricted class I epitopes from human Ad5 hexon 
HLA 
restriction 
Epitope sequence Ad5 hexon amino acids References 
A*24 TYFSLNNKF 37-45 (Leen et al., 2004b) 
B*7 KPYSGTAYNSL 114-124 (Leen et al., 2004b) 
B*7 MPNRPNYIAF 320-329 (Leen et al., 2004b) 
A*2 TFYLNHTFKK 711-721 Leen et al., 2004b) 
A*1 TDLGQNLLY 886-894 Leen et al., 2004b) 
B*13/49 LFEVFDVVRV 918-927 (Tang et al., 2006) 
A*2 YVLFEVFDVV 916-925 Tang et al., 2006) 
A*2 LLYANSAHAL 892-901 Tang et al., 2006) 
B*53 LPGSYTYEW 575-583 (Leen et al., 2008) 
A*2 GLRYRSMLL 542-550 (Leen et al., 2008) 
B*35/53 IPYLDGTFY 705-713 (Leen et al., 2008) 
B*35 MPNRPNYIAF 320-329 (Leen et al., 2008) 
B7 FRKDVNMVL 585-593 (Zandvliet et al., 
2010) 
B35 IPFSSNFMSM 873-882 (Zandvliet et al., 
2010) 
B52 ETYFSLNNKF 36-45 (Zandvliet et al., 
2010) 
B63 YSYKARFTL 78-86 (Zandvliet et al., 
2010) 
 
 
 
 
 
Table 1.3 HLA-restricted class I epitopes targeting ADV early region 2 proteins 
HLA restriction Epitope sequence Ad5 Pol amino 
acids 
References 
A*02 GLTDASFNV 608-617 (Joshi et al., 2009) 
A*02 TLNHRGWRV 779-788 (Joshi et al., 2009) 
A*02 VLAWTRAFV 977-986 (Joshi et al., 2009) 
HLA restriction Epitope sequence Ad5 DBP amino 
acids 
References 
A*02 MMGRFLQAYL 206-215 (Joshi et al., 2009) 
A*02 KLLPDQVEAL 243-252 (Joshi et al., 2009) 
A*02 FLGRQLPKL 407-416 (Joshi et al., 2009) 
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1.2 ADENOVIRAL INFECTION IN IMMUNOCOMPROMISED HOSTS 
1.2.1 Epidemiology 
 
Adenovirus is endemic in paediatric populations with 80% of children between 1 
and 5 years of age having antibody to one or more serotypes (Hale et al., 1999).  
Infections in immunocompetent hosts are usually benign and short-lived, and 
most commonly manifest as upper respiratory tract infections (Hale et al., 1999).  
ADV causes 2-7% of respiratory tract infections in children in the first 5 years of 
life (Munoz et al., 1998).  Infections can also result in lower respiratory infection, 
gastroenteritis, cystitis, myocarditis, and keratoconjunctivits.  The virus is 
responsible for 5-11% of cases of viral pneumonia and bronchiolitis in infants 
and children.  Illness typically lasts less than 2 weeks, but the virus remains 
latent in lymphoid or renal disease (Hale et al., 1999; Munoz et al., 1998).  Once 
infected adenovirus persists within lymphoreticular tissue including tonsils, 
adenoids, and intestines.  In healthy children viral shedding can persist for 
months or years and in children with congenital immunodeficiency disorders, 
ADV has been recognised as a cause fatal infections since 1960 (Wigger and 
Blanc, 1966) . The immunosuppressed paediatric host is particularly susceptible, 
most notably in the allogeneic transplant setting where cellular immunity is 
compromised and ADV can cause severe and protracted systemic illnesses 
such as hepatitis, pneumonitis, colitis, haemorrhagic cystitis, and encephalitis 
(Carrigan, 1997; Hale et al., 1999).  The incidence of ADV infection reported in 
bone marrow transplant recipients ranges from 5% to 29% (Baldwin et al., 2000; 
Flomenberg et al., 1994; Hale et al., 1999; Hierholzer, 1992; Howard et al., 
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1999; Runde et al., 2001; Shields et al., 1985). In these earlier studies ADV was 
detected via routine weekly surveillance cultures usually up to first 100 days 
post-transplant. With the advent of robust PCR based detection, serial ADV 
PCR has become the mainstay of routine surveillance.  Using serial real-time 
PCR to identify ADV, the incidence of viral isolation is between 17-27% in 
paediatric transplant recipients (Kampmann et al., 2005; Lion et al., 2003).  
 
1.2.2 Risk factors and mortality 
These retrospective and prospective studies have facilitated the identification of 
several risk factors that are predictive for the development of ADV infection 
and/or disease in transplant recipients. One risk factor identified is T-cell 
depletion either ex vivo by CD34+ positive selection, or in vivo with 
Alemtuzumab or Antithymocyte globulin (ATG). In a group of 153 children 
receiving HSCT, adenoviraemia occurred in 26 children (17%), all of whom had 
received T-cell-depleted grafts (Kampmann et al., 2005). Similarly Lion and 
colleagues found a significant increase (p value = 0.014) in incidence of ADV 
infection in a group of 132 paediatric patients transplanted with T-cell depleted 
grafts (in vivo ATG combined with ex vivo CD34+ positive selection) where 27% 
of patients developed adenovriaemia and all who died from disseminated 
adenoviraemia had received heavily T-cell depleted grafts (Lion et al., 2003). In 
an adult cohort of 76 allograft recipients, adenovirus was isolated exclusively (15 
of 76 patients, 20%) in recipients of T-cell depleted grafts. Patients who received 
50 or 100 mg of alemtuzumab had 45% probability of developing adenovirus 
infection, regardless of donor type (Chakrabarti et al., 2002). 
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 Other identified risk factors for ADV infection include type of transplant and age 
of recipient. In a mixed population (adults and children) of 532 HSCT recipients, 
those who received allogeneic stem cells were more likely to have a ADV 
positive culture compared to group who received autologous stem cells (16% vs 
3%, p <0.0001). And paediatric recipients of partially matched related donors 
were at significantly greater risk of infection compared to their adult counterparts 
(p <0.001) (Howard et al., 1999). Similar findings have been reported – in a 
group of 572 transplanted patients the incidence of ADV infection was higher in 
children than adults (21% vs 9%, p<0.001); and in unrelated donor vs matched 
sibling donor transplants (26% vs 9%, p<0.001) (Baldwin et al., 2000). In 
Kampmann’s group of 153 children, none of the children transplanted from a 
matched sibling donor developed adenoviraemia (p=0.05) (Kampmann et al., 
2005). Detection of ADV infection at multiple sites has also been correlated with 
increased risk for invasive disease in children (Baldwin et al., 2000; Howard et 
al., 1999; Lion et al., 2003) but not in adults (Chakrabarti et al., 2002).  
 
However, the most significant predictor of adenovirus infection identified in the 
majority of studies was lympopaenia, with all patients who developed adenovirus 
disease or with persistent adenoviraemia having an absolute lymphocyte count 
(ALC) of less than 300/μL (Chakrabarti et al., 2002; Kampmann et al., 2005).  In 
patients with established adenoviraemia, an increase in lymphocyte counts 
correlated with clearance of infection and survival of the host whereas those 
who died of adenoviraemia had continuously increasing ADV DNA loads in 
plasma with no lymphocyte recovery (Heemskerk et al., 2005). To further 
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illustrate the importance of immune reconstitution in clearance of 
adenoviraemia, 46 children post HSCT were prospectively studied.  Children 
who died (7/21) of ADV infection had no adenovirus-specific T cells and had 
significantly reduced T-cell reconstitution, although absolute lymphocyte count 
was above 0.3x109/L at 30 days post-transplant.  93% of patients who 
successfully cleared ADV infection had presence of virus specific T cells, 
compared to 54% of children without any ADV infection.  They also had good T-
cell reconstitution, especially CD8+ T cells (>0.4x109/L) at 60 days post-
transplant (Feuchtinger et al., 2005a). In the current era of prospective 
monitoring, Hiwarkar and colleagues reported the impact of ADV reactivation in 
291 paediatric HSCT procedures and again found reduced CD4 counts of less 
than 0.15x109/L in the first 3 months after transplantation as a significant risk 
factor for developing adenoviraemia (Hiwarkar et al., 2012).    
 
Overall mortality from ADV infection after HSCT ranges from 6%-60% in studies 
of mixed populations with adults and children (Flomenberg et al., 1994; 
Hierholzer, 1992; Howard et al., 1999; Runde et al., 2001); and between 19% to 
83% amongst paediatric patients (Hale et al., 1999; Kampmann et al., 2005; 
Munoz et al., 1998).  There is significant association of ADV positivity in 
peripheral blood with transplant related mortality (relative risk, 5.8; P <0.001).  
The median days adenoviral DNA was detected in peripheral blood before death 
was 29 days in Lions’ study; and Kampmann reports a median of 21 days post-
transplant before adenoviraemia was evident (Kampmann et al., 2005; Lion et 
al., 2003).  In a prospective study that identified 21 paediatric HSCT patients 
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with ADV infection, 90% of infections occurred during the first 3 months post-
transplant, with more than 50% of patients having ADV infection within 30 days 
post HSCT (Feuchtinger et al., 2005a). Most prevalent group of Adenovirus 
identified had been subgroup C (Chakrabarti et al., 2002; Kampmann et al., 
2005; Lion et al., 2003), and subtypes 2, 5, 1, 6, 31, and 4 (in decreasing 
frequency) are the most prevalent (Feuchtinger et al., 2005b). 
 
1.2.3 Diagnosis and Monitoring 
The American Society of Transplantation 2013 guidelines define asymptomatic 
ADV infection as detection of ADV from stool, blood, urine, or upper airway 
specimens in the absence of signs and symptoms. ADV disease is defined as 
presence of attributable organ signs and symptoms combined with virus 
detection in biopsy specimens. Disseminated ADV disease requires involvement 
of two or more organs, not including viraemia (Florescu et al., 2013).  
 
Historically the standard method to detect adenovirus in clinical samples was by 
cellular viral culture (Walls et al., 2003).  Samples were inoculated into a range 
of different cell lines including A549, human foreskin fibroblast, Hep 2, monkey 
kidney (RhMK) and human embryo kidney (HEK) cell lines, and cultured for 
several weeks. Cultures were observed for evidence of characteristic adenovirus 
cytopathic effect (rounding and clustering of infected cells) generally seen by the 
10th day, but this can range from 3-21 days (Baldwin et al., 2000; Flomenberg et 
al., 1994; Hale et al., 1999; Howard et al., 1999; Munoz et al., 1998; Walls et al., 
2003). Positive cultures were confirmed by indirect immunofluorescence 
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antibody assays and serotyping performed by neutralisation tests with 
hyperimmune type-specific animal antisera (Baldwin et al., 2000; Hierholzer, 
1992). Virus can also be identified in stool and urine samples by electron 
microscopy which shows the typical adenoviral particles of 70-80 nm diameter 
within the nuclei and cytoplasm of tubular epithelial cells (Baldwin et al., 2000; 
Chakrabarti et al., 2000) and in respiratory secretions by immunofluorescence 
and ELISA (Walls et al., 2003). Histopathology remains the gold standard 
method to diagnose invasive disease. The presence of ADV in biopsy samples 
is suspected by the identification of “smudge cells,” which are cells with large 
basophilic nuclei surrounded by a thin rim of cytoplasm, and confirmed through 
immunoperoxidase and/or in situ hybridization staining (Echavarria, 2008; 
Sandkovsky et al., 2014).  
 
However, culture method is impractical from the clinical viewpoint due to its 
labor intensiveness and possibility of longer turnaround times and potential 
bacterial contamination in non-sterile sites (Sandkovsky et al., 2014). More 
recently, using qualitative PCR method, it has been shown that detection of 
adenoviral DNA in serum preceded the development of severe or fatal 
adenovirus infection in 14 recipients of haematopoietic stem-cell grafts 
(Echavarria et al., 2001).  The sensitivity of PCR is very high, usually detecting 
quantities as low as 100 copies/mL, regardless of the ADV serotype 
(Sandkovsky et al., 2014). Since then, the development of real-time quantitative 
PCR assays has allowed for accurate detection of ADV in a variety of tissues, 
including blood, stool, and urine (Walls et al., 2003); and allows for prospective 
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monitoring of adenoviraemia in the post-transplantation setting.  Several studies 
have described a correlation between high viral load and a fatal outcome (Erard 
et al., 2007; Schilham et al., 2002), as well as between onset of ADV-related 
disease and mortality.  For example, in a study of 132 consecutive paediatric 
patients undergoing SCT, adenoviral DNA was detected in peripheral blood at a 
median of 29 days before death and in those who developed disseminated ADV 
disease, virus was detected in blood by a median of more than 3 weeks before 
onset of clinical symptoms.  82% of patients who had detectable ADV in 
peripheral blood died from infectious complications (Lion et al., 2003). These 
earlier studies all suggest that high viral load precedes symptoms of 
disseminated disease, therefore prospective monitoring of ADV load is now 
implemented in many of the paediatric transplant centers.   
 
1.2.4 Current Management of Adenoviral Infections in 
Immunocompromised Children 
1.2.4.1 Antiviral drugs 
 1.2.4.1.1 Cidofovir (CDV) 
Cidofovir is an acyclic nucleoside phosphate derivative of cytosine which is 
converted to an active intracellular metabolite, cidofovir diphosphate, by cellular 
kinases (Legrand et al., 2001; Sellar and Peggs, 2012).  The active intracellular 
diphosphate form of the drug exerts its mechanism of action as both a 
competitive inhibitor and an alternative substrate for 2’-deoxycytidine 5’-
triphosphate in the viral DNA polymerase reaction (Hoffman et al., 2001), thus 
inhibiting viral replication.  Antiviral selectivity results from the higher affinity for 
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the viral DNA polymerase compared to cellular DNA polymerases (Lenaerts et 
al., 2008).  Cidofovir-resistant Ad mutants, discovered through serial passages 
in vitro, have been found to contain sequence changes in a conserved region of 
the viral DNA polymerase that is involved in nucleotide binding (Kinchington et 
al., 2002).   
 
Several studies have reported on the success of CDV in the treatment of ADV 
infection in immunocompromised hosts after HSCT (Hoffman et al., 2001; 
Legrand et al., 2001), especially when given early (Bordigoni et al., 2001; 
Ljungman et al., 2003c; Neofytos et al., 2007; Yusuf et al., 2006) and combined 
with withdrawal of immunosuppression (Kampmann et al., 2005).  At our center, 
if blood  ADV reaches > 1000 copies per mL on two consecutive occasions CDV 
is started at 5mg/kg once every week for 2 weeks, followed by maintenance 
dose of 5 mg/kg once every fortnight. Notable side-effects of Cidofovir include 
nephrotoxicity, especially when used in combination with other nephrotoxic 
drugs such as cyclosporine or tacrolimus (Ljungman, 2004).  CDV is a dianion 
that is taken up into the proximal renal tubular cells by an organic anion 
transporter at the antiluminal membrane.  Once taken up into the cells, a slow 
diffusion rate into the tubule lumen as well as CDV’s long intracellular half-life, 
can lead to toxic intracellular accumulation and subsequent tubular necrosis. 
Toxicity can be reduced by concomitant use of oral probenecid and intravenous 
hyperhydration (Sellar and Peggs, 2012).  Probenecid competes for the kidney 
anion transporter, and along with hyperhydration can help protect tubular cells 
by decreasing plasma clearance rate of CDV 
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(Lacy et al., 1998; Lindemans et al., 2010).  Two studies examined the use of 
CDV as therapy for ADV and CMV infection in 126 stem cell transplant patients 
combined (Ljungman et al., 2001; Ljungman et al., 2003b).  The risk of renal 
toxicity in both studies was 26% and most of the renal toxicity was mild (low-
degree proteinuria or mild elevation of serum creatinine), but approximately half 
had remaining signs of renal impairment after discontinuation of CDV (Ljungman 
et al., 2003c). It is recognized that ADV clearance requires T-cell immunity. The 
impact of CDV in the absence of T cell reconstitution post-transplant was 
investigated in a group of 36 paediatric allogeneic HSCT recipients. ADV 
viraemia was controlled in 75% of Cidofovir treatments, but the role of 
concurrent NK cell reconstitution could not be ruled out. In 17% (7 of 42 CDV 
treatments), CDV treatment could not prevent the progression of ADV viraemia, 
all in the absence of T cell reconstitution or during high-dose steroid treatment 
(Lugthart et al., 2015). These findings suggest that whilst CDV can help stabilise 
viral load, T cell reconstitution remains essential for viral clearance. 
 
  1.2.4.1.2 Ribavirin/Ganciclovir/Immunoglobulin 
Ribavirin is a nucleoside analogue for which in vitro anti-ADV activity has been 
reported but it differs against different subtypes.  It is active on most ADV 
isolates from species A, B and D, and in all isolates from species C (Morfin et 
al., 2009).  There is anecdotal evidence of successful treatment of ADV in 
immunocompromised patients but larger studies have not been as supportive 
(Bordigoni et al., 2001; Lankester et al., 2004) (reviewed in (Ljungman, 2004). 
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There is no provable role for ganciclovir or immunoglobulin therapy in 
immunocompromised patients (Legrand et al., 2001; Ljungman, 2004).  
 
  1.2.4.1.3 Brincidofovir 
More recently a new oral therapy has been trialed for the treatment of 
Adenovirus infections in immunocompromised patients.  CMX001 
(hexadecyloxypropyl cidofovir, Brincidofovir) is an orally bioavailable lipid 
conjugate of cidofovir with good oral bioavailability. It can achieve higher 
intracellular levels of active drug compared with cidofovir due to rapid transport 
across target cell plasma membranes, and has 5 to >2,500-fold greater potency 
against different ADV serotypes (Painter et al., 2012; Sandkovsky et al., 2014). 
It may also have a better safety profile relative to cidofovir as it is not associated 
with myelosuppression or nephrotoxicity. The most common side effect is 
diarrhoea, especially at doses of 200 mg weekly or biweekly (Marty et al., 2013) 
(Florescu et al., 2012).  Of 13 immunocompromised patients who received 
CMX001, nearly two-thirds had a ≥ 10-fold drop in viral load after 1 week of 
therapy (Florescu et al., 2012).  A Phase III, multicenter trial evaluating safety 
and efficacy of CMX001 for the treatment of disseminated ADV infection is 
currently underway (CMX001-304, AdVise Study; NCT02087306). Preliminary 
results from the study are available on 26 subjects, 20 of whom had allo HSCT 
(16 had disseminated ADV disease) (Grimley et al., 2014). Dosing schedule was 
BCV 100mg for t50kg or 2mg/kg for <50kg twice a week. Median viral load in 
plasma at baseline was 4.8 log10 copies/mL and median duration of treatment 
was 54 days. Suppression of plasma ADV viral load to < level of detection by 
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quantitative PCR was 61% (14/23) at any time on treatment and 52% (12/23) at 
last on-treatment value. Two subjects had severe diarrhoea requiring early 
cessation of treatment. The overall mortality rate was < 40% across subjects 
with disseminated and limited ADV and across populations with varying 
identified risk factors (HCT, Solid organ transplant) which is lower than those 
reported with disseminated disease. 
 
1.2.4.2. Withdrawal of Immunosuppression 
Immunosuppression is required post-HSCT for the prevention of Graft-versus-
Host-Disease (GvHD). However the trade-off is viral reactivation/infection owing 
to delayed reconstitution of immunity. Preemptive reduction or withdrawal of 
immunosuppressive therapy at first detection of adenovirus in this setting has 
been reported to be successful.  In a group of 76 adult allograft recipients, 15 
developed adenovirus disease/infection.  12 patients had immunosuppression 
withdrawn or reduced and only 3 developed adenovirus disease; whereas all 3 
patients in whom immunosuppression had to be continued succumbed to 
adenovirus disease (Chakrabarti et al., 2002).   
 
Similarly in paediatric transplant recipients withdrawal of immunosuppression 
together with early antiviral therapy led to the resolution of adenoviraemia in 
19/26 (86%) patients (Kampmann et al., 2005). Hence in the post-transplant 
setting we would recommend the following algorithm for the treatment of ADV 
(see figure 1.2). 
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Figure 1.2 Algorithm for the management of ADV reactivation in children after 
allogeneic  
                  stem cell transplantation 
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1.3 VIRAL INFECTIONS POST ALLOGENEIC STEM CELL TRANSPLANT 
AND TREATMENT WITH ADOPTIVE CELLULAR THERAPY 
 
1.3.1 Viral infections post allogeneic stem cell transplant 
Viral infections continue to be a major cause of morbidity and mortality in 
immunocompromised patients, particularly after allogeneic haematopoietic stem 
cell transplantation. Reactivations of adenovirus, along with herpes viruses such 
as human cytomegalovirus (CMV), Epstein-Barr virus (EBV) are amongst the 
most challenging complications; and viral clearance requires cellular immune 
reconstitution. In a 5-year period at a large Paediatric transplant center in 
London, the incidence of viraemia in 291 transplant procedures was 16% for 
CMV, 15% for ADV and 11% for EBV. The median time to onset of ADV and 
CMV reactivation was 15 and 20 days, respectively. Median time to EBV 
reactivation was 74 days after transplant (Hiwarkar et al., 2013). Although 
antiviral pharmacological agents are available, their use is costly, associated 
with side-effects and emergence of drug-resistant mutants. Therefore adoptive 
immunotherapy using both unmanipulated T cells and virus-specific T cells has 
been evaluated as an attractive approach to reconstitute antiviral immunity. 
 
1.3.2 Adoptive Cellular Therapy 
The use of adoptive cellular therapy where T-cells with specificity for diseased 
cells, virus or tumor can be engineered for the purposes of the targeted therapy 
of human viral and malignant diseases was first described in 1988. Autologous 
tumor-infiltrating lymphocytes (TIL) were administered to patients with metastatic 
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melanoma with 34% clinical response rate (Rosenberg et al., 1988). The 
process of adoptive cellular therapy includes the isolation, with or without ex vivo 
activation and proliferation of antigen-specific T cells, and reinfusion into the 
recipient. There are broadly three main therapeutic strategies in the use of 
adoptive cellular therapy in viral infections post HSCT: administration of cells 
before active viral infection is detected to prevent its occurrence (prophylaxis), 
targeted therapy in groups with highest risk of viral disease based on rapid 
surveillance PCR-based methods to diagnose viraemia (pre-emptive), or 
treatment of established disease. 
 
Over the last decade, advances have been made in the field of adoptive cellular 
therapy for the treatment of viral reactivations/infection post HSCT; from proof-
of-concept studies to adoption in clinical safety trials. The next section will 
examine the progress made so far in cellular therapy for EBV, CMV and ADV 
infections post HSCT. 
 
1.3.3 Unmanipulated donor lymphocytes 
Unmanipulated donor lymphocyte infusions (DLI) contain virus-specific T cells 
with particularly high frequencies for latent viruses such as CMV and EBV 
(Gillespie et al., 2000; Papadopoulos et al., 1994; Walter et al., 1995). Five 
patients with EBV-associated lymphoproliferative disorders (LPD) after T-cell 
depleted allogeneic bone marrow transplant were treated with infusion of 
unirradiated donor leukocytes between 0.12 to 1x106 CD3+ T cells/kg body 
weight. All recipients received cells from HLA-matched unrelated donor and did 
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not receive GvHD prophylaxis except for T-cell depletion. Complete 
pathological/clinical response was documented in all treated patients with 
clinical remissions achieved within 14 to 30 days after infusion. Two patients 
died but not directly attributed to infusion. Of the 3 who survived and in whom 
the EBV-associated LPD resolved, 2 had acute Grade II skin GvHD and mild 
chronic GvHD of skin that responded to topical corticosteroids (Papadopoulos et 
al., 1994). This showed that transferring unmanipulated lymphocytes from EBV-
seropositive donors can restore immune response to EBV and eradicate Post 
Transplant Lymphoproliferative Disease (PTLD). However there is a significant 
risk of GvHD due to the high frequency of alloreactive cells (Heslop et al., 1994). 
Similarly, Hromas and colleagues reported the first successful treatment of 
adenovirus infection with DLI in a patient who developed severe ADV-
associated haemorrhagic cystitis after a T cell-depleted graft, and failed to 
respond to anti-viral drugs or immunoglobulin.  After infusion of 1x106/kg CD3+ 
cells on day +61 the patient improved over a period of 5 weeks without 
developing GvHD (Hromas et al., 1994).  These pioneering studies supported 
the rationale for the adoptive transfer of virus-specific T cells (VSTs). 
 
1.3.4 T-cell therapy for EBV 
 1.3.4.1 EBV infection and PTLD 
Epstein-Barr virus (EBV) is an enveloped herpes virus that infects more than 
95% of the world’s population. It enters its human host via a mucosal route, 
infects and replicates in oropharyngeal epithelial cells and then infects 
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lymphocytes in the oropharynx (Bollard et al., 2012). Primary infection in the 
immunocompetent host results in a mild self-limiting illness, but the virus 
persists lifelong as a latent infection in B cells and spreads in the community by 
productive replication in B cells and mucosal epithelium (Fujita et al., 2008). 
Infected B cells do not produce infectious virus, but instead express viral 
latency-associated proteins that induce B-cell proliferation and then drive the 
infected B ell into ‘true latency’, in which no viral genes are expressed (Bollard et 
al., 2012). There are four EBV latency states in B cells, three of which are found 
in Post-transplant lymphoproliferative Disease (PTLD) and each is associated 
with a different type of virus-gene expression, different levels of immunogenicity, 
and different types of lymphoma (Bollard et al., 2012; Thorley-Lawson and 
Gross, 2004). B cells expressing type 3 latency express all the 9 latency-
associated EBV proteins, including the immunodominant EBNA3 viral antigens. 
These T cells express cell adhesion and costimulatory molecules rendering 
them immunogenic and susceptible to immune-mediated killing by EBV-specific 
cytotoxic T lymphocytes (CTLs) (Bollard, 2013; Rickinson and Moss, 1997). 
After HSCT, the lack of functional CTLs can mean the type 3 latency EBV-
infected B cells can proliferate unchecked and cause a lymphoproliferative 
disorder that can progress to lymphoma with increased levels of EBV DNA 
detected by PCR (Bollard, 2013; Bollard et al., 2004a).  PTLD developing after 
HSCT usually results from donor B cells and appears within the first 6-12 
months of the post-transplant period, before immune-reconstitution of EBV-
specific CTL takes place (Bollard et al., 2012). EBV-PTLD represents a 
heterogeneous group of EBV-related diseases characterized by: (i) populations 
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of monoclonal or oligoclonal cell proliferation defined by cellular markers; (ii) 
evidence of EBV infection by detecting specific DNA, RNA, or proteins; and (iii) 
disruption of the underlying cellular architecture by a lymphoproliferative process 
(Bordon et al., 2012). The overall frequency of PTLD post HSCT is 
approximately 1%, but varies from 0.45% after HSCT from matched family 
donors to 11.7-29% after HSCT from T-cell-depleted unrelated donors (Patriarca 
et al., 2013). Risk factors for the development of PTLD include reduced intensity 
conditioning in combination with in vivo  or ex vivo  T-cell depletion [including 
use of anti-thymocyte globulin (ATG)], mismatches in HLA and serological EBV 
status between donor and recipient, degree and duration of immunosuppressive 
treatment after the transplant (Bollard et al., 2012; Uhlin et al., 2014); and low 
CD4+ lymphocyte count at day +30 after transplantation (Hiwarkar et al., 2013; 
Patriarca et al., 2013). After HSCT, PTLD may present with a clinical picture 
similar to infectious mononucleosis with B symptoms (fevers, sweats, anorexia) 
and tonsilar enlargement and cervical lymphadenopathy. In highly 
immunosuppressed patients, the clinical presentation may also be more 
fulminant with diffuse multiorgan involvement and a clinical picture that is similar 
to sepsis or GvHD (Bollard et al., 2012).  
Initial treatment for PTLD comprises reduction of immunosuppression and 
rituximab, with or without chemotherapy (Heslop, 2009; Messahel et al., 2006). 
Treatment by reduction of immunosuppression may be limited by the onset of 
graft rejection and development of GvHD. The introduction of the monoclonal 
anti-CD20 antibody rituximab has decreased the PTLD mortality rate 
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substantially. It has proven effective both as pre-emptive therapy in patients with 
high EBV viral loads and as treatment for patients with established PTLD, with 
response rates of 55-100% in both scenarios. However PTLD often recurs 
because cellular immunity against EBV has not been restored (Bollard et al., 
2012; Messahel et al., 2006; Uhlin et al., 2014). Uhlin and colleagues (Uhlin et 
al., 2014) described clinical outcome of cohort of 1021 patients who underwent 
HSCT at Karolinska University Hospital in Stockholm between 1996 and 2011 in 
regards to EBV-related PTLD, with the aim to report on long-term follow-up of 
patients after the initial viral clearance. The overall frequency of PTLD in the 
cohort was 4% and only 28% of patients with PTLD were alive 1 year after 
diagnosis. Thirty-five patients (88%) were treated with rituximab according to 
standard protocol. The authors conclude that even if rituximab initially resolves 
the PTLD in most cases, a considerable proportion of patients will eventually 
succumb from other causes. 
 1.3.4.2 EBV CTLs 
For this reason, alternative strategies to restore EBV-specific immunity have 
been explored, namely by infusing T cells that target EBV antigens. Because 
many PTLDs express type III latency, it provides a good model for testing T-cell-
based therapies designed to target EBV antigens that are presented on the cell 
surface by major histocompatibility molecules (Bollard et al., 2012). Also the risk 
of PTLD correlates inversely with anti-EBV T cell activity in patients, especially 
in children who have not previously encountered the virus (Abu-Elmagd et al., 
2009). 
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As mentioned previously, unmanipulated donor lymphocyte infusions after bone 
marrow transplantation have been shown to be effective against PTLD 
(Papadopoulos et al., 1994).  More recently, Doubrovina and colleagues 
(Doubrovina et al., 2012) reported on a single-center experience with a cohort of 
49 patients who were treated with unmanipulated Donor Lymphocyte Infusions 
(DLIs), EBV-CTL, or both for biopsy proven EBV-LPD emerging after HSCT. 
73% of the patient series treated with DLIs and 68% of those treated with EBV-
CTLs achieved a sustained CR. However infusing unmanipulated DLIs is 
associated with an increased incidence of severe or fatal GvHD, due to the 
presence of alloreactive T cells in the infused cell product (Bollard et al., 2012). 
Therefore similar to the development of ADV and CMV CTLs, different strategies 
have been employed to enhance effectiveness of CTLs including collecting 
donor lymphocytes responding to EBV by apheresis and selecting by cytokine 
secretion and infusion within days of diagnosis into patients (Moosmann et al., 
2010; Uhlin et al., 2012),and developing bank of EBV-specific CTLs from third 
party donors for recipients with seronegative donors or naïve donors such as in 
cord blood transplants (Barker et al., 2010; Doubrovina et al., 2012; Vickers et 
al., 2014).  
Heslop and colleagues (Heslop et al., 2010) completed studies in 114 patients 
who had received infusions of EBV-specific CTLs to prevent or treat EBV+ LPD 
post HSCT at 3 different centers. Donor T-cell lines directed against EBV 
antigens were selectively expanded using EBV-LCLs (lymphoblastoid cell lines) 
generated according to Good Manufacturing Practice. None of the 101 patients 
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who received CTL infusions as prophylaxis (resulting in up to a 4-log expansion 
of infused CTLs) developed EBV+ LPD. Thirteen patients were treated with 
CTLs for biopsy-proven or probable LPD, 11 of whom achieved sustained 
complete remissions without recurrence. One patient died very early after 
treatment of progressive disease and a second patient did not respond because 
the tumor had a deletion of the two epitopes in the EBNA3B recognized by the 
infused line ((Bollard et al., 2012). Importantly, none of the patients developed 
de novo GvHD after CTL infusion. However this method of production is lengthy 
and costly due to time needed to generate donor-derived LCLs and the repeated 
restimulation of donor T cells. The complete production period requires 2 to 3 
months of processing time. This precludes the preparation and use of such T 
cells after PTLD has become manifest. Therefore, more rapid methods to 
prepare EBV-specific T cells are required to make EBV-specific T-cell therapy 
more widely applicable. 
Moosmann and colleagues (Moosmann et al., 2010) described a method for 
rapid isolation of clinical-grade EBV-specific T cells from donor blood cells in 
less than 36 hours by stimulation with a pool of 23 class I and II EBV peptide 
epitopes derived from 11 EBV antigens, followed by isolation of responding cells 
by antibody-mediated surface IFN-γ capture and immunomagnetic separation. 
Six patients with PTLD – three of whom had early stage disease – who received 
an average dose of 4x106 selected T cells had complete responses and rapid 
reconstitution of EBV-specific immunity; whereas three patients with more 
advanced disease did not respond to the treatment. However a note of caution 
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is that all patients had received additional treatment in addition to EBV-specific 
CTLs (reduction in immunosuppression, Rituximab and Cidofovir). Similarly 
Icheva and colleagues (Icheva et al., 2013) described a rapid protocol (30 
hours) for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) –specific T 
cells by using an IFN-γ capture technique. EBNA-1 protein is involved in the 
replication of viral episomes, is crucial for the persistence of EBV infection and is 
the only viral protein required for replication of EBV in its latent form. It is 
universally expressed in EBV+ PTLD and contains immunodominant T-cell 
epitopes that induce CD4+ and CD8+ T-cell responses in healthy population 
(Jones et al., 2010). In the study recombinant EBNA-1 protein was used as 
stimulant for the earlier enrolled patients and changed to the GMP-grade EBNA-
1 Peptivator (overlapping peptides) for the latter patients once became 
commercially available. Enrichment of cytokine-secreting cells was performed 
using the cytokine secretion system and the CliniMACS device for 
immunomagnetic separation (Miltenyi Biotec). Cells were infused directly or 
cryopreserved without further in vitro expansion. Ten patients with 
chemorefractory EBV viraemia or EBV+ PTLD were treated with infusion of 
EBNA-1 specific T cells at mean dose of 5,794 CD3+ cells per kilogram of body 
weight. One patient developed transient grade 1 to 2 acute skin GvHD 15 days 
after first donor lymphocyte infusion which responded well to treatment and 
resolved within 3 to 4 weeks. Eight of 10 patients showed in vivo expansion of 
EBNA-1-specific T cells detected by intracellular cytokine staining by flow 
cytometry after stimulation with EBNA-1 antigen. This was associated with a 
clinical and virological response in 7 of the 8 responders (decrease of viral load 
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more than 1 log and resolution of PTLD). One patient showed T-cell expansion 6 
days after transfer but succumbed as a result of haemophagocytic 
lymphohistiocytosis and multiorgan failure 11 days after transfer. Overall 2 of 10 
patients had died of EBV-related disease, and another patient had ongoing 
viraemia without clinical symptoms at last follow-up. 
Another alternative to increase availability of EBV-CTLs to a larger number of 
patients (for example, those with EBV-seronegative donors) is the creation of a 
bank of characterized HLA-typed EBV-specific T cell lines. Haque and 
colleagues (Haque et al., 2007) first described this approach of generating EBV-
specific CTLs from EBV-seropositive blood donor to treat patients with EBV 
PTLD on the basis of the best HLA match and specific in vitro cytotoxicity. The 
group reported data from a phase 2 multicenter trial enrolling 33 patients with 
EBV-positive PTLD from 19 transplant centers who had not responded to 
conventional therapy and were given EBV-specific CTLs generated from 
unrelated third-party blood donors. No adverse events were observed from CTL 
infusions, and response rate (complete or partial) was observed at 64% at 5 
weeks and 52% at 6 months. Sixteen patients had no response at 6 months, 5 
died before completing treatment. The best results were observed in patients 
receiving CTLs that were best-HLA matched with the recipient. More recently, 
Vickers and colleagues (Vickers et al., 2014) also described the establishment 
of a GMP-compliant allogeneic EBV-specific cytotoxic cell bank from peripheral 
blood mononuclear cell (PBMC) donations supplied by New Zealand Blood 
Service (in order to minimize risk of Creutzfeldt-Jacob disease transmission). 
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Donors are HLA-typed at HLA Class I and Class II (DRB1, DQB1) loci. EBV 
CTLs are generated by stimulating mononuclear cells with purifed EBV and 
LCLs and expanded over approximately 2 months. Cells are then cryopreserved 
in 10% DMSO in bags of 50x106 or 150x106 cells using a controlled rate freezer, 
before being placed in nitrogen vapour-phase storage at <-150°C. These cells 
are supplied as an Advanced Therapy Medicinal Product (ATMP) under MHRA 
‘Specials’ Licence. CTLs are infused at doses of 1-2x106/kg body weight as a 
course of four infusions given at weekly intervals. Over a 2 year period, CTLs 
were issued and infused into 11 patients; all had PTLD except for 1 patient with 
leiomyosarcoma. Overall outcome was good with 8/10 achieving complete 
remission and only two dying of refractory PTLD. The minimum number of 
antigens shared was 3/10 and the maximum 9/10. Poor HLA class II matching 
appears to have contributed to non-clinical response in 2 patients. Overall CTLs 
were well-tolerated with only one case of likely skin GvHD observed in the 2 
days after one of the infusions (Vickers et al., 2014).  
 1.3.4.3 Solid organ transplant 
In the setting of solid organ transplantation, the use of EBV CTLs had been less 
effective due to the requirement for long-term immune suppression. In order to 
increase their persistence in vivo, EBV-CTLs have been genetically engineered 
to render them resistant to calcineurin (CN) inhibitor FK506 through retroviral 
transfer of a calcineurin A mutant (CNA12) (Ricciardelli et al., 2014). 
Xenogeneic mice bearing human B-cell lymphoma were injected with 
autologous CTLs transduced with either CNA12 or eGFP in the
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presence/absence of FK506. Adoptive transfer of autologous CNA12-CTLs 
induced dramatic lymphoma regression despite the presence of FK506, 
compared to eGFP-CTLs. They also persisted longer, homed to the tumor, and 
expanded more than eGFP-CTLs in mice treated with FK506; with longer 
survival in mice receiving CNA12-CTLs and treated with FK506. This novel 
approach proves to be promising but application in the clinical setting is awaited. 
 
 
1.3.5 T-cell therapy for CMV 
Human cytomegalovirus (CMV) is a member of the β-herpesvirus family and is 
latent in approximately 70% of the adult population (Ciaurriz et al., 2015). In 
immunocompetent individuals, life-long asymptomatic latency is established 
following primary infection. However historically before preemptive treatment 
was in place, untreated CMV infection and disease in the immunocompromised 
host had been associated with significant morbidity in the early days after HSCT 
and led to mortality in nearly 25% of seropositive patients (Boeckh et al., 2003). 
In patients following allo-HSCT, several risk factors predispose to increased 
incidence of CMV infection. Positive CMV serostatus of the recipient is a poor 
prognostic factor, especially in recipients of T cell-depleted marrow or stem cells 
(Ljungman et al., 2003a). Other risk factors include mismatched donors, 
immunosuppressive regimens, and use of nonmyeloablative conditioning 
regimens with addition of alemtuzumab treatment. The most frequently used 
drugs for prophylactic or preemptive treatment for CMV are ganciclovir, 
valganciclovir and foscarnet. Although these drugs have been successful in 
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reducing mortality associated with CMV infection (Bollard et al., 2004b), they 
have significant side effects with neutropaenia and nephrotoxicity and have 
been found to impair and delay the development of CMV-specific CTLs (Ciaurriz 
et al., 2015). 
 
 1.3.5.1 CMV-specific T cell clones 
As mentioned earlier transfer of unselected donor lymphocytes for treatment of 
EBV LPD resulted in GvHD in recipients (Papadopoulos et al., 1994). 
Subsequent approach evaluated use of T-cell clones with specificity for the 
antigens of the pathogen being treated. Walter and colleagues isolated clones of 
CMV-specific CD8+ cytotoxic T lymphocytes from blood of sibling donors 
donating bone marrow by stimulating with autologous fibroblasts pulsed with 
CMV. Escalating doses of CMV clones (from 3.3x106/kg to 1 x109/kg) were 
infused prophylactically into 14 recipients beginning 30 to 40 days after marrow 
transplantation. The predominant specificity of the clones is directed against 
CMV structural proteins, such as the matrix proteins pp65 and pp150, which are 
presented for recognition by cytotoxic T lymphocytes before new virions are 
formed in infected cells. None of the 14 recipients experienced toxic effects 
related to the infusion, with 11 patients showing significantly increased cytotoxic 
activity against CMV in in vitro measurements. Two patients had analysis of 
rearranged T-cell receptor genes in T cells showing persistence of transferred 
clones for at least 12 weeks. However, anti-CMV activity declined in those 
deficient in CD4+ CMV-specific T cells, suggesting that helper T cell is needed 
for long-term persistence. None of the 14 patients developed CMV viraemia or 
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disease (Walter et al., 1995). Although this study demonstrated proof of principle 
in terms of measures of immune reconstitution, the patient group was at 
relatively low risk for CMV-related disease. All patients had undergone T-cell-
replete HLA-matched sibling transplants and majority were CMV seronegative. 
Also the expansion of T-cell clones to achieve adequate dose levels was 
extremely time-consuming and was therefore limiting in terms of costs and 
logistics (Peggs, 2009).  
 
 1.3.5.2 CMV-specific T cell lines 
In another prophylactic study, Peggs and colleagues (Peggs et al., 2003) 
produced and characterized polyclonal CMV-specific CD4+ and CD8+ T cells by 
stimulating reactive T cells 2 or 3 times with dendritic cells (DCs) pulsed with 
CMV antigens derived from a CMV-infected human lung fibroblast cell line to 
stimulate reactive T cells. The use of the entire CMV antigen therefore enables a 
broad CTL response to be generated, as opposed to a solely pp65-specific 
response, for example (Bollard et al., 2004b). Patients were monitored for CMV 
reactivation and 16 patients were infused with CMV-specific CTL (1x105 CTL/kg) 
at the of first PCR reactivity (at a median of 36 days post-transplant). There 
were no infusion-related toxicities and study showed small doses of CTLs were 
able to reconstitute immunity with considerable in vivo  expansion of CMV-
specific CTLs, and with no requirement for further antiviral drugs in eight cases 
(Peggs et al., 2003).  
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Similarly Einsele and colleagues investigated the therapeutic application of 
adoptively transferring CMV-specific CTLs to patients with persisting or recurring 
CMV infection despite the prolonged use of antiviral medications. Polyclonal 
CMV-specific CTLs were generated by pulsing donor-derived PBMCs with CMV 
lysate and expanded by using autologous irradiated feeder cells, CMV lysate, 
and interleukin 2. Eight patients received 1x107 T cells/m2 after a CD34-selected 
HSCT from a family donor. Infusions of CTLs were effective in reducing viral 
load in 7 evaluable patients and 5 patients had sustained antiviral effect (Einsele 
et al., 2002). This production method avoids the use of DCs and relies on 
monocytes infected with the CMV lysate for antigen presentation. However the 
use of infectious CMV in the form of CMV lysate means this method is not 
suitable for clinical production (Bollard et al., 2004b).  
 
To avoid the use of CMV lysate, monocyte-derived DCs can be pulsed with the 
immunodominant CD8+ HLA-A2 restricted epitope NLVPMVATV (NLV) derived 
from pp65. Using this method Micklethwaite and colleagues (Micklethwaite et 
al., 2007) treated 9 patients who had mostly undergone non-myeloablative 
HSCT without in vitro or in vivo T cell depletion with DC co-cultured NLV-specific 
CTLs. Six of the nine patients showed evidence of an increase in the frequency 
of specific T cells post infusion, but response did not persist beyond several 
days to weeks. Three patients developed GvHD within 14 days of T-cell therapy 
and one patient died of GvHD. However all patients had GvHD prior to cell 
infusion therefore it could not be concluded the CMV-specific T cells were 
causative of GvHD but may have caused exacerbation 
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 (Micklethwaite et al., 2007). It was unclear why expansion of NLV-specific T 
cells were only modest and did not persist; but both exhaustion of antigen-
specific T cells during in vitro expansion and lack of antigen-specific CD4+ T cell 
help could have contributed (Peggs, 2009).  
 
 1.3.5.3 Direct selection method 
Many seropositive individuals have high frequencies of CMV-reactive T cells; 
making direct selection of CMV-specific T cells from donor samples an attractive 
option for CMV immunotherapy. This method eliminates the need for ex vivo 
manipulation and offers potential for more rapid production allowing therapeutic 
rather than prophylactic use of isolated CTL. Two strategies of direct selection 
have been investigated for production of CMV-specific CTLs. One is based on 
isolating a pure population of CMV peptide-specific CD8+ T cells directly from 
donor peripheral blood using staining with specific tetramers followed by 
selection with magnetic beads (Cobbold et al., 2005; Cwynarski et al., 2001). 
This method was explored and applied clinically in 2005 where HLA-peptide 
tetramers containing peptides derived from pp65 or CMV-IE-1 were used to 
purify CMV-specific CD8+ T cells followed by selection with magnetic beads. 
CMV-specific CD8+ T cells were infused directly into 9 HSCT recipients within 
4h of selection. The median cell dose was 8.6x103 /kg with high purity (median 
95.6%). Seven of the patients received the CTLs following initial CMV virus 
reactivation while 2 patients were treated for persistent viraemia. CMV-specific 
CD8+ T cells were detectable in all patients within 10 days of infusion and 2 
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patients had long-term detectable CMV-specific response. Only 2 out of 7 
patients treated pre-emptively required antiviral therapy; and 1 patient whose 
CMV reactivation was refractory to antiviral drugs achieved control within 8 days 
of T cell infusion. All patients had a reduction in the level of CMV viraemia and 
there was no significant increase in GvHD rates (Cobbold et al., 2005).  
A variation on the HLA-multimer technology is the use of Streptamers£ which 
allows reversible binding to the TCR and thus may have less effect on the T-cell 
phenotype. Labeling of Strept-Tactin, which functions as “backbone” for the 
streptamer complex, with fluorochromes or magnetic microparticles allows 
specific visualization and/or enrichment of antigen-specific CTLs in combination 
with FACS or MACS. The multimeric peptide MHC class I complexes, which use 
the binding of Strep-tag II to Strept-Tactin to form complexes, can be easily 
disassembled by the addition of d-biotin. Because of their low affinity, peptide-
MHC class I monomers dissociate from their cognate TCR spontaneously within 
seconds, without altering T-cell function or activating T cells through cross-
linking TCRs, therefore leaving ‘untouched’ T cells (Odendahl et al., 2014).  
Another method of rapid, direct selection is based on induction of IFN-J 
secretion in response to viral proteins or peptides and selection of responding 
cells. Using this method, Feuchtinger’s group (Feuchtinger et al., 2010) infused 
polyclonal CMV-specific T cells generated by stimulation with pp65 followed by 
isolation of IFN-J producing cells into 18 patients after allo-SCT with CMV 
disease or antiviral refractory viraemia. The mean infused cell dose of 21x103/kg 
resulted in clearance or reduction in viral load in 83%. In-vivo expansion of 
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CMV-specific T cells was demonstrated in 12 of 16 evaluable patients, without 
causing induction of GvHD. 
 
Recently, a large Phase II study (Australian Clinical Trial Registry 
#ACTRN12605000213640 and #ACTRN12607000224426) prophylactically 
treated 50 allogeneic HSCT recipients with donor-derived CMV-specific CTLs 
and compared outcomes with a contemporaneous control group of transplant 
recipients (Blyth et al., 2013). CMV CTLs were initially generated by pulsing 
dendritic cells with an HLA-A*0201-restricted immunodominant peptide NLV 
from the CMV pp65 antigen. This method was restricted to donors who were 
HLA A0201-positive and produced CTLs with restricted specificity that may have 
been predisposed to escape mutants (Heslop, 2013). The investigators 
subsequently modified their manufacturing methods to use dendritic cells 
genetically modified by an adenoviral vector encoding the full pp65 antigen 
(ad5f35pp65; obtained from the Center for Cell and Gene Therapy, Houston, 
TX). This method allowed a broader immune response to be produced but is 
lengthy and requires live virus. Irradiated peptide pulsed or transfected mo-DC 
were used to stimulate donor T cells (obtained either from peripheral blood or 
stem cell harvest product) and cells were expanded in culture over 21 days. A 
single dose of 2 x 107 CMV CTLs/m2 was infused into 50 eligible patients on or 
after day 28 post-transplant. Nine patients received a lower cell dose at median 
of 1.2x107 cells/m2 due to insufficient cell expansion. All patients had undergone 
conditioned allogeneic HSCT for haematological malignancies, 26 of whom had 
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T-cell depletion. Twenty-six patients (52%) who received CTLs reactivated CMV 
(5 post CTL infusion). Nine patients required treatment with Ganciclovir or 
Foscarnet (1 post CTL infusion). There was 1 case of fatal CMV disease, 
attributable to high levels of ATG at time of T cell infusion. Although the 
investigators did not observe a significant difference in CMV reactivation rate 
between CTL recipients and controls, there was a difference in the requirement 
for CMV-directed antiviral therapy (17% vs 36%; P = .01). Notably there was no 
increase in acute or chronic GvHD in the treatment group.  
In the UK a randomized controlled trial to evaluate safety of CMV-CTLs has 
recently been completed (CMV-IMPACT:NCT 01077908). The study enrolled 
CMV-seropositive patients > 16 years old, undergoing T-cell depleted 
(alemtuzumab) HSCT from a matched sibling CMV-seropositive donor, in 14 UK 
transplant centers. CMV-specific cells were manufactured by direct selection 
using either a StreptamerTM (if donor expressed a suitable HLA allele) or 
gamma-capture technique (CliniMACS® Cytokine Capture System, IFN-
gamma). Clinical outcome from this study is awaited. 
 
 1.3.5.4 CMV-specific TCR-transgenic T cells for immunotherapy 
Some patients undergoing allo HSCT have CMV-negative donors and are at 
highest risk of reactivation of CMV. Adoptive therapy is difficult as naïve CMV-
specific T cells are difficult to isolate from CMV-seronegative donors. One way 
to overcome this is by utilizing retroviral transduction to introduce a TCR with 
specificity for CMV into polyclonal T cells, thereby redirecting their specificity. 
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The generated CMV-specific T cell clones are of several HLA restrictions and 
can recognise the endogenously processed antigen pp65. In a pre-clinical study 
the genes of four TCRs were cloned and inserted into retroviral vectors to 
transduce primary T cells from CMV-negative donors. The transgenic T cells 
expanded in vivo in response to endogenously processed antigen and 
demonstrated increased antigen-specific cytotoxicity and cytokine secretion. 
These CMV-TCR-transgenic T cells are expected to be effective in controlling 
acute CMV disease and establishing antiviral memory (Nicholson and Peggs, 
2015; Schub et al., 2009). The feasibility of generating donor-derived CMV TCR 
transduced T cells for treatment of CMV infection post HSCT is currently being 
investigated in a UK Phase I/II proof of concept pilot study (CMV TCR001; 
EudraCT 2008-006649-18).  
 
1.3.6 T-cell therapy for ADV 
Recovery from ADV infection requires cellular immune reconstitution after 
allogeneic HSCT. Adoptive immunotherapy using both unmanipulated T cells 
and virus-specific T cells has been evaluated as approaches to reconstitute 
antiviral immunity. 
 
As mentioned earlier, Hromas and colleagues (Hromas et al., 1994) reported on 
the first successful treatment of a patient with severe ADV-associated 
haemorrhagic cystitis with DLI. However much like the development of CMV and 
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EBV-specific immunotherapy, strategies have evolved to produce more antigen-
specific CTLs in the treatment of ADV infection post-transplant to avoid GvHD. 
 
 
 1.3.6.1 Generation of T cells against ADV 
In order to increase antiviral efficacy and to reduce the risk of alloreactivity, 
techniques were developed to isolate only ADV specific T cells to be given to 
patients.  In 1996, Smith and colleagues (Smith et al., 1996) used donor 
peripheral blood dendritic cells as antigen-presenting cells to manufacture 
cytotoxic T cells (CTLs) that recognise ADV.  Dendritic cells (DCs) from donors 
were infected with either wild-type adenovirus serotype 5 (Ad) or Ad5 strain 
dl312, an Ad5 mutant with the E1A region deleted resulting in a virus defective 
in early and late viral gene transcription.  The adenovirus-specific T cells were 
subsequently expanded using virion-pulsed irradiated DCs.  The majority of the 
CTLs were CD4+ T cells and were directed against the input virion proteins.  
The group also demonstrated cross-reactivity of the adenovirus-specific CTLs, 
as CTLs generated against a subgroup C adenovirus recognised and killed cells 
infected with a subgroup B adenovirus (Smith et al., 1996). Although the  ADV-
specific CTLs reported by Smith et al were able to recognise ADV from different 
serologic groups, these CTLS were unable to kill target cells in a standard 4-6-
hour assay (requiring 18 hours to kill) and could not be adequately expanded 
into CTL lines (Leen et al., 2004a) 
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In 2004 Leen and her group developed a protocol to reactivate ADV-specific 
memory T cells from donors’ PBMCs using clinical grade ADV vector.  PBMCs 
from 6 healthy ADV-seropositive volunteers were stimulated twice with 
autologous DCs transduced with Ad5f35 (replication-defective ADV vector). Both 
CD4+ and CD8+ ADV-specific T cells were expanded with autologous 
Ad5f35GFP-transduced lymphoblastoid cell lines (LCLs) and showed ADV 
specific killing (Leen et al., 2004a). Because the generation of DCs to act as 
stimulator cells requires a large volume of blood, a second protocol using 
Ad5f35GFP-transduced PBMCs as both stimulators and responders were used.  
Expansion was again carried out with Ad5f35GFP-transduced LCLs, the 
resultant expanded T cells had specific reactivity against both EBV and ADV.  
These CTL lines generated using Ad5f35 vector were able to recognise and kill 
autologous cells infected with wild-type adenovirus isolates from different 
serotypes and groups including Ad2, Ad4, Ad7 and Ad11 (Leen et al., 2004a). 
 
In 2006 Leen et al reported on the prophylactic clinical use of tri-specific (EBV, 
CMV, ADV) CTLs on 11 adult and paediatric patients post haematopoietic stem 
cell transplant.   Donor PBMCs transduced with a recombinant adenoviral vector 
encoding the CMV antigen pp65 (Ad5f35pp65) were used to reactivate CMV 
and ADV-specific T cells.  Subsequent stimulation with EBV transformed LCLs 
transduced with the same vector reactivated EBV-specific T cells whilst 
maintaining the expansion of activated ADV and CMV-specific T cells (Figure 
3c).  Fourteen out of 15 CTL lines responded to all viruses (one individual 
responded to CMV and EBV but not ADV); and 15/15 donor CTL lines showed 
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cytolytic activity against all three viruses (Fujita et al., 2008; Leen et al., 2006). 
Eleven patients received from 5 x 106 to 1 x 108 cells/m2 at 35 to 150 days after 
HSCT.  CMV and EBV-specific CTLs consistently expanded in all individuals 
treated within 4 weeks of administration; whereas ADV-specific CTLs expanded 
only in those with active or recent infection.  All patients with pre-infusion viral 
infection/reactivation had reduction in viral titer and resolution of disease 
symptoms, coinciding with expansion of virus-specific T-cells (Leen et al., 2006). 
  
In order to increase the frequency of adenovirus-specific T cells within their CTL 
lines, Leen and her group removed competition from the immunodominant CMV 
antigen and manufactured bivirus-specific CTL lines directed only to EBV and 
adenovirus (Leen et al., 2009).  20 CTL lines were made of which 13 were 
administered to paediatric stem cell transplant recipients: 7 unrelated and 6 
haploidentical transplants.  The frequency of adenovirus hexon-specific T cells 
in the bivirus CTL was significantly higher than in the trivirus CTL study (median 
ADV cells 308 SFC/105 CTL [range 46-350] compared to 86 SFC/105 CTL [46-
350] in bivirus product) (Leen et al., 2009; Leen et al., 2006). Each patient 
received from 5x106 to 1.35x108 cells/m2 at 40 to 150 days after HSCT.  There 
were no toxicities related to CTL therapy and no subject developed de novo 
GVHD after cell infusion.  None of the 13 patients developed EBV-associated 
lymphoproliferative disease, and 2 of the subjects had resolution of their 
adenoviral disease (Leen et al., 2009).   
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Once it has been established that ADV-specific T cells can be expanded in vitro 
and that they are effective and protective in vivo, the next challenge was to 
overcome logistics of manufacturing these products.  The protocol described 
above of activating donor PBMCs with autologous monocytes transduced with 
the Ad5f3pp65 vector followed on days 9, 16 and 23 by restimulation with 
Ad5f35pp65-transduced EBV-LCL takes in total 10-14 weeks.  This implies that 
products have to be manufactured in advance if they were to be made 
immediately available for acutely ill patients; and comes with it cost implications. 
Different cell selection and culture practices were therefore explored to develop 
more rapid and cost-effective strategies for production of CTLs. 
 
1.3.6.2 Cytokine based selection of antigen-specific T cells from 
donor peripheral blood mononuclear cells 
 
In 2004 Feuchtinger’s group in Germany (Feuchtinger et al., 2004) described a 
clinical-grade strategy to isolate and expand donor-derived human ADV-specific 
T lymphocytes using the Miltenyi Biotec (Bergisch Gladbach, Germany) 
interferon-γ (IFN-γ) secretion assay.  PBMCs were isolated from suitable donors, 
0.1-2x109 cells were stimulated with type C adenoviral antigen (BioWhittaker, 
Verviers, Belgium) for 16 hours.  T cells with antigen-specific secretion of IFN-γ 
were detected on the following day and these cytokine-secreting cells were 
magnetically enriched using ClinicMACS device (Miltenyi Biotech).  A mean 
number of 3.4x106 cells were obtained with a mean purity of 85% ADV-specific 
T cells.  These isolated cells were then expanded ex vivo in a median of 18 days 
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(range 7-29 days) to greater than 108 total cells using IL-2 and autologous 
feeder cell stimulation.  The generated T cells showed ADV-specific IFN-γ 
release and specific killing of ADV-infected B-LCL.  Alloreactive proliferation of 
the generated lines in mixed lymphocyte cultures was significantly reduced 
when compared to unmanipulated PBMCs (Lang et al., 2004). 
 
The above method of generating ADV-specific T cells was adopted clinically in 
2006 by Feuchtinger’s group for nine children with systemic ADV infection after 
HSCT for mainly leukaemia or lymphoma.  These children underwent 
myeloablative conditioning regimen with T-cell depletion for HSCT with either 
matched or mismatched unrelated, or haploidentical donors.  All eligible patients 
had ADV viraemia not controlled by antivirals and lacked ADV-specific T cells.   
T-cell transfer was performed if a sufficient ADV-specific T-cell response was 
detectable in the donor (>0.01% of T cells).  The percentage of ADV specific T 
cells rose from 1.1% to 45.7% after stimulation with ADV antigen. A mean of 
14x103/kg (range 1.2-50 x 103/kg) T cells were infused at a median of +77 days 
post-transplant (range +40-+378). T-cell infusion was well tolerated in all nine 
patients, except for one case with aggravation of pre-existing skin GVHD that 
was seen at days 10-14.  Five out of six evaluable patients had significant 
decrease of viral DNA in peripheral blood and stool with an in vivo expansion of 
specific T cells.  Those without a specific T cell response post adoptive T-cell 
transfer had either increasing or unchanged viral DNA-load in peripheral blood.  
Three patients in whom follow-up were possible had sustained ADV-specific T-
cell response detected 4-6 months after T-cell transfer.  3 patients died from 
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adenovirus-associated, pre-existing multi-organ failure; 1 patient died from 
relapsed NHL.  Three out of 4 patients who died did not have specific T-cell 
response post-immunotherapy.  Efficacy was independent of T-cell dose 
transferred, suggesting efficient in vivo expansion (Feuchtinger et al., 2006). 
 
Chatziandreou and colleagues  also reported on the successful isolation of ADV-
specific T cells using a similar protocol. Again using the Miltenyi IFN-γ secretion 
and capture assay with adenovirus lysate derived from ADV SpC-infected 
human embryonic lung fibroblasts, ADV-specific T cells were isolated, expanded 
and restimulated over 2 weeks. The numbers of eluted virus-specific cells from 
six ADV-positive donors ranged from 1 to 7 x 105 cells, majority being CD4+ 
cells.  After a 2–week culture period, a 1.5-2 log expansion was seen with cell 
numbers averaging at 1 x 107 cells.  This would enable infusions of up to 105 
ADV-specific cells/kg for most adults and larger amounts of paediatric patients. 
This approach offers the advantage of a short 14-day culture period, which 
allows for generation of cells in response to first detection of virus during routine 
screening.  Therefore it is less labour intensive and has a more favourable 
cost:benefit profile (Chatziandreou et al., 2007).  Using a similar IFN-J capture 
protocol, five patients have been treated at Great Ormond Street Hospital with 
ADV-specific T cells either from the original donor (n=3) or third-party 
haploidentical parents (n=2) (Qasim et al., 2013).  All 5 children had undergone 
either in vivo or ex vivo T cell depletion as part of their conditioning regimen and 
had peak ADV loads in blood ranging from 5.6 x 104/mL to 22 x106/mL before 
cell infusion.  IFN-J secreting ADV-specific T cells in the donations were 
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enriched to between 19-64% after 24 hours and infused directly without ex vivo 
expansion (Figure 1.2a), with 4 children receiving 104 T cells/kg and 1 child 
receiving 105 T cells/kg at an average of 80 days after the original stem cell 
graft.  Three patients cleared ADV in blood after a single infusion of 104/kg and 
had demonstrable ADV-specific T cells in circulation detected by IFN-J secretion 
assay.  No acute, infusion-related toxicities were observed. Three patients died, 
one due to bystander GVHD after cell infusion even though viraemia had 
resolved (Qasim et al., 2011) the other two failed to clear virus and died at days 
175 and 56, respectively (Qasim et al., 2013).  
 
1.3.6.3 Peptide expanded T cells 
 
More recently in order to generate CTLs from a greater majority of healthy 
donors in a short period of time, Comoli et al used a pool of five 30-mer peptides 
derived from HAdV5 hexon protein, to generate 21 T-cell lines with limited 
alloreactivity starting from median of 20x106 donor PMBC and expanded to 75 x 
106 cells at end of 26 days.  This would have been sufficient for infusion aimed 
at 0.5 x 106 cells/kg (Comoli et al., 2008).  In 2010 Aissi-Rothe et al used 
clinical-grade PepTivator-ADV5 Hexon (Miltenyi Biotec, Germany) and 6-hr 
incubation time to generate IFN-γ secreting ADV-specific T cells which were 
expanded over a median of 2-week period with IL2 and irradiated autologous 
feeder cells (Figure 1.2b).  Up to 85x106 ADV T cells were generated with a 
mean of 1.7 log expansion and a reduction of 1.3 log in alloreactivity (Aissi-
Rothe et al., 2010). 
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In order to broaden the antiviral coverage Papadopoulou and colleagues were 
able to rapidly manufacture single preparation of multivirus VSTs (mVSTs) by 
direct stimulation of PBMCs with overlapping peptide libraries that incorporate 
EBV, CMV, ADV, BK virus (BKV) and human herpesvirus 6 (HHV6) antigens.  
Fourty-eight clinical-grade mVSTs lines were manufactured by exposing PBMCs 
(3x107 cells/sample) to overlapping peptide libraries spanning immunogenic 
ADV (Hexon, Penton), CMV (pp65, IE1), EBV (LMP2, EBNA1, BZLF1), BK 
(Large T, VP1) and HHV-6 (U11, U14, U90) antigens. VSTs were then 
expanded over 9-11 days with IL4 and IL7 in a G-Rex device. A mean of 40.1 x 
107 polyclonal CD4+ and CD8+ cells were produced. T cell subsets expressed 
central CD45RO+CD62L+ and effector memory markers CD45RO+/CD62L-. 
Fourteen out of the 48 lines (29%) generated had activity against all five 
stimulating viruses (pentavalent) as assessed by IFN-γ ELIspot assay, 19% 
were tetravalent, 25% were trivalent and 22% were bivalent. Only one mVST 
line was found to be monovalent and one failed to recognize any of the targeted 
viruses. None of the CMV-seronegative donors produced lines containing CMV-
directed T cells. These mVSTs were infused prophylactically (n=3) or as 
treatment for active infection/reactivation (n=8) for up to four viruses at doses of 
0.5 to 2 x107 cells/m2 between days 38 and 139 post transplant. One patient 
developed de novo GvHD of the skin (stage II) 4 weeks after receiving cells and 
resolved with topical steroids. In all patients with viral reactivation expansion of 
the mVSTs and clinical responses were observed and those patients treated 
prophylactically remained virus-infection free for >3 months
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(Maecker-Kolhoff and Eiz-Vesper, 2015; Papadopoulou et al., 2014); 
Papadopoulou et al., 2013). This represents the first successful attempt using 
adoptive T cell transfer for the treatment of BKV and HHV6 in HSCT recipients. 
BKV is a ubiquitous polyomavirus that establishes latent, asymptomatic infection 
in >90% of general population. It can cause severe and intractable disease in 
HSCT recipients with 60 to 80% having urinary shedding of BKV and 5-15% 
developing BKV-associated haemorrhagic cystitis (Tomblyn et al., 2009). HHV6 
is a member of the β-herpesvirus family and persists lifelong in a latent form 
after primary infection which occurs in >90% of individuals by age of 2 years. 
HHV6 reactivation and viraemia occur in 40 to 60% of HSCT recipients and has 
been found to be an independent predictor of acute and chronic GvHD and 
lower survival rates, mainly because of non-relapse mortality (de Pagter et al., 
2008). In this study, among the 7 patients who reactivated BKV, 5 had complete 
and 1 had partial responses; including 3 who had severe haemorrhagic cystitis 
pre-infusion and achieving marked symptomatic and virological responses within 
2 to 4 weeks of receiving cells. And in two patients who reactivated HHV6, VSTs 
produced clinical benefit and viral clearance coincided with an increase in the 
frequency of T cells targeting HHV6 antigens (Papadopoulou et al., 2014). 
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Figure 1.3 Protocols for generating virus-specific T cells 
 
 
 
A – Donor identified as ADV responder by IFN-γ secretion assay (Miltenyi 
Biotec, Bergisch Gladbach, Germany).  Peripheral blood mononuclear cells 
(PBMC) isolated and incubated overnight with ADV Hexon protein.  Responding 
cells captured with IFN-γ reagent, anti-IFN-γ microbead and magnetically 
enriched with CliniMACS (Miltenyi Biotec). (Qasim et al., 2013) 
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B – Donor PBMC incubated over 10 days with ADV5 hexon peptide and 
cytokines.  Expanded cells isolated and infused into patients after QA/QC 
testing. (Aissi-Rothe et al., 2010) 
C – EBV-transformed B cell lines (EBV-LCLs) generated from donor PBMCs by 
infecting with EBV virus.  Donor PBMCs are transfected with Ad5f35pp65 vector 
(replication-competent adenovirus-negative) and later restimulated several times 
by EBV-LCLs that have been transduced with the same vector.  (Leen et al., 
2006) 
 
  
1.3.6.4 Stimulation with viral DNA plasmids 
 
In 2011 the Baylor group took an alternative approach to rapidly select virus-
specific T cells.  Instead of using adenovectors to stimulate T cells, dendritic 
cells nucleofected with DNA plasmids encoding LMP2, EBNA1 and BZLF1 
(EBV), Hexon and Penton (ADV), and pp65 and IE1 (CMV) were used as 
antigen-presenting cells.   Secondly, EBV-LCLs were removed and replaced by 
gas permeable culture device (G-Rex) that promotes expansion and survival of 
large cell numbers after a single stimulation.  Activated T-cells were cultured in 
the presence of IL-4 (1,000 u/mL) and IL-7 (10ng/mL).  This approach reduced 
the time of manufacturing from 10 weeks to 10 days, as well as the cost of 
production by >90% (Gerdemann U, 2011).  Using this method, 22 trivirus and 
14 bivirus CTL lines were produced with a 1.5 log expansion from 15x106 
starting PBMCs. 10 patients with viral reactivation (either single or dual) were 
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treated between day 27 and 52 months post HSCT, with each patient receiving 
0.5 to 2x107 cells/m2.  Complete virological responses associated with increased 
frequency of virus specific T cells was seen in 80%.  One patient developed 
stage 2 skin GVHD post infusion but no other toxicities were observed 
(Gerdemann et al., 2013a). Similarly this approach was used to develop a single 
preparation of polyclonal (CD4+ and CD8+) CTLs that is specific for 7 viruses 
(EBV, CMV, Adenovirus, BK, human herpes virus-6, respiratory syncytial virus, 
and Influenza) (Gerdemann et al., 2012). 
 
 1.3.6.5 Isolation protocols using T-cell activation markers 
 
Apart from using IFN-J production as a way to capture antigen-specific T cells, 
alternative isolation strategies based on other T-cell activation markers have 
been investigated.  Khanna et al. generated antigen-specific T cells lines for 
ADV, EBV, CMV, A fumigatus, and C albicans based on magnetic cell 
separation of CD154+ T cells after 16 hours of stimulation with antigens, 
followed by expansion in presence of IL2, IL7 and IL15 over 14 days.  Purity of 
the product was between 8 to 15%, with a higher frequency of virus-specific T 
cells compared to fungus-specific T cells (Khanna et al., 2011). Leibold et al 
compared the specificity, expansion/differentiation potential, and Th1 response 
against CMV and ADV after isolation of antigen specific T cells based on IFNJ 
release or expression of activation markers (CD137 ND CD154).  Isolation of T 
cells based on expression markers is feasible and less time consuming, but it 
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resulted in smaller proportion of Th1 cells compared to IFNJ capture which may 
correspond to less effector function in vivo (Leibold et al., 2012).  
 
Because CD4+ T cells are critical in human ADV infection, Haveman and 
colleagues explored the possibility to selectively expand and isolate ADV-
specific CD4+ T cells.  PBMCs were stimulated with 15-mer pan-DR binding 
CD4+ T cell epitopes of ADV serotype 5 peptides using artificial APCs, 
composed of liposomes harbouring ADV peptide/HLA class-II complexes 
(Haveman et al., 2013).  The resultant T-cell lines after 7-day culture period 
produced mainly pro-inflammatory cytokines (TNFD, IFNJ, MDC, RANTES and 
MIP-1D), expressed perforin and granzyme B, had specific ADV-killing and were 
not alloreactive (Haveman et al., 2013). 
 
1.3.6.6 Selection of Adenovirus-specific T cells by HLA-peptide 
multimer 
 
As described in the previous section on generation of CMV-CTLs, peptide-major 
histocompatibility complex (pMHC) multimers (tetramers or pentamers) 
containing immunodominant CMV CD8+ epitopes have been used to 
demonstrate the safety and efficacy of direct adoptive transfer without ex vivo 
expansion. Similarly Chakupurakal and colleagues (Chakupurakal et al., 2013) 
(Gunther et al., 2015)developed pMHC tetramers containing 8 ADV-specific 
class I epitopes within the hexon and major capsid protein, and used these to 
determine the properties of ADV-specific CD8+ T cells directly ex vivo, and to 
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identify the optimal ADV peptides for future development in CD8+ T-cell 
immunotherapy. 
 
Table 1.4 8 ADV-specific class I epitopes used to identify optimal tetramer for 
enriching ADV-specific CD8+ T cells (Chakupurakal et al., 2013) 
 
Class I HLA Restriction Sequence Abbreviation 
A*01 TDLGQNLLY TDL 
A*02 GLRYRSMLLGNGRY GLR 
A*02 TFYNHTFKKV TFY 
A*02 LLYANSAHAAL LLY 
A*02 YVLFEFFDVV YVL 
A*24 TYFSLNNKF TYF 
B*07 KPYSGTAYNSL KPY 
B*07/35 MPNRPNYIAF MPN 
 
Of the 8 tetramers tested, HLA-A*01 TDL tetramer appears to be most 
appropriate for use in enriching ADV-specific CD8+ T cells. Enriched TDL-
specific T cells from donors recognized Ad5 and peptide-loaded antigen 
presenting cells and secreted IFN-γ in response (as measured by ELISA). They 
also showed proliferative potential in CFSE assay. Immunophenotyping of fresh 
PMBCs by flow cytometry in 8 HLA A*01 donors revealed that TDL-specific T 
cells displayed a minimally differentiated central memory phenotype: 
CD45RAhigh, CD45ROhigh, CCR7high, CD62Llow, CD27high, CD28high, CD57low, and 
LFA-1high. TDL-specific T cells were also shown to lyse target cells infected with 
heat-inactivated wild-type viruses responsible for the majority of infections in 
HSCT recipients, including ADV3,5,11,12,19a, and Ad40 (species B1, C, B2, A, 
D and F, respectively). Gunther and colleagues (Gunther et al., 2015) adoptively 
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transferred TDLGQNLLY-HLA-A*01 streptamer selected donor T cells to a HLA-
A*01-positive HSCT recipient who had become infected with adenovirus 2 and 
not able to clear infection with pharmacological treatment. The frequency of 
specific T cells 5 weeks after adoptive T-cell transfer was 2.33% of all CD3+ T 
cells compared to 0.03% in healthy HLA-A*01 donor. There was also concurrent 
decrease of viral load from 105 virus copies/mL before transfer to undetectable 
levels after infusion. The group also identified a novel immunodominant HLA-
B*07:02-restricted peptide epitope VPATGRTLVL from protein 13.6 K and 
demonstrated the high proliferative, cytotoxic, and IFN-γ-producing capacity of 
peptide-specific T-cells. The results suggest that the peptide epitope 
VPATGRTLVL may be suitable for paediatric adoptive transfer therapy as this 
peptide is conserved in species C adenoviruses which cause the majority of 
adenoviral infections in children. Taken together it would appear that ADV 
epitope-specific CD8+ T cells enriched by tetramer selection may be therapeutic 
in HSCT recipients after adoptive transfer; as these cells appear to be minimally 
differentiated with a high proliferative potential and could therefore expand in the 
presence of virus and maintain effector functions. The phenotype of these T 
cells should also allow them to persist in the recipient for a longer duration in 
comparison with differentiated T cells.  
 
 
1.3.7 Third-party Virus-specific T cells (VSTs) 
For patients receiving an allogeneic cord blood transplant or a transplant from a 
virus-seronegative donor, an alternative option for VSTs is with partially HLA-
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mismatched third-party T-cell donors. Recently an allogeneic cell registry 
alloCELL was established in 2013 at Hannover Medical School to gain more 
insight into virus specific memory T cell repertories and to identify the most 
efficient target antigens for adoptive immunotherapy. The T cell frequencies 
against ADV, CMV, EBV, HHV6 peptides and peptide pools available in good 
manufacturing practice (GMP) quality were determined in 204 healthy donors via 
IFN-J enzyme-linked immunospot (ELISpot) assay and by flow cytometric 
analysis using pMHC multimers. It has now also been extended to provide data 
on the assessment of specific individual memory T cell repertoire in response to 
polyoma (BK) virus as well as melanoma (Melan-1/Mart-1) and tumor antigens 
(WT-1). The registry now contains record of memory T-cell repertoire for more 
than 550 donors, as well as the HLA type (class I and II). The enrichment of 
clinical-grade antigen-specific T cells from donors is performed under GMP 
conditions using the IFN-γ CliniMACS cytokine capture system and overlapping 
GMP-grade peptide pools spanning the entire sequence of an immunogenic 
epitope (Sukdolak et al., 2013; Tischer et al., 2014) (www.alloCELL.org).  
 
In a recent multicenter study, banked third-party virus-specific T cells (VSTs) 
were administered to 50 patients with severe, refractory CMV, ADV or EBV 
infections (Leen et al., 2013). Thirty-two virus-specific lines were generated from 
individuals with common HLA polymorphisms immune to EBV, CMV or ADV; of 
which 18 lines were administered to 50 post-HSCT patients with severe, 
refractory illness due to infection with one of these viruses. The virus specific T 
cells were generated by transduction of PBMC with clinical grade Ad5f35pp65 
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vector followed by stimulation with EBV-transformed LCL that had been 
transduced with the same chimeric vector.  The VSTs were then cryopreserved 
until required. Patients were excluded from the study if they had received T-cell 
serotherapy within 28 days of proposed administration date.  The cumulative 
rates of complete or partial responses at 6 weeks post infusion were 74% for the 
entire group.  No immediate infusion-related adverse events were noted, 2 
patients developed de novo GVHD (grade 1).  Six out of eight patients who did 
not have line available and continued with standard therapy died of their viral 
disease.  The lineage of the VSTs is largely central or effector memory-derived 
T cells. This approach of using ‘off-the-shelf’ third-party VSTs appear to remove 
some of the barriers to the wider application of cell therapy in viral reactivations 
post-transplant.  It avoids the lengthy time and cost of producing individual lines, 
and does not appear to cause GVHD from alloreactivity of the third-party cells 
(Leen et al., 2013).  
 
 
1.3.8 Virus-specific T cells (VSTs) from umbilical cord blood 
 
Increasingly umbilical cord blood (UCB) has emerged as an important 
alternative source of stem cells for patients undergoing allogeneic stem cell 
transplant. UCB transplants (UCBT) allow more rapid procurement of the graft, 
requirement for less-stringent HLA matching, higher likelihood of finding a match 
for ethnic minorities, and decreased incidence of GvHD. However a major 
drawback is delayed engraftment and immune recovery and subsequent 
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increased susceptibility to viral infections post-transplant (Walker et al., 2007). 
Unlike adoptive transfer of VSTs from an adult stem cell donor, there are 
considerable barriers to successful use of adoptive immunotherapy with VSTs 
post UCBT, including small numbers of T-cells available for manipulation and 
their naïve phenotype (Thompson et al., 2015). Cord blood (CB) T cells also 
have lower cytotoxic activity and higher activation-induced cell death than do 
peripheral blood-derived T cells. Development of CB CTLs requires priming of 
naïve T cells rather than simple expansion of preexisting memory T cells. To 
overcome these obstacles Hanley et al described a method to generate single 
cultures of CTLs from CB that are specific for multiple viruses. EBV-infected B 
cells are transduced with a clinical-grade Ad5f35pp65 adenoviral vector and 
expanded in the presence of cytokines IL-7, Il-12 and IL-15 over a 2 week 
period. These cytokines decrease antigen concentration threshold, direct T-cells 
toward a central memory phenotype and influence TH1 and T-cytotoxic type 1 
cell differentiation. In combination these cytokines augment the generation of 
antigen-specific CTLs from naïve T cells. T-cell lines were prepared from 9 
different CB units and a median of 85.5x106T cells were harvested which would 
have been sufficient for T-cell adoptive transfer at 1x107/m2.  The generated 
VSTs showed specific IFNγ response in response to EBV, CMVpp65- and ADV-
hexon-expressing target cells by ELISpot assays (Hanley et al., 2009). Also by 
use of the G-rex culture device, expansion of VSTs to clinically relevant 
numbers (>6x107) was possible using only 20% fraction of thawed UCB units 
(Hanley et al., 2012). To date, 9 patients have been treated at the Center for 
Cell and Gene Therapy at Baylor College of Medicine in Texas with UCB-
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derived mVSTs. Six were treated prophylactically and 3 preemptively on 
evidence of viral reactivation/infection (one with CMV and ADV; two with EBV 
reactivation). Viral infections were resolved in all three patients with detection of 
transferred virus-specific T cells in peripheral blood by means of IFNγ ELISpot 
and/or deep T-cell receptor sequencing. All infusions were well tolerated and not 
associated with GvHD (Hanley et al., 2015). 
 
 
1.3.9 Virus specific T cells (VSTs) from seronegative donors 
About 20% of the adult population is seronegative to ADV (Garnett et al., 2002) 
which renders the approaches described above of manufacturing ADV-specific T 
cells by expansion of memory T cells impossible. Similar to the use of TCR-
redirected CMV-specific T cells to treat CMV-infections, Dorrie and colleagues 
described a method of expanding ADV-specific T cells by stimulation with the 
HLA-A*0101-restricted, immunodominant, and cross reactive epitope 
LTDLGQNLLY (LTD) from the hexon protein of ADV-species C. ADV-specific 
TCR α/β chain sequences are then cloned and transfected via mRNA 
electroporation into CD8+ α/β and γ/δ T cells. Both TCR-transfected α/β and γ/δ 
T cells secreted cytokines after antigen-specific stimulation, and efficiently lysed 
adenovirus-infected target cells (Dorrie et al., 2014). However γ/δ T cells, when 
compared to α/β counterparts, offer the advantage of being involved in viral 
defense without the potential to induce GVHD in patients (Oevermann et al., 
2012). This has not been trialed in clinical studies but could potentially be an 
alternative means of ADV immunotherapy to using third-party ADV specific T-
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cells for patients whose original HSCT donors have no detectable ADV-specific 
T-cells. 
 
1.4 AIMS of THESIS 
Adenovirus infection is an important cause of morbidity and mortality in HSCT 
recipients, especially in the paediatric group. Current antiviral treatment can be 
unsatisfactory in their side-effect profile and does not always facilitate viral 
clearance. Reconstitution of viral immunity in the post-transplant setting is 
essential for viral clearance and prevention of severe disease. The ASPIRE 
(Adenovirus Specific Paediatric Immune REconstitution) study is a Phase I/II 
clinical trial aimed to investigate the safety of Adenovirus- specific T cells given 
to high-risk paediatric patients post allogeneic transplant to treat 
reactivation/infection of adenovirus. The trial product, Cytovir ADV, is an 
Advanced Therapy Medicinal Product (ATMP) comprising ADV specific T cells 
derived from donor peripheral blood mononuclear cells (PBMCs) that have been 
expanded ex vivo. 
 
The aim of this thesis is to: 
 
1. Evaluate the safety and efficacy of Cytovir ADV by collecting clinical data on 
patients who are registered on the study. Data collected include stem cell 
transplant details, days of viral reactivation and viral load, adverse events after 
cell infusion, and immune reconstitution as evaluated by IFN-γ cytokine capture 
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assay. This group is compared with a contemporaneous group of patients who 
developed adenoviraemia but were not registered on the study. 
 
2. Generate ADV-specific T cells from PBMCs collected from healthy adult 
volunteers  using the same method as in the ASPIRE study and characterise the 
expanded T-cell population in regards to their phenotype as well as antigen-
specific function, ability to cause bystander activation and defining the cytokine 
profile in supernatant collected after T-cell expansion. 
The data collected helps to define a group of paediatric patients who will benefit 
from adoptive T-cell therapy for treatment of ADV infection/reactivation post-
HSCT. The optimal T-cell population to be infused will also be discussed. 
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Table 1.5 Clinical trials using virus-specific cytotoxic T cells in the HSCT setting  
Ref (Centre) Virus-
specificity 
Expansion protocol Antigen Used Infused number & 
type of cells 
Patients treated Clinical results (Leen et al., 2006) (Texas) EBV, CMV, ADV Donor PBMCs infected with vector; restimulated repetitively with irradiated EBV-LCLs transduced with same vector over 10-12 weeks.     
Clinical grade Ad5f35pp65 vector.   
Median 5 x 107 polyclonal cells/m2 infused at 35-150d after HSCT (median 62d) 
11 infused (children and adults; 10 prophylactically, 1 treated for ADV infection)   
3/3 cleared CMV and 3/3 cleared EBV infection/PTLD without antivirals; 3 patients with infection and 1 with disease cleared ADV post-CTL. No GVHD   (Feuchtinger et al., 2004) (Tuebingen)  
ADV IFN-γ selection after 16h stimulation. Cytokine secreting cells magnetically enriched .   
Adenoviral antigen type C (nonclinical grade) 
1.2-50x103/kg ADV-reactive polyclonal T cells infused 9 children with ADV infection.   5 out of 6 with ADV responded. 1 died at 30 days from ADV infection.  5 deaths (3 due to ADV infection)  
 (Leen et al., 2009) (Texas)  
EBV + ADV PBMCs infected with vector.  Responder cells restimulated weekly with irradiated autologous LCL transduced with same vector IL-2 was added twice weekly from day 14.  CTLs cryopreserved after 3 or 4 simulations. 
 
Ad5f35null vector MOI 200vp/cell 20 CTL lines with EBV and ADV specificity produced, 13 lines infused.  Dose of 5x106 to 1.35 x 108 cells/m2 at 40 to 150 days after HSCT (median 77 days).   
13 children [(M)MUD or haplo] 2 with active ADV disease; 11 prophylactic   
No toxicities or GVHD, monitored for 3 months.    Only detected increases in ADV-sp T cells in peripheral blood in those with active ADV infection (2 out of 13).                   
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(Qasim et al., 2013) (London)  
ADV PBMCs stimulated for 16hrs with ADV-hexon antigen.  Cytokine secreting cells selected using anti-IFN-g microbeads and Miltenyi Mini-MACS column within 24h 
Commercially available purified ADV-hexon antigen (The Binding site, UK) 
3 received γ-captured cells from original stem cell donor  Cells (104 – 105 /kg)  received on average 80 d after original graft (range 34-122) 
5 patients treated (3 with original donor; 2 third-party haploidentical donor) - 
Blood viraemia resolved in 3.  IFN-γ secreting ADV specific T cells present in 4 patients.  3 died – 1 of bystander GVHD after clearing virus (Leen et al., 2013) (Texas) ADV, CMV, EBV Banked 3rd-party PMBCs transduced with vector and stimulated with EBV-LCL transduced with same vector Ad5f35pp65 vector 32 virus-specific lines from individuals with common HLA polymorphisms immune to EBV, CMV or ADV.  Each patient received up to 2x107 cells/m2 
18 lines administered to 50 patients with severe viral illness with one of the viruses 
Cumulative rates of complete or partial responses at 6 weeks was 74% for whole group.  2 de novo GVHD (grade 1). 
(Gerdemann et al., 2013c) (Texas)  
ADV, CMV, EBV Donor PBMCs stimulated with nucleofacted DCs and cultured over 2-3 weeks with IL4 and IL7. DCs nucleofacted with range of EBV, CMV, ADV viral antigens. 
22 trivirus and 14 bivirus CTL lines Each patient received 0.5 -2 x107 cells/m2 
10 patients with viral reactivation treated between day 27 and month 52 post HSCT 
Viral clearance and increased frequency of VSTs in 80%.  1 stage 2 skin GVHD  
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CHAPTER 2 
ASPIRE – Adenovirus Specific Paediatric Immune Reconstitution 
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2.1 STUDY SYNOPSIS 
Protocol Title A Phase I/II study to investigate the safety of Adenovirus 
specific T cells given to high-risk paediatric patients post 
allogeneic haematopoietic stem cell transplant (allo-
HSCT) to treat reactivation of adenovirus. 
Protocol Number CM-2011-02 
Eudra CT Number 2011-001788-36 
ISRCTN number ISTCTN22322271 
Investigational Product ADV specific T cells derived from donor peripheral blood 
mononuclear cells (PBMCs) expanded ex vivo (Cytovir 
ADV) 
Indication Treatment of ADV infection post allogeneic 
haematopoietic stem cell transplant 
Objectives Primary Objective:  
x To evaluate the safety of ADV specific T cells 
Secondary Objectives:  
x To evaluate the pharmacokinetics (PK) of ADV 
specific T cells with respect to absolute T cell counts 
x Time to absence of ADV viraemia 
x Use of antiviral  and other anti-infective drugs 
x Time in-hospital stay 
Exploratory Objective: 
x To evaluate persistence and expansion of adoptively 
transferred ADV specific T cells 
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Study Design 
 
This is an open-label safety study assessing the effect of 
pre-emptive administration of ADV-specific T cells 
(Cytovir ADV). A maximum of 15 patients will receive 
these cells.   
Planned Number of 
Subjects 
It is estimated that donor cell therapy will be prepared for 
50 patients with the aim of registering and treating a 
maximum of 15 patients who have reactivated ADV.  
Subject Population 
 
Paediatric recipients of an allo-HSCT using T cell 
depletion from a matched unrelated, mis-matched 
unrelated or family donor, or haploidentical donor. 
Mismatched is defined as mismatches at ≥ 1/10 alleles. 
Treatment Regimen: 
 
Patients will commence the study and be consented to 
receive Cytovir ADV on reactivation of ADV (defined as 
two consecutive positive PCRs > 1000 copies/ml) post-
transplant, in addition to antiviral drugs that would be 
administered as part of standard of care.  Patients will 
only be treated if they are considered stable as deemed 
by the attending physician.  The primary dose will be 
1x104/kg total CD3+ T cells.  Patients will be monitored at 
these approximate time points post-Cytovir ADV 
administration; 14, 30, 60, 90, 120, 150 and 180 days. If 
the patient exhibits significant levels of ADV viraemia 
requiring treatment ≥ 4 weeks post-infusion they will be 
assessed to receive a secondary maximum target dose of 
1x105/kg total CD3+ T cells and will be monitored for a 
further 180 days.  
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Endpoints: 
 
Primary Endpoint:  
x Toxicity: incidence and severity of GvHD, 
cytopaenias, grade 3-4 AEs 
 Secondary Endpoints:  
x Number of reported serious adverse events (SAEs) 
(Suspected, Unexpected Serious Adverse Reactions 
[SUSARs] and Suspected, Expected Serious Adverse 
Reactions [SESARs]) 
x Absolute (by PCR) ADV viraemia at each time point  
x Number of treatment days with antiviral drugs 
x Number of treatment days with other anti-infective 
drugs 
x Number of in-hospital days during study period 
Exploratory Endpoint: 
x Number of detectable ADV specific T cells in vivo 
assessed at each time point 
Statistical Methods: 
 
This is primarily a safety study so analysis will be of 
numbers of adverse events related to treatment.  No 
control group is included in this Phase I/IIa study but data 
on allo-HSCT outcomes in 273 recipients performed at 
GOSH/ ICH has been collated as part of the preparation 
for this study.  This large database is available as an 
historical comparison. 
 
 
 83 
 
Independent Review of 
Data 
An Independent Data and Safety Monitoring Committee 
will review data as they emerge from the study.  The 
IDSMC will have the ability to halt the trial if pre-agreed 
stopping criteria are reached.  These criteria will be 
documented in a Charter signed by all Committee 
members. 
 
2.2 INTRODUCTION  
Cytovir™ ADV has been developed by Cell Medica Ltd. as an Advanced 
Therapy Medicinal Product (ATMP) comprising Adenovirus (ADV)-specific T 
cells derived from peripheral blood mononuclear cells, expanded ex vivo - for 
the treatment of ADV infection in immunocompromised transplant recipients. 
The purpose is to accelerate reconstitution of the immune system with respect to 
its ability to control ADV infection or reactivation; and ultimately to provide 
patient with protective immunity to control de novo ADV infection or reactivation.  
Clinical experience is drawn from previous trial conducted at Great Ormond 
Street Hospital where 5 children were treated with ADV-specific T cells derived 
from the original donor (n=3) or third-party haploidentical parents (n=2) (Qasim 
et al., 2013). Enrichment of IFN-γ secreting cells was performed using the 
Cytokine Secretion SystemTM and the CliniMACSTM device for immunomagnetic 
separation (both Miltenyi Biotec, Bergisch Gladbach, Germany) and ADV-
specific T cells were infused directly after 24 hours without ex vivo expansion. 
Three patients cleared ADV in blood after a single infusion of 104 /kg and had 
demonstrable ADV-specific T cells in circulation detected by IFN-γ secretion 
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assay. However there was time delay in treatment with recalling of original 
donors and children received cell therapy at an average of 80 days after original 
stem cell graft; whilst median days to viral reactivation is 15 days (Hiwarkar et 
al., 2012). Hence the need for quicker access to immunotherapy was identified. 
In the current study, Cytovir ADV will be manufactured upfront at time of HSCT 
rather than at time of viral reactivation, to ensure timely administration at time of 
need. 
CytovirTM ADV contains a population of naturally occurring ADV-specific T cells 
which are recovered from the peripheral blood of a donor who is fully or partially 
HLA matched with the recipient. Cells are expanded ex vivo by cultivation with 
synthetic ADV peptide antigens, cytokines and human serum. The expanded 
ADV specific T cells are harvested, washed and cryopreserved.  At the time of 
administration CytovirTM ADV is thawed and infused intravenously. The 
therapeutic mode of action is adoptive immune reconstitution following the 
transplantation of virus specific T cells. The T cells will be derived from the same 
donor who provides the graft for the recipient’s allo-HSCT procedure. 
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2.3 PRODUCT CHARACTERISTICS AND ADMINISTRATION 
The raw material for Cytovir ADV is peripheral blood mononuclear cells derived 
from whole blood or mobilised apheresis obtained from HLA matched donors. 
To manufacture Cytovir ADV, Peripheral Blood Mononuclear Cells (PBMCs) are 
isolated by density gradient centrifugation with ficoll-paque. ADV-specific T cells 
are selectively expanded with synthetic ADV peptides and specific cytokines (IL-
4 and IL-7) that promote rapid proliferation of the stimulated T cell 
population.ADV specific T cells are selectively expanded for ten days. At the end 
of the process the cells are harvested, washed, counted and re-suspended at 
the appropriate concentration in cryopreservation medium containing Human 
Serum Albumin (HSA) and Dimethyl Sulfoxide (DMSO) prior to controlled rate 
freezing for storage in liquid nitrogen vapour.  
Following Qualified Person (QP) release (purity, enumeration of ADV specific T 
cell content) the patient-specific dose of ADV specific T cells can be made 
available for infusion. Appropriate aerobic and anaerobic cultures will be 
performed and confirmation of negative results subsequently passed to the 
Principal Investigator (PI). Cells that are unused will be destroyed as clinical 
waste following study closure or with appropriate consent, may be used 
anonymously for research or training purposes 
The frozen cells are supplied to the hospital in a sterile, IV bag. Prior to patient 
administration the frozen cells are thawed and infused within 30 minutes of 
thawing.  Cytovir™ ADV is administered as a single IV infusion following allo-
HSCT on PCR evidence of ADV reactivation (two consecutive positive PCRs). 
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Each infusion is patient specific (HLA matched) and will contain ADV specific T 
cells typically comprised of CD4+ and CD8+ cells with minor cell populations 
including monocytes, B lymphocytes and NK cells. The first dose given will be at 
1x104 /kg body weight total CD3+ T cells. A second dose of 1x105 /kg can be 
given at least 28 days after the first dose if patient experiences persistent 
significant adenoviraemia requiring treatment.  
 2.3.1 Release criteria 
TEST TEST LIMITS 
Appearance Clear and colourless solution 
Purity > 80% CD3+ T cells 
Viability > 70% CD3+ T cells 
Safety 
- Sterility 
- Mycoplasma 
- Endotoxin 
 
Absence of growth 
Not Detected 
< 10.0 (EU of endotoxin per mL of product) 
Potency ≥ 102 IFNγ+ T cells per kg BW of recipient 
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 2.3.2  Composition of one dose of Cytovir ADV 
COMPONENT QUANTITY PER DOSE 
CD3+ ≤ 1x105 per kg BW of recipient 
ADV specific T cells ≥ 1x102 per kg BW of recipient 
Infusion bag with 15-70mL of the ATMP in 
4.5% human serum albumin (HAS), 10% 
dimethyl sulphoxide (DMSO) 
One to several depending on final CD3+ 
numbers and patient body weight 
 
2.4 ADVERSE EVENTS 
There is little clinical experience with Cytovir™ ADV. The transfusion could 
theoretically cause GvHD. Events which are recognised and expected 
complications of the preceding allogeneic transplantation procedure, 
conditioning or concurrent medications used in the transplantation procedure or 
follow-up phase, will be exempt from the requirement to report serious adverse 
events if they are included in the list below:  
 
x Central line, cannula, or gastrostomy tube complications requiring 
revision 
x Cytopaenias (either autoimmune, drug-induced or due to hypoplastic 
graft) with resultant need for transfusion, risk of bleeding and infection  
x Deranged liver function or Jaundice 
x Deranged renal function 
x Electrolyte disturbances 
x Enteropathy or pneumatosis intestinalis  
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x Haemorrhagic cystitis  
x Hypertension or Hypotension 
x Infections (bacterial, fungal and viral) 
x Mixed chimerism 
x Mucositis 
x Pancreatitis 
x Pericardial or pleural effusion  
x Pneumonitis  
x Rejection or secondary graft failure 
x Relapse of malignancy 
x Seizures related to infection, hypertension/electrolyte imbalance/drugs  
x Thrombotic thrombocytopenic purpura  
x Toxicities related to drugs given independent of the study including 
derangement of electrolytes, renal and liver function, hypertension  
x Veno-occlusive disease of the liver  
2.5 STUDY DESIGN 
The study will test the hypothesis that human ADV specific T cells can enhance 
ADV specific immune responses post allo-HSCT, and reduce the requirement 
for antiviral therapy and hospitalisation without toxicity or increasing GvHD. See 
Figure 2.1 (Outline of the Study) below. In advance of study participation, the 
manufacturer will prepare cells for 50 patients of whom a maximum of 15 
patients will be enrolled and registered if they reactivate ADV and are eligible to 
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receive cells: patients are treated when they exhibit ADV viraemia of at least 
1000 copies/mL. The use of standard antiviral therapy will not be amended. The 
dosing will be one single dose of 1x104/kg total CD3+ lymphocytes with the 
option of a second dose, if available. The second dose will be a maximum of 
1x105/kg (minimum 1x104/kg) total CD3+ lymphocytes given if the patient has 
significant ADV viraemia requiring antiviral therapy at ≥ 4 weeks after the first 
infusion. Cell administration will not occur until 28 days post-transplant due to 
continuing in vivo persistence of conditioning antibodies such as alemtuzumab 
or Antithymocyte Globulin (ATG). These could directly impact on the viability of 
infused T-cells. ADV specific T cells will be administered from days 28 post allo-
HSCT and patients will be followed up for 6 months following infusion, with 
assessments at approximately 14, 30, 60, 90, 120, 150 and 180 days post-
infusion. 
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Allo 
HSCT 
Recipient 
ADV infection 
*ADV PCR 
>1000copies
/mL 2x 
X GVHD > Grade II 
X Significant 
pneumonitis 
X Significant 
hepatobiliary 
disease 
Viral surveillance 1st dose 104 CD3+ T 
cells/kg 
Follow-up 
assessments at 
allocated days up to 6 
months post infusion 
4 weeks after 1st dose if 
significant viraemia 
requiring ongoing 
antiviral treatment – 
2nd dose at 105/kg 
Pre-emptive antiviral pharmacotherapy as per local guidelines 
+/- early withdrawal of immunosuppresion 
Day 0 
Enrolled if eligible 
& consent  
Day +28 
Patient counselled 
about treatment 
in BMT clinic 
Request of donor sample  Request for processing at Cell Medica Day +21 – product available or not 
MUD 
MMUD 
MFD 
Haplo 
X MSD 
X MUCBT 
T-cell 
depletion 
Figure 2.1 ASPIRE Study Outline 
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The study opened at Great Ormond Street Hospital in Q1 2013, and two new 
sites were recently recruited and opened in December 2014 – The Great North 
Children’s Hospital in Newcastle-upon-tyne, and Royal Manchester Children’s 
Hospital, UK. Patients will be enrolled up till June 2015 with the last patient visit 
conducted in December 2015. These centers are specialist paediatric UK 
transplant centers experienced in the management of children undergoing allo-
HSCT.  The study is conducted in compliance with the protocol, International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) for Good Clinical Practice (GCP) and all 
applicable regulatory requirements.  All necessary regulatory and ethical 
approvals have been obtained before patient recruitment began. Potential 
donors will be flagged by the transplant team at the relevant study site and Bone 
Marrow Donor registries requested to procure from donors in accordance with 
standard procedures. These donors may be seen at any of the procurement 
sites under the jurisdiction of the relevant registry. 
 
2.6 SELECTION CRITERIA 
 2.6.1  Patient Inclusion Criteria – for the manufacture of Cytovir   
                         ADV (Screening Phase) 
 
The patient inclusion criteria include:  
1) Age < 16 years of age  
2) Laboratory tests to determine negative serology for HIV1+2, HepBcAb & 
HepBsAg, HepC, HTLV 1&2, Syphilis.  
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3) Recipient of allo-HSCT with in vivo or ex vivo T cell depletion from matched 
unrelated, mis-matched unrelated or family donor, or haploidentical donor 
 
 2.6.2  Patient Inclusion Criteria – for study enrolment and cell    
                         infusion (Treatment Phase) 
 
A patient will be eligible for enrolment in the study if, in addition to the screening 
patient inclusion criteria listed above, all of the following criteria apply:  
1)  For all subjects, a parent or legal guardian must give informed consent. 
Patients  aged 11-15 will be encouraged to provide witnessed written assent.  
2) The patient has two consecutive positive ADV PCR results >1000 
copies/ml 
 
 2.6.3  Patient Exclusion Criteria – for the cell infusion of Cytovir  
                         ADV 
 
A patient will NOT be eligible for enrolment in the study if any of the following 
criteria are met: 
1)  Significant GvHD ≥ Grade II 
2) Significant pneumonitis 
3) Significant hepato-biliary disease 
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 2.6.4  Donor Inclusion Criteria 
 
Donors for suitable participants will be selected for the manufacture of Cytovir 
ADV from patients already scheduled to undergo an allo-HSCT. Eligible 
unrelated, haploid or mismatched family donors will have already passed a 
medical for stem cell donation.  
 
The donor inclusion criteria include:  
1)  The donor will be selected from a registry that has approved the protocol 
and  consent procedure. 
2) Donor must have met all regulatory requirements for transplant.  
3) Laboratory tests as described in Appendix 6  
4) Healthy donor – having passed medical for stem cell donation  
5) Negative serology for HIV (type 1 & 2), Hepatitis B and C and Syphilis  
6) Written informed consent  
7) Age 16 years or older 
 
 2.6.5  Donor Exclusion criteria in accordance with registry criteria 
 
1) Pregnant or lactating and to be assessed prior to donation 
2) Platelets < 50x109/L 
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2.7 SUMMARY OF CLINICAL USE OF CYTOVIR ADV TO DATE 
Patient 
Study ID 
 
Date of 
dose (Day 
post HSCT) 
ADV PCR on 
administration  
% of CD3 
IFNγ ADV 
response in 
donor T 
cells 
No. of 
Cidofovir 
doses (pre 
/post 
Cytovir 
ADV) 
Serious 
Adverse 
events 
A1/02 1st dose –  
10th April 
2013 (Day 
+43) 
 
2nd dose –  
8th May 2013 
(Day +71) 
PCR 1: 3890  
PCR 2: 5900  
17.79 1/2 None 
A1/03 14th May 
2013 
(Day +97) 
PCR 1: 9659  
PCR 2: 50,151  
21.99 1/2 Severe Grade 4 
GvHD skin and 
gut. Died 23 
months post 
SCT. 
A1/04 25th April 
2014 
(D+28) 
PCR 1: 26,280  
PCR 2: 201,697  
1.36 1/4 Astrovirus 
encephalitis 
Died 9 months 
post SCT.  
A1/13 14th 
November 
2013 
(D+30) 
PCR 1: 241,411 
PCR 2: 28, 687  
3.98 3/0 Pancreatitis 
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A1/17 8th January 
2014 
(D+62) 
PCR 1: 919,156 
PCR 2: 523,863 
11.8 5/0 None 
A1/42 15th October 
2014 
(D+28) 
PCR 1: >20 
million 
PCR 2: >20 
million 
1.49 2/0 None 
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Patien
t Study 
ID 
Age Primary Condition Graft Donor 
type 
Conditioning regimen GvHD 
prophylaxi
s 
Co-
infection 
at T-cell 
transfer 
Other 
sites of 
ADV 
infection 
at T-cell 
Transfer 
Immuno-
suppressi
on at T-
cell 
Transfer 
Antiviral 
drugs 
before 
T-cell 
Transfer 
A1/02 5yrs 
8 
mth 
Relapsed Acute 
Lymphocytic 
Leukaemia (ALL) 
BM 9/10 (1A) 
mismatche
d related 
(father) 
-TBI (200cGyx4 Days -
7 to -4) 
-Etop (60mg/kg Day -
3) 
-ATG (20mg/kg x3 
Days -3 to -1) 
-CSA-A 
-MTX 
EBV 
viraemia 
(>2m 
copies/mL
) 
- Stool - Topical 
steroids 
for Grade 
1, stage 2 
skin GvHD 
 
- 
Rituximab 
for EBV 
viraemia 
1 dose 
of CDV 
A1/03 9 
mth 
Haemophagocytic 
lymphohistiocytos
is (HLH) secondary 
to MUNC 18-2 
deficiency 
PBSC 9/10 
(1DQ) 
mismatche
d 
unrelated 
-Flu (30 mg/m2 x5 
Days -6 to -2) 
-Treo (14g/m2 x3 Days 
-6 to -4) 
-Alem (0.2mg/kg x5 
Days -7 to -3) 
- CSA-A 
- MMF 
- - Stool 
- NPA 
- Low dose 
Prednisolo
ne 
(0.2mg/kg
) 
1 dose 
of CDV 
A1/04 18 
mth 
Cartilage Hair 
Hypoplasia (RMRP 
mutation) and 
associated 
immunodeficiency 
PBSC 10/10 
matched 
unrelated 
-Flu(30mg/m2 x5 Days 
-7 to -3) 
-Mel (140mg/m2 Day -
2) 
-Alem (0.2mg/kg x5 
Days -8 to -4) 
- CSA-A 
- MMF 
Sapovirus 
in stool 
- Stool - 1 dose 
of CDV 
A1/13 11 
yrs 
X-linked 
adrenoleukodystr
ophy 
PBSC 9/10 (1C) 
mismatche
d 
unrelated 
-Cyclo (60mg/kg x2 
Days -7 to -6) 
-TBI (3cGy x1 Day -4) 
-Flu (30mg/m2 x5 
Days -8 to -4) 
-Alem (0.2mg/kg x5 
Days -8 to -4) 
- CSA-A 
- MMF 
BK virus – 
haemorrh
agic 
cystitis 
- Stool - 3 doses 
of CDV 
Table 2.1 Characteristics of enrolled patients before infusion of Cytovir ADV 
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A1/17 5 yrs Relapsed Acute 
Myeloid Leukaemia 
(AML) 
PBSC Haplo with 
alpha/beta/
CD19 
depletion 
-Flu (40mg/m2 x4 Days -
6 to -3) 
-Treo (14 g/m2 x3 Days -
7 to -5) 
- Thio (5mg/kg x2 Day -
4) 
- ATG (5mg/kg x3 Days -
5 to -3) 
- CSA-A - - - 5 doses 
of CDV 
A1/42 13 
year 
old 
Juvenile Idiopathic 
Arthritis/Macropha
ge Activation 
Syndrome/Haemop
hagocytic 
Lymphohistiocytosis 
PBSC 10/10 
matched 
unrelated 
-Flu (30mg/m2 x5 Days -
7 to -3) 
-Mel (140mg/m2 Day -2) 
-Alem (0.2mg/kg x5 
Days -8 to -4) 
- CSA-A 
- MMF 
- 
Prednisolon
e 
- - Stool 
- Gut 
biopsy 
- 2 doses 
of CDV 
Alem = Alemtuzumab; ATG = Anti-thymocyte globulin (Fresenius); BM = bone marrow; CDV = Cidofovir; CSA-A = Cyclosporine A; Cyclo = 
Cyclophosphamide; Etop = Etoposide; Flu = Fludarabine; Haplo = haploidentical; Mel = Melphalan; MMF = Mycophenolate Mofetil; MX = 
Methotrexate; NPA = Nasopharyngeal Aspirate; PBSC  = peripheral blood stem cell; TBI = Total Body Irradiation; Treo = Treosulphan 
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Table 2.2 Cytovir ADV infusion and response 
Patient 
Study ID 
Adoptive T-
cell transfer 
(days after 
SCT) 
Blood ADV load 
(copies/mL) at 
time of T-cell 
transfer 
% of CD3 
IFNγ ADV 
response 
Virologic Response Immunologic 
response/in-vivo 
expansion of 
transferred ADV 
T cells 
No. of 
Cidofovir 
doses post 
Cytovir ADV 
Serious 
Adverse Events 
Clinical 
Outcome 
A1/02 1st dose (1x104 
CD3+/kg) – 10th 
April 2013 
(Day +43) 
 
2nd dose 
(1x105 
CD3+/kg) – 8th 
May 2013 (Day 
+71) 
PCR 1: 3890 
 
PCR 2: 5900 
17.79 ADV load continued 
to rise to 
250,000copies/mL; 
Load reduced to 
261 copies/mL 12 
days after 2nd dose; 
remained negative 
at 6months follow-
up 
Detectable ADV 
specific 
responses by 
Elispot 56 days 
post 2nd dose (20 
spots/105 cells), 
53 spots/105 
cells at 91 days. 
2 None Alive  
A1/03 14th May 2013 
(Day +97) 
PCR 1: 9659 
 
PCR 2: 50,151 
21.99 ADV load 
undectable 38 days 
post infusion. 
No IFNg 
response 85days 
post infusion 
2  Severe Grade 4 
GvHD skin & 
gut 
Died 23 
months post 
SCT 
A1/04 25th April 2014 
(Day +28) 
PCR 1: 26,280 
 
PCR 2: 201,697 
1.36 ADV load reduced 
to 820 copies/mL 12 
days post infusion. 
 4 Astrovirus 
encephalitis 
Died 9 
months post 
SCT 
A1/13 14th November 
2013 (Day 
+30) 
PCR 1: 241,411 
 
PCR 2: 28,687 
3.98 ADV load reduced 
to 2,142 copies/mL 
7 days post infusion 
but rose to 32,324 
11 days post. 
Undetectable since 
39 days post. 
Detected ADV 
specific response 
by IFNγ capture 
27 days post 
infusion. 
Response 
sustained at 6 
months detected 
by Elispot 
(501spots/105 
cells) 
0 Pancreatitis 
(associated 
with rise in ADV 
load) 9 days 
post infusion. 
Alive 
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A1/17 8th January 
2014 (Day 
+62) 
PCR 1: 919,156 
 
PCR 2: 523,863 
11.8 ADV load decreased 
to 29,091 copies/mL 
23 days post; 
undetectable since 
113 days post. 
Detected ADV 
specific response 
by Elispot 126 
days post 
infusion (75.3 
spots/105 cells) 
0 None Alive 
A1/42 15th October 
2014 (Day 
+28) 
PCR 1: 
>20million 
 
PCR 2: > 20 
million 
1.49 ADV load decreased 
to 26,892 5 days 
post; remained 
undetectable since 
2 weeks post 
infusion. 
Detected ADV 
specific response 
by Elispot and 
IFNγ capture by 
13 days post 
infusion  
0 None Alive 
 
 
 
 
 
 
 100 
 
 2.7.1  Detailed description of each treated subject (Fig. 2.2) 
A1/02 – a 5 year and 8 month old boy with relapsed Acute Lymphocytic 
Leukaemia (ALL) underwent a 1A mismatched (9/10) related bone marrow graft 
from his father on 26.2.2013 with TBI (200cGy x4 Days -7 o -4), Etoposide 
(60mg/kg Day-3) and ATG-Fresenius (20mg/kg x3 Days -3 to -1).GvHD 
prophylaxis was undertaken with Cyclosporin and Methotrexate. Full donor 
chimerism was detected on D+37 post transplant. He developed mild skin 
GVHD (stage 2, grade 1) that was under control with topical steroids. 
Adenoviraemia was first detected on D+36 with 3890 copies/mL rising to 15,189 
copies/mL one week later. Adenovirus had been detected in the stools since 
D+11. Cidofovir treatment was initiated and subject received Cytovir ADV on 
D+43 post HSCT. Subject also experienced EBV reactivation on D+34 with viral 
load rising to and remaining at greater than 2 million copies/mL despite 
receiving 4 doses of Rituximab. At the same time subject also developed mild 
liver derangement with conjugated hyperbilirubinaemia (highest Bilirubin 41 
uMol/L, GGT 1090 U/L, ALT 532 U/L). Persistent culture-negative fevers raised 
the possibility of EBV Lymphoproliferative Disease, and whilst there was no 
radiological or tissue confirmation of LPD, a trial of methylprednisolone 1mg/kg 
was initiated on D+58. This brought about control of fever and dose was 
weaned to 0.5mg/kg on D+70 and stopped in D+74. A GI endoscopy showed no 
macroscopic evidence of GvHD or LPD.   
After the initial dose of Cytovir ADV at 1x104 CD3+/kg, subject continues to 
have adenoviraemia up to 250,130 copies/mL and was given second higher 
dose at 1x105 on D+71.  ADV viral load reduced to 261 copies/mL 12 days later 
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and remained undetectable at follow-up 6 months after the second dose. EBV 
viral load also became undetectable by D+83 (12 days after receiving second 
dose of Cytovir ADV). Because of persistent cytopaenia (neutrophils and 
platelets) subject also received a CD34 top-up on Day +84. 
ADV specific responses were first detected by Elispot 56 days after 2nd dose (20 
spots/105 cells) and at 91 days post (53 spots/105 cells). On 56th day after 2nd 
infusion, interferon-γ capture assay also detected ADV specific response in the 
CD8+ population (0.51% of lymphocytes were CD8+ IFN-γ+ when stimulated with 
ADV, compared to 0.26% of unstimulated lymphocytes. An increase >0.05% 
from unstimulated background level is taken as a positive response). 
 
A1/03 - a 9 month-old girl with haemophagocytic lymphohistiocytosis (HLH) 
secondary to MUNC 18-2 deficiency underwent a 1DQ mismatch (9/10) 
unrelated haematopoietic stem cell transplant conditioned with Fludarabine 
(30mg/m2 x5 Days -6 to -2), Treosulfan (14mg/m2 x3 Days -6 to -4) and 
Alemtuzumab (0.2mg/kg x5 Days -7 to -3); and received GvHD prophylaxis with 
Cyclosporin and Mycophenolate mofetil. Pre-transplant therapy for HLH 
included Dexamethasone, Etoposide, Cyclosporin as well as rabbit ATG. Full 
donor chimerism was first detected on D+13. Subject developed late 
reactivation of adenovirus in the blood on D+89 with 9659 copies/mL rising to 
50,151 copies/mL 3 days later, but without clinical signs of ADV infection; 
although the virus had been detected in the stools since Day +13 and was also 
present in NPA. Pre-transplant subject had EBV viraemia and was treated with 
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three doses of Rituximab.  Treatment for ADV viraemia was started with 
Cidofovir and subject received Cytovir ADV at 1x104 CD3+ /kg on Day +97. 
ADV viral load became undetectable 38 days after CTL infusion. However 
subject developed stage 2 skin GvHD 64 days post infusion (D +161 post 
HSCT). This initially improved with topical steroid treatment but subject 
presented to the local hospital with profuse diarrhoea 29 days later with an 
upper and lower GI endoscopy showing histological features of GVHD. Subject 
was diagnosed with late acute Grade 3 GvHD (stage 3 skin, stage 2 gut). 
Treatment was started with systemic steroids, infliximab, cyclosporin and gut 
rest. The event was reported as a serious adverse event (SAE) possibly related 
to study treatment and subject was taken off study due to the development of 
>Grade 2 GvHD.  At 22 months post-transplant subject continued to have 
severe skin and gut GvHD. Her gut GvHD further deteriorated to stage 4 and 
became refractory to steroid treatment. Treatment with basiliximab, infliximab, 
mycophenolate mofetil, sirolimus and mesenchymal stromal cells failed to bring 
about improvement in her symptoms of melena and gut failure. Due to the 
extensive amount of immunosuppression required to treat her GvHD, patient 
experienced ADV reactivation associated with respiratory failure with imaging 
showing signs consistent with a pneumonitis. There was also concurrent EBV 
reactivation with viral load up to 3 million copies/mL in blood, but no clear 
clinical signs of LPD. Patient was placed on palliative care and sadly passed 
away 23 months post her stem cell transplant for MUNC 18-2 HLH from acute 
respiratory failure due to ADV pneumonitis in the context of gut failure and 
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chronic steroid dependent gut and skin GvHD. IFNγ capture 85 days after CTL 
infusion failed to show ADV specific response. 
 
A1/04 – please refer to summary of adverse events below. 
 
A1/13 – an 11-year-old boy with X-linked adrenoleukodystrophy underwent a 
reduced intensity (RIC) Busulfan (AUC=60mg/L/hr), Fludarabine and 
Alemtuzumab conditioned bone marrow transplant with a low CD34 dose of 
1.07x106/kg from a 1C mismatched unrelated donor. Initially subject fully 
engrafted but developed fevers associated with dropping counts on D+32 with a 
bone marrow trephine showing aplastic marrow confirming acute graft rejection. 
Subject proceeded to an immunosuppressive second transplant with peripheral 
blood stem cells from the same donor, conditioned with cyclophosphamide 
(60mg/kg x2 Days -7 to -6), TBI (3 gy x1 Day -4), Fludarabine (30mg/m2 x5 
Days -8 to -4) and Alemtuzumab (0.2 mg/kg x5 Days -8 to -4); and Ciclosporin 
and Mycophenolate Mofetil as GvHD prophylaxis. Full donor chimerism was 
detected on D+13. 
Subject experienced Adenovirus reactivation during his first transplant on D+17 
with a peak titer of 324,370 copies/mL. A single dose of Cidofovir was given with 
good response with undetectable ADV in blood until D-1 of the second 
transplant. ADV load of 45,210 copies/mL was detected on D+2, peaking at 
241,411 copies/mL on D+21. ADV was also detectable in the stool. Cidofovir 
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treatment was started and although subject did not have clinical signs of ADV 
infection he developed haemorrhagic cystitis secondary to BK virus. Cytovir 
ADV at dose of 1x104 CD3+/kg was given on D+30. ADV viral load in blood 
dropped from 16,257 copies/mL on day of infusion to 2,142 copies/mL one week 
later. ADV specific T cell response was first detected in the CD4+ population by 
IFNγ capture 27 days after infusion (0.42% of lymphocytes were CD4+ IFNγ+ 
when stimulated with ADV compared to 0.31% when unstimulated). Response 
was sustained at 6 months post as detected by Elispot (501 spots/105 cells ADV 
stimulated c.f 274 spots/105 cells with negative control). 
One serious adverse event (SAE) was reported for A1/13 as 9 days after cell 
infusion subject developed pancreatitis with raised lipase and amylase. This co-
incided with a rise in ADV load to 32,324 copies/mL on D11 peaking to 409,159 
copies/mL 4 days later. The pancreatitis was thought to be possibly related to 
Cytovir ADV but other possible causes included conditioning subject received for 
the transplant, concurrent adenovirus infection, a known complication of 
transplant or medication mycophenolate mofetil that was used as GvHD 
prophylaxis. Subject was started on treatment with octreotide, analgesics, total 
parenteral nutrition and intravenous antibiotics. He made complete recovery 
after 39 days and ADV load in blood remained undetectable since. The SAE 
was subsequently closed and patient remained on study. 
 
A1/17 – is a 5 year old girl with relapsed AML who underwent a haploidentical 
stem cell transplant with alpha/beta/CD19 depletion conditioned with 
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Fludarabine (40mg/m2 x4 Days -6 to -3), Treosulfan (14 g/m2 x3 Days -7 to -5), 
Thiotepa (5mg/kg x2 Days -4) and ATG (Fresenius) (5mg/kg x3 Days -5 to -3); 
with Ciclosporin as GvHD prophylaxis. Full donor chimerism in peripheral blood 
was detected on D+18.  
Subject experienced early reactivation of ADV in blood with low levels detected 
on D+4 at 870 copies/mL. This rose to 17, 814 copies/mL on D+7 and treatment 
was started with cidofovir. After two doses, ADV level hovered between 6000-
9000 copies/mL for two weeks before rising again to 25,765 copies/mL on 
D+29. Two further doses of cidofovir were given one week apart but despite 
total of 4 doses of cidofovir ADV load continued to rise and peaked at 919,156 
on D+53. Subject remained clinically well with no signs of ADV disease. Subject 
had good initial T-cell recovery with CD3 count of 0.32x106/mL on D+60 but 
there was no specific IFN-gamma response to ADV stimulation. Subject 
received Cytovir ADV at 1x104 CD3/kg on D+62. ADV load reduced from 
523,863 copies/mL day before infusion to 49,091 copies/mL 23 days later and 
became completely undetectable from 113 days onwards. ADV specific T cell 
response by Elispot was first detected 126 days after infusion (75.3 spots/105 
cells ADV stimulated c.f to 28.3 spots/105 cells unstimulated). Subject did not 
experience any serious adverse events. 
 
A1/42 – is a 13 year old girl with JIA/MAS/HLH who received a fully matched 
unrelated stem cell transplant conditioned with Fludarabine (30mg/m2 x5 Days -
7 to -3), Melphalan (140mg/m2 Day -2) and Alemtuzumab (0.2mg/kg x5 days -8 
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to -4); and ciclosporin, mycophenolate, and prednisolone as GvHD prophylaxis. 
Full donor chimerism in peripheral blood was detected on D+13. Subject 
developed early adenoviraemia on D+12 with load of 28, 712 copies/mL. 
Cidofovir (5mg/kg) was started on D+15 when load had risen to 166, 049 
copies/mL; followed by second dose one week later. Clinically subject had 
evidence of Adenovirus gut disease with diarrhoea and vomiting and isolation of 
the virus in stool and endoscopic biopsies. She did not have evidence of 
pneumonitis or hepatitis. Adenovirus in blood continued to rise quickly to a peak 
of >20 million copies/mL on D+22, where it stayed until subject received Cytovir 
ADV at 1x104 CD3/kg on D+28. ADV load reduced to 26,892 after 5 days and 
became and remained undetectable after 2 weeks. ADV specific T cell response 
was detected by Elispot and IFNγ capture from 13 days post infusion up until 
the last monitoring visit, although the degree of positive response decreased as 
viral load decreased. 
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Figure 2.2 ADV viral load and CD4 count vs days from HSCT for subjects   
                  A1/02, A1/03, A1/04, A1/17, A1/42  
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Figure 2.3 ADV specific T-cell response in treated patients (as determined by IFNγ   
                  cytokine assay) 
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2.7.2 Summary of adverse events 
To date, three serious adverse events have been reported to the Clinical 
Administration Office for study CM-2011-02. Of these, only one was initially 
classified as possibly related to the study treatment and reported to the MHRA 
and NRES as a SUSAR on 16th May 2013 in line with mandatory requirements. 
Following additional investigations the event was subsequently downgraded to 
‘unlikely related’. A summary is provided below for information. 
Study subject A1/04, an 18 month old boy with Cartilage Hair Hypoplasia and 
associated immunodeficiency due to RMRP mutations, underwent a peripheral 
blood stem cell transplant on 28 March 2013 from a 10/10 HLA matched 
unrelated donor following conditioning with fludarabine (150mg/m2 x5 Days -7 to 
-3), melphalan (140mg/m2 Day -2) and alemtuzumab (0.2mg/kg x5 Days -8 to -
4) for in vivo T cell depletion. Ciclosporin A and Mycophenolate Mofetil were 
given as GvHD prophylaxis. Transplant was uncomplicated with neutrophil 
engraftment achieved by day +13 and full donor chimerism detected on day +19. 
Persistent stool viruses (Sapovirus, Adenovirus) were detected on stool PCR.  
Adenoviraemia occurred from day 18 onwards with peak load of 201,697 
copies/mL on day 21. This required treatment with Cidofovir (5mg/kg 1x dose) 
and Cytovir ADV (donor-derived Adenovirus-specific CTLs at 1x104/kg total 
CD3+ cells) on Day +28. Adenovirus load reduced to 820 copies/mL 12 days 
after infusion. Two weeks later the child became acutely unwell with irritability, 
dystonia and reduced consciousness. Encephalopathy secondary to drug 
toxicity, infectious complications or inflammation associated with immune 
reconstitution were considered in the differential diagnosis. Ciclosporin was 
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stopped on Day +43 and replaced by methylprednisolone therapy (1mg/kg). MRI 
of the brain showed progressive changes with loss of volume (Figure 1) and 
EEG revealed increased amplitudes of on-going slow activity over posterior 
regions with no focal features or epileptiform abnormalities.  PCR of CSF 2 
days, 2 weeks and 1 month after the onset of symptoms did not detect 
adenovirus, herpes simplex virus (HSV) 1 and 2, varicella zoster virus, 
cytomegalovirus, Epstein Barr virus (EBV), BK virus, norovirus, sapovirus, 
astrovirus (HAstV 1-8), rotavirus, enterovirus, measles, parechovirus, JC virus, 
HHV6, HHV7 and Toxoplasma. Brain biopsy (Fig 2.6) performed 8 weeks after 
neurological deterioration was also negative for these pathogens as well as 18s 
(fungal) and 16s (bacterial) ribosomal PCRs. Histological examination of the 
brain showed an unusual pattern of pathology with neuronal cell death and 
microglial activation. Lymphocytes were inconspicuous on microscopy and there 
were no acute inflammatory cells. Immunohistochemistry for CD68 showed 
diffuse cortical and subcortical microgliosis. Staining for a range of infectious 
agents, including prion disease, was negative. And immunostaining for 
adenovirus showed occasional cells with cytoplasmic staining, which was likely 
to be non-specific. To further elucidate on the cause for this patient’s 
deterioration, unbiased pyrosequencing using RNA isolated from the brain 
biopsy was performed by virology laboratory. This identified a novel strain of 
Astrovirus, HAstV-VA1/HMO-C-UK1(a) and was determined to be cause of 
child’s encephalitis after confirmation by PCR assays (Brown et al., 2015). PCR 
assays confirmed presence of the novel astrovirus in retrospective samples of 
CSF, serum and stool. Withdrawal of immunosuppresion was associated with 
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the development of skin GVHD (grade 2 stage 3) requiring treatment with 
methylprednisolone (2mg/kg/d). As a result kinetics of T cell reconstitution were 
reduced with CD3 count of 0.35x109/L 6 months post HSCT, and in the context 
of ongoing neurological impairment with recurrent respiratory and 
gastrointestinal complications, the patient died 9 months after transplantation. 
A meeting of the IDSMC concluded the death of patient A1/04 was unlikely to be 
related to treatment with the study drug and recommendation was given that the 
study may continue without modification.  
 
Figure 2.4 Clinical summary for A1/04 (ADV viral load and CD4 count vs post-
transplant  
                  days) 
 
 
Time points when Astrovirus was identified in retrospective 
samples. C = CSF S = serum St = stool 
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Figure 2.5 MRI scans on A1/04 1 month apart showing progressive cerebral 
atrophy  and widening of ventricles and sulci 
  
  
 
 
 
 
 
May 2013 June 2013 
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Figure 2.6 Brain biopsy slides on A1/04 
a) Neuronal death 
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b) Neurophagia 
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c) Microglia 
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d) No increase in CD3 staining 
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 2.8 PATIENTS WITH ADENOVIRAEMIA DURING TRIAL PERIOD WHO DID 
NOT RECEIVE CYTOVIR ADV  
During the trial period from January 2013 to May 2015 a total of 21 patients 
became viraemic by median Day +25 (range +2 to +113) (Figure 2.7). Out of 
these 21 patients, 14 patients were registered on ASPIRE study of which 6 were 
treated with Cytovir ADV. The remaining 8 patients did not meet criteria to 
receive treatment with Cytovir ADV because of 1) ADV viral load in blood 
decreased spontaneously or with Cidofovir treatment (n=6) 2) active ADV 
infection and met exclusion criteria (n=2). Five of these 8 patients eventually 
died of multiorgan failure (n=3) or relapse of leukaemia (n=2). Two of the deaths 
were attributable to ADV infection. Seven patients were not registered on 
ASPIRE study (and therefore did not have Cytovir ADV products made) due to 
various reasons: 1) donor center was not registered with the study (n=2) 2) 
donor center did not respond in time with donor consent (n=1) 3) bone marrow 
donor from Germany early on in the trial when overseas shipment of peripheral 
blood had not gained approval (n=1) 4) missed consent (n=2) 5) donor declined 
(n=1). Out of these 7 patients, 4 died of ADV related diseases. 
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Fig 2.7 Patients eligible to enter ASPIRE (January 2013 to May 2015) 
 
2.8.1 Patients who were registered on ASPIRE but not eligible for Cytovir 
ADV on reactivation 
Out of the 14 patients who were registered on ASPIRE study and had products 
made from their original donors, 8 developed adenoviraemia post HSCT but did 
not receive ADV CTLs either because 1) viral load decreased spontaneously or 
with treatment with Cidofovir (n= 6) or 2) because exclusion criteria for product 
administration were met (n=2). The details of each of these patients around 
their transplant periods are as follows: 
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A1/11 was a 2-year and 9-month old boy with Idiopathic Severe Aplastic 
Anaemia who underwent a fully-matched 10/10 family donor peripheral blood 
stem cell transplant with Fludarabine/Cyclophosphamide/Alemtuzumab 
conditioning. ADV became detectable in blood on D+31 post transplant at load 
of 3,001 copies/mL, and again on D+32 at 4,655 copies/mL. ADV viral load in 
blood became and stayed undetectable from D+35 onwards without antiviral 
treatment. ADV was also detectable in stool from D+21 and became 
undetectable from D+87. Patient received treatment with Ganciclovir and 
Foscarnet for CMV viraemia from D+35 onwards with good response. Patient is 
currently well 2 years post-transplant. 
 
A1/16 was a 4 year old boy with Autosomal recessive chronic granulomatous 
disease who had undergone a fully-matched 10/10 unrelated donor bone 
marrow transplant with reduced intensity Fludarabine/Busulphan/Alemtuzumab 
conditioning. ADV became detectable in blood on D+41 post transplant at load 
of 11,635 copies/mL and again on D+46 (38,206 copies/mL) and D+48 (24,322 
copies/mL). ADV became undetectable in blood from D+52 onwards. ADV was 
detectable in stool from D+17 to D+52 and became undetectable from D+87 
onwards. Patient did not require antiviral treatment with Cidofovir for 
adenoviraemia however did receive ganciclovir and foscarnet treatment for 
CMV viraemia (D+27 to D+40) and one dose of Rituximab for EBV viraemia on 
D+52. Patient is well 2 years post-transplant. 
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A1/19 was a 5-year old boy with XIAP deficiency and EBV-driven HLH who 
initially underwent a fully matched bone marrow transplant with 
Fludarabine/Cyclophosphamide/Alemtuzumab/Anti-CD45 monoclonal antibody 
conditioning. Six months later he developed relapse of HLH as well as 
adenoviraemia with load up to 6 million copies/L. He received a second 
transplant from the original donor this time with peripheral blood as stem cell 
source and reduced intensity conditioning regimen with 
Fludarabine/Cyclophosphamide/Alemtuzumab. Patient was in intensive care at 
the time and died 6 days after the second transplant with a high adenovirus load 
in blood of 11 million copies/mL.   
 
A1/23 was an 8-month old boy with RAG1 Severe Combined Immunodeficiency 
who underwent haploidentical stem cell transplant with 
Treosulfan/Fludarabine/Thiotepa/ATG conditioning and alpha/beta T cell 
depletion. ADV was detectable in blood before transplant up to 14,000 
copies/mL on D-22. Adenoviraemia peaked post-transplant on D+9 to 236,950 
copies/mL but decreased to low level by D+30 (1344 copies/mL). ADV was also 
detectable in stool and nasopharyngeal aspirate. Given the low level of viral 
load patient did not meet criteria for ADV CTLs. Respiratory failure on D+35 
resulted in admission to intensive care for invasive ventilation and patient 
passed away on D+51 from pulmonary haemorrhage and multiorgan failure. 
ADV viral load in blood on D+48 was 3564 copies/mL. 
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A1/25 was an 18-month old girl with bilineage acute leukaemia who underwent 
a 9/10 1A mismatched unrelated bone marrow transplant conditioned with 
treosulfan/fludarabine/thiotepa/ATG. She developed adenoviraemia on D+20 
with viral load peaking at 42,500 copies/mL on D+24. Patient was treated with 3 
doses of Cidofovir (D+22, D+29, D+41) with eventual clearance of ADV in blood 
on D+67. As viral load had reduced to 3000 copies/mL by D+31 decision was 
made to continue with Cidofovir treatment alone. Unfortunately patient 
experienced a relapse 4 months after transplant and eventually died 8 months 
post-transplant. 
 
A1/27 was a 7-year old boy with secondary AML/MDS diagnosed after 
treatment for cerebellar medulloblastoma. He received a fully matched 
unrelated donor stem cell transplant with reduced intensity 
Fludarabine/Melphalan/Alemtuzumab conditioning.  Patient developed low level 
adenoviraemia on D+36 at 1,019 copies/mL which peaked to 662,281 
copies/mL on D+47. One dose of Cidofovir was administered on Day +57 with 
resultant decrease in viral load and disappearance from blood by D+84. Given 
good response to Cidofovir decision was made not to treat with ADV CTLs. Six 
months after transplant patient suffered relapse and severe gut GvHD and 
eventually died. 
 
A1/29 was a 3-year old boy with XIAP deficiency and EBV-driven HLH. He 
underwent a 9/10 1DQ mismatched unrelated donor transplant conditioned with 
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Fludarabine/Cyclophosphamide/Alemtuzumab/Anti-CD45 monoclonal antibody. 
Adenovirus was first detected in blood on D+25 at 6,954 copies/mL rising to 
55,000 copies/mL two days later. Patient was already unwell in PICU intubated 
and ventilated and eventually died on D+29. Because of concurrent pneumonitis 
at time of viral reactivation, patient did not meet eligible criteria to receive CTLs. 
 
A1/51 was a 4.5 year old boy with X-linked Chronic Granulomatous Disease 
who underwent a 9/10 (1A) mismatched unrelated bone marrow transplant with 
reduced intensity Busulfan/Fludarabine/Alemtuzumab conditioning. ADV 
reactivation occurred in blood on D+34 starting with level of 1,910 copies/mL 
and peaking to 55,525 copies/mL on D+45. Treatment with Cidofovir was 
commenced on D+40 and total of 3 doses were given with good response. ADV 
viral load reduced to 3,633 on D+62 and became undetectable from D+68. 
Stool samples were positive for ADV from D+21 to D+111 and became 
undetectable from D+140. ADV was also detected in nasopharyngeal aspirates 
from D+32 to D+52 without causing respiratory symptoms. Patient is well 8 
months post-transplant. 
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Figure 2.8 Graphs of ADV viral load and CD4 count (where available) of patients who  
                  were registered on study but not eligible for Cytovir ADV 
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Table 2.3 Patient Characteristics (those with viraemia who received Cytovir  
                ADV vs those with viraemia who did not receive Cytovir ADV) 
 Received Cytovir ADV (n) Did not receive Cytovir ADV 
(n)  
Age [Years]   
<1 0 1 
1-3 2 2 
3-5 0 3 
5-10 2 2 
10-15 2 0 
Diagnosis   
ALL 1 1 
Familial HLH 2 0 
Immunodeficiency 1 3 
AML 1 1 
ALD 1 0 
XIAP deficiency 0 2 
SAA 0 1 
Donor Graft Type   
MUD 2 3 
MMUD 2 3 
Haplo 1 1 
MMFD 1 0 
MFD  1 
Donor Source   
BM 1 3 
PBSC 5 5 
T cell depletion   
In vivo depletion (ATG) 2 2 
Alemtuzumab 4 6 
Graft manipulation 1 1 
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Antiviral Drugs   
Cidofovir before ACT 6 5 
Cidofovir after ACT 3 NA 
Time of 1st positive ADV PCR in 
blood [days post HSCT] 
(median, range) 
12 (2-89) 3 (2-36) 
Peak ADV load >20 million 11 million 
Site of local infection   
Stool 5 5 
Nasopharyngeal Aspirate 2 3 
Urine 1 0 
Outcome   
Alive 4/6 3/8 
Abbreviations: ALL = Acute Lymphoblastic Leukaemia; HLH = Haemophagocytic 
Lymphohistiocytosis; AML = Acute Myeloid Leukaemia; ALD = Adrenal Leukodystrophy; XIAP = 
X-linked inhibitor of Apotosis Protein; SAA = Severe Aplastic Anaemia; MUD = Matched 
unrelated donor; MMUD = Mismatched unrelated donor; Haplo = haploidentical; MMFD = 
Mismatched family donor; BM = bone marrow; PBSC = peripheral blood stem cell; ACT = 
advanced cell therapy 
 
2.8.2  Patients who were eligible to enter ASPIRE but not registered and 
developed ADV reactivation/infection during transplant 
During the trial period 26 patients (Figure 2.7) were eligible to enter the study 
but for a number of reasons were not registered. These reasons included 1) 
missed consent 2) overseas bone marrow donor (the approval to process bone 
marrow harvest as starting material came later for the German registry. 
Approval not gained for NMDP registry) 3) A German donor center not 
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registered with the study 4) non-response from registry 4) lab closure 5) donor 
declined consent. Out of these 26 eligible patients, 7 patients developed 
adenoviraemia post-transplant; 4 patients died, with ADV a contributing cause in 
all cases. The clinical details of each of these patients are as follows: 
 
Patient KD – KD was an 11 year old boy with Chediak-Higashi Syndrome and 
Haemophagocytic Lymphohistiocytosis who underwent a 9/10 (1C) mismatched 
unrelated donor stem cell transplant with CD34 selection and CD3 add-back. 
Conditioning with carried out with Fludarabine (30mg/m2 x5 Days -7 to -3), 
Melphalan (140mg/m2 Day -2) and Alemtuzumab (0.2mg/kg x5 Days -8 to -4); 
with Ciclosporin and Mycophenolate Mofetil (MMF) as GvHD prophylaxis. He 
was not registered on the ASPIRE study because the NMDP donor center was 
not registered with the study. He developed adenoviraemia on D+75 at 1,210 
copies/mL which quickly rose to 216,020 copies/mL on D+82. Treatment with 
Cidofovir was started and adenoviral load in the blood became non-detectable 
from D+140. This also co-incided with immune reconstitution with CD4 count 
rising to 0.13x109/L on D+140 and steadily rising since. 
 
Patient RL – RL was a 9 month old boy who presented at the age of 4 months 
old with M5 Acute Myeloid Leukaemia with a high risk MLL rearrangement 
t(10:11). He received chemotherapy and underwent a fully-matched 10/10 
unrelated donor bone marrow transplant for high risk AML in second 
morphological remission. Conditioning was carried out with Busulfan (targeted 
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AUC <70mg/Lhr), Cyclophosphamide (60mg/kg x2 Days -3,-2), melphalan 
(140mg/m2 Day -1), and Alemtuzumab (0.2mg/kg x5 Days -7 to -3). Cyclosporin 
A was used as GvHD prophylaxis. He was not registered on the ASPIRE study 
as the donor was from a German registry and donating bone marrow, and the 
required approvals were not yet in place to receive and process peripheral 
blood sample necessary for manufacturing of CTLs (Cytovir ADV) from 
overseas donor. RL developed adenoviraemia early in the post-transplant 
period with viral load of 5,000 copies/mL on D+15 and quickly progressed to >2 
million copies/mL on D+22. The viral load remained persistently high. And 
although he achieved 100% donor chimerism on D+28, he had no donor T cell 
recovery with lymphocyte count steadfastly remaining zero. RL also developed 
high level and persistent CMV viraemia despite treatments with foscarnet, 
ganciclovir, and cidofovir for his adenoviraemia. On D+43 RL developed oxygen 
dependence requiring up to 2L via nasal cannulae along with interstitial 
changes on CXR suggestive of viral pneumonitis. Adenovirus was detected in 
nasopharyngeal aspirates from D+28 onwards. Adenoviral load in blood 
reached a peak of 15 million copies/mL on D+89. In addition, a bone marrow 
investigation on D+90 revealed frank relapse with 70% blasts. He also 
developed hepatitis with raised liver enzymes and bilirubin, thought most likely 
secondary to adenoviral and/or CMV infection. Child was eventually taken to a 
hospice for end of life care and died shortly after. 
 
Patient AW – AW was an 8 year old girl who received a mismatched (9/10 
1DQ) unrelated donor peripheral blood stem cell transplant for relapsed Acute 
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Lymphoid Leukaemia. Conditioning was carried out with Total body irradiation 
(200 cGYx2# Days -8 to -6), Etoposide (60mg/kg D-3) and Anti-thymocyte 
Globulin (ATG; 20mg/kg Days -2,-1). GvHD prophylaxis was undertaken with 
ciclosporin and methotrexate. AW was not registered on the ASPIRE study as 
opportunity to take consent from the donor was missed. Full donor chimerism 
was achieved on D+25. AW developed adenoviraemia on D+50 initially at low 
level of 571 copies/mL but rising to 823,541 copies/mL on D+77. Treatment with 
Cidofovir was started. Adenoviral load peaked at 13 million copies/mL on D+85. 
Cidofovir treatment was continued until D+105 and adenovirus became 
undetectable in blood from D+133 onwards. This co-incided with reconstitution 
of CD4 count from zero to 0.15x109/L on D+133. AW has remained virus free 
since. 
 
Patient EH – EH was a 7 month-old boy who received a 12/12 fully matched 
unrelated donor peripheral blood stem cell transplant for hereditary multiple 
intestinal atresia. Conditioning was carried out with Treosulfan (12 g/m2 x3 Days 
-6 to -4), Fludarabine (30 mg/m2 x5 Days -6 to -2), and Alemtuzumab (0.2 
mg/kg x5 Days -8 to -4); and patient received Ciclosporin and Mycophenolate 
Mofetil as GvHD prophylaxis. EH was not registered on the ASPIRE study as 
opportunity to take consent from the donor was missed. He achieved full donor 
chimerism on D+18. Significant adenoviraemia was first detected on D+13 at 
1,542 copies/mL, with a maximum load of 7,213 copies/mL on D+20. He was 
not started on treatment with Cidofovir and had no signs of ADV infection. 
Adenovirus became non-detectable in blood from D+75 onwards with steady 
 141 
 
increase in CD4 count from D+75 at 0.80x109/L and increasingly steadily to 
0.85x109/L on D+354. Adenovirus was also detected in nasopharyngeal 
aspirates between D+4 to D+52; and detected at low levels in stool between 
D+3 and D+59. 
 
Patient BJ – BJ was a 2year 11month old boy with X-linked CGD who received 
a fully matched unrelated donor bone marrow transplant with reduced intensity 
conditioning. Conditioning regimen consisted of Busulphan (targeting 
cumulative AUC 45-65mg/L/hr), Fludarabine (30mg/m2 x6 Days -8 to -3), and 
Alemtuzumab (0.5 mg/kg total split over days -8 to -6). Patient received 
Ciclosporin and Mycophenolate Mofetil as GvHD prophylaxis. BJ was not 
registered on the ASPIRE study as the German donor center was not registered 
with the study at the time. He achieved full donor chimerism in peripheral blood 
on D+18 post transplant. Adenovirus was detected in the blood on D+56 at 
49,419 copies/mL and remained persistent with a peak level of 81 million 
copies/mL on D+270, despite treatment with Cidofovir (total of 13 doses). BJ 
also developed other complications including gut GvHD requiring heavy 
immunosuppressants including steroids, infliximab, basiliximab and tacrolimus. 
He also developed TMA and failed treatment with Eculizumab. He was later 
found to be heterozygous for the CFH c.3356A>G p.(Asp1119Gly) pathogenic 
mutation which most likely explained his post BMT thrombotic microangiopathy. 
He was also heterozygous for the C5 c.2654G>A polymorphism which is 
associated with a poor response to eculizumab. The highest CD4 count 
recorded during the post-transplant period was 0.12x109/L on D+209. After 
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much discussion with other specialist teams and centers, and with his parents, 
symptom care took over active management and child passed away D+275 
post transplant. 
 
Patient CD – CD was a 6 year old boy with relapsed Acute Lymphoid 
Leukaemia who received a fully matched unrelated donor peripheral blood stem 
cell transplant. Conditioning was undertaken with Total Body Irradiation (200 
cGy x 2# - Days -9 to -7), Etoposide (60mg/kg Day -4) and Anti-thymocyte 
globulin (20mg/kg x3 – Days -4 to -2). Patient received Ciclosporin and 
Mycophenolate Mofetil as GvHD prophylaxis. CD was not registered on the 
ASPIRE study due to lack of response from donor center regarding donor 
consent for the study. He achieved full donor chimerism in peripheral blood on 
D+24 post transplant. Adenovirus was first detected in the blood on D+13 at 
46,273 copies/mL. The viral load rose to 329,632 copies/mL on D+17 and 
treatment with Cidofovir was started. Eventually viral load decreased to <200 on 
D+194. Adenovirus was also detected in the stools from D+11. CD also 
developed EBV viraemia on D+39 starting at 60,872 copies/mL and quickly 
rising to 256,895 copies/mL 3 days later. Treatment with Rituximab was started. 
Despite being treated with a total of 7 doses of Rituximab, his EBV viral load 
remains elevated with image findings consistent with Lymphoproliferative 
Disease. CD’s post-transplant period was also complicated by the development 
of acute grade 4 gut and grade 3 skin GvHD requiring treatment with high dose 
steroids, infliximab, basilixumab, and mesenchymal stem cells. He was 
discharged home on D+186 post-transplant. He continued to be on 
 143 
 
immunosuppression for control of his GvHD. He was readmitted on D+552 with 
non-specific symptoms of lethargy and fatigue, and finding of palpable 
abdominal mass on examination. This was later confirmed to be monomorphic 
Post Transplant Lymphoproliferative Disease on biopsy. He was started on 
treatment with methylprednisolone 60mg/m2 according to COP protocol, 
cyclophosphamide 300 mg/m2, Vincristine 1mg/m2 and Rituximab 375 mg/m2. 
Two days after the start of his chemotherapy he developed respiratory distress 
and required admission to PICU for intubation and ventilation. Adenovirus was 
detected in the blood on D+556 at 5,414 copies/mL quickly rising to 18,194 on 
D+559 with peak of 1,134,740 copies/mL on D+570. A bronchoalveolar lavage 
detected adenovirus with CT of 14. Treatment with Cidofovir was started but 
ADV load continued to rise. Because of the heavy immunosuppression he 
required immune reconstitution remained poor with only CD4 count of 0.04 x 
106/L by D+570. Sadly CD did not show any sign of clinical improvement 
despite maximal therapy and died D+575 post-transplant of ADV pneumonitis 
complicating EBV associated PTLD. 
 
Patient NR – NR was 7 year old girl with RAG 1 and 2 deficient SCID who 
received a 9/10 (1C) mismatched unrelated donor peripheral blood stem cell 
transplant. Reduced intensity conditioning was carried out with Fludarabine 
(30mg/m2 x5 Days -7 to -3), Melphalan (140mg/m2 Day -2) and Alemtuzumab 
(0.2mg/kg x5 Days -8 to -4). NR received Ciclosporin and Mycophenolate 
mofetil as GvHD prophylaxis. NR was not registered on the ASPIRE study as 
donor declined consent. NR developed 100% donor chimerism on D+21. 
 144 
 
Adenoviraemia was detected early post-transplant on D+5 at 6,716 copies/mL. 
The viral load quickly rose to 10,682,000 copies/mL on D+12; peaking and 
persisting at >20 million copies/mL (max detectable level by PCR in our lab). 
Taking into account a high risk of GvHD but acknowledging the severity of ADV 
reactivation, immunosuppression was weaned from day +13 onward. Treatment 
with weekly cidofovir was started on Day+11. NR also developed deranged liver 
function from D+21 with rising ALT, gammaGT and bilirubin most likely 
reflecting an ongoing ADV related hepatitis. NR also developed gastro-enteric 
bleeding likely reflecting ADV enteritis. NR further deteriorated on D+28 post-
transplant with deranged clotting, rising ALT and ascites. She developed signs 
of confusion, rising ammonia and sustained a sudden onset of seizures followed 
shortly after by hypoxic related cardiac arrest. CT scan of the head revealed an 
intracranial right parietal haematoma. Unfortunately NR’s condition did not 
stabilize on PICU and sadly passed away on day +29 after another severe 
hypotensive episode which caused irreversible cardio-vascular arrest. The 
cause of death was identified as liver failure as a consequence of Adenovirus 
hepatitis; in the context of severe immunosuppression 29 days after a 
mismatched unrelated stem transplant for RAG I/II deficient severe combined 
immunodeficiency. 
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Figure 2.9 Graphs of ADV viral load and CD4 count (where available) of patients who  
                  were eligible to enter study but did not get registered 
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CHAPTER 3  
EXPANSION OF ADV VIRUS SPECIFIC T-CELLS (VSTs) FROM HEALTHY 
VOLUNTEERS AND CHARACTERISATION OF THESE VSTs 
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3.1 EXPANSION OF ADV-SPECIFIC T-CELLS 
Objective: 
To generate ADV-specific T cells from 10 healthy volunteers using peripheral 
blood as starting material. 
Methods: 
The starting material is a voluntary donation of 50mL heparinised whole blood. 
Peripheral blood mononuclear cells (PBMCs) are derived from the starting 
material by Ficoll/Paque (Pharmacia, Uppsala, Sweden) density gradient 
separation and resuspended at a cell density of 106/mL in culture medium RPMI 
1640 (LifeTechnologies, New York, USA) supplemented with 10% human AB 
serum (Lonza, Walkersville, USA). A total of 2x107 PBMCs (20mL of cell 
suspension) are transferred to a cell expansion system (G-Rex 10, Wilson Wolf, 
New Brighton, USA) along with AdV5 Hexon PepTivator (Miltenyi Biotec, 
Bergisch Gladbach, Germany) (100ng/peptide) + rh IL4 (recombinant human 
Interleukin-4, CellGenix, Freiburg, Germany) (4μg) + rh IL7 (recombinant human 
interleukin-7, CellGenix, Freiburg, Germany) (0.2μg) and incubated at 37°C, 5% 
CO2 for total of 10 days. Remaining PBMCs are cryopreserved at 5x106 per vial 
in 10% DMSO and Human AB serum to be used as comparison in subsequent 
experiments. 
At the end of incubation period of 10 days, supernatant is collected on 5 of the 
donors and frozen down in 1mL vials at -80°C. ADV-specific T cells are collected 
in 50mL falcon tube and washed with RPMI 1640. After washing cells are 
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resuspended in suitable volume of RPMI/10% human AB serum and cell 
numbers counted. Cells are cryopreserved in at 5x106 in 1mL vial in RPMI/10% 
AB serum and 10% DMSO, and stored in liquid nitrogen tanks. 
Preparation of stock solutions: 
PepTivator-AdV5 Hexon - A stock solution of PepTivator-AdV5 Hexon of 
30nmol (approximately 50 μg) of each peptide per mL is prepared by dissolving 
6nmol PepTivator-ADV5 Hexon in 200μL of sterile water. 2μL of stock solution is 
added to each biopot to give 100ng/peptide per pot. 
Rh IL-4 – 50 μg freeze dried stock added to 250 μL sterile water to make stock 
solution of 200 μg/mL. 20μL of stock solution is added to 20mL cell culture to 
give final concentration of 0.2 μg /mL. 
Rh IL-7 – 50 μg freeze dried stock added to 200 μL sterile water to make stock 
solution of 250 μg/mL. To make a working solution of 10 μg/mL dilute 1:25 by 
adding 10 μL of stock solution to 240 μL sterile water. Add 20μL of working 
solution to 20mL of cell culture to give final concentration of 10 ng/mL. 
Results: 
Number of ADV-specific T cells per donor (starting from 20x106 PBMCs) 
Donor Expanded number of cells Fold increase  
Donor 1 54 x 106 1.7 
Donor 2 68 x 106 2.4 
Donor 3 32 x 106 0.6 
Donor 4 35 x 106 0.75 
Donor 5 45 x 106 1.25 
Donor 6 47.4 x 106 1.34 
Donor 7 55 x 106 1.75 
Donor 8 50 x 106 1.5 
Donor 9 55.2 x 106 1.76 
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Donor 10 77 x 106 2.85 
Median (SD) 52x106 (12.91) 1.6 (0.68) 
 
Figure 3.1 Cell count of ADV expanded cells for 10 donors 
 
 
Conclusion: 
 
ADV-specific T cells were expanded successfully from all 10 donors with a 
median final product of 52 x 106 , median fold increase is 1.6. 
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3.2  Th 1, 2, 17 PHENOTYPING ON EXPANDED ADV-SPECIFIC T-CELLS 
 
CD4+ T cell subsets have been identified based on their distinctive patterns of 
cytokine secretion. As a signature cytokine, Th1 cells selectively produce large 
amounts of IFN-γ. Th2 cells selectively produce Il-4, and Th17 express high 
levels of IL-17A. Through secretion of IFN-γ and other effector molecules, Th1 
cells activate macrophages, natural killer (NK) cells, and CD8+ T cells and are 
responsible for cell-mediated immunity. Th1 cells provide protection against 
intracellular bacteria, fungi, protozoa and viruses; and are involved in 
autoimmune responses. IL-4 produced by Th2 cells is involved in driving B cells 
to generate IgE-secreting cells which play a role in basophil/mast cell mediated 
immune reactions. Th2 cells mediate protection against extracellular parasites 
but also involved in allergic reactions. Through the secretion of Il-17A, Th17 
cells recruit and activate neutrophils and mediate immune responses against 
extracellular bacteria and fungi. Th17 cells are also implicated in autoimmune 
responses. 
 
Aim: 
To characterize cell phenotypes between unexpanded and ADV-expanded T 
cells; and to determine if one class of T helper cells are expanded at the 
expense of another.  
 
Method: 
A) Stimulation of cells 
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Using Th1/Th2/Th17 phenotyping kit (BD Biosciences, Oxford, UK) 
cryopreserved cells are thawed and stimulated at a concentration of 1 – 10 
million cells per ml in media (RPMI + 5% human serum) for 5 hours with 
PMA/Ionomycin (at 50 ng/mL and 1 μg/mL respectively) in the presence of BD 
GolgiStopTM Protein Transport Inhibitor. Cells are plated out in 6-well plates, 4 
μL of BD GolgiStop is added for every 6 mL of cell culture. 
 
B) Staining of cells 
1. Harvesting of cells 
- Collect cells from in vitro stimulatory cultures treated with a protein transport 
inhibitor. - Spin down cells at 250 x g for 10 minutes at room temperature and 
wash once with stain buffer (FBS) or phosphate-buffered saline (PBS). 
- Count cells and transfer approximately 1x106 cells to each flow test tube for 
immunofluorescent staining. Cells need to be protected from light throughout the 
staining procedure and storage. 
 
2. Fixing the cells 
- Suspend cells with 1mL of cold BD CytofixTM Fixation buffer and incubate for 
20 minutes at room temperature. 
- Spin down cells at 250 x g for 10 minutes at room temperature. Be careful not 
to disturb the loose cell pellet after centrifugation. Do not aspirate all of the 
buffer but leave 50-150µL of solution in the tubes to avoid cell loss for all 
subsequent wash steps below. 
- Wash cells once at room temperature in stain buffer (FBS) or PBS and spin 
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down the cells at 300 x g for 10 minutes at room temperature. 
- Cells can be stored in stain buffer (1mL per tube) at 4°C for up to 72 hours. 
 
3. Permeabilising the fixed cells 
- For cells kept at 4°C, spin down cells at 300 x g for 10mins at room 
temperature and remove stain buffer. 
- Dilute 10X BD Perm/WashTM buffer in distilled water to make a 1x solution prior 
to use.  
- Suspend cells in 1ml of 1x BD perm/WashTM buffer and incubate at room 
temperature for 15 minutes. 
- Spin down cells at 300 x g for 10 minutes at room temperature and remove 
supernatant. 
 
4. Staining with the Cocktail 
- Thoroughly suspend fixed/permeabilised cells in each tube in 50 µL of 1x BD 
Perm/WashTM buffer and add 20 µL of cocktail or appropriate negative control: 
Tube 1 – unstimulated cells unstained 
Tube 2 – APC alone 
Tube 3 – FITC alone 
Tube 4 – PE alone 
Tube 5 – PerCp Cy5.5 alone 
Tube 6 – Unstimulated 4 colour cocktail 
Tube 7 – Stimulated with iso antibody 
Tube 8 – Stimulated cells with 20µL 4 colour cocktail (CD4 PerCp-Cy5.5, IL-17A 
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PE, IFN-γ FITC, IL-4 APC) 
- Incubate with antibodies at room temperature for 30 mins in the dark. 
- Wash cells once with 3mL of 1x BD Perm/WashTM buffer at room temperature. 
- Suspend cells in PBS or stain buffer prior to analysis (400 µL for all tubes 
except for 4-colour cocktail tube – use 500 µL). 
 
C) Flow Cytometric Analysis 
- Cells are gated first on forward and size scatter to obtain lymphocyte 
population, then CD4+ cells. CD4 expression on T cells can decrease after 
activation. Acquire at least 20,000 to 30,000 CD4+ve lymphocytes. Flow 
cytometry was performed on a BDTM LSR II System. 
 
Figure 3.2 Gating strategy for Th1, 2,17 phenotyping analysis 
 
 
 
 
Reagents: 
 
PMA (Promega, Madison, USA) – 5mg reconstituted in 1.62 mL DMSO to 
produce a 5mM stock solution and stored in 10 μL  aliquots. Working solution 
produced by diluting stock solution 1:100 in sterile PBS. 5μL of PMA working 
solution is used per mL of cell culture to give final concentration of 50 ng/mL. 
 
IL4 IFNγ IL4 
IL-17 IL-17 IFNγ 
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Ionomycin (MP Biomedical, California, USA) – 1mg reconstituted in 400 μL 
DMSO to produce stock solution of 2.5mg/mL stock and stored in 40 μL aliquots. 
Working solution produced by diluting stock solution 1:25 in sterile PBS. 10μL of 
Ionomycin working solution is used per mL of cell culture to give final 
concentration of 1μg/mL. 
 
 
Results: 
 
The experiment was performed on cells from 6 donors. However the ADV 
expanded cells from all donors died after stimulation and incubation with 
PMA/Ionomycin cocktail.  
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Figure 3.3 Representative dot plot of Th1,2,17 phenotyping from one donor  
A) Unexpanded cells 
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CD-4 CD4+ cells: 43%  
(as percentage of CD4+ cells)  - Th1 (IFNγ) cells: (14.5+2.05+11.5+4.62)% / 2 = 16.34% => 7.03% 
                          - Th2 (IL4) cells: (8.95+1.55+5.87+4.62)% / 2 = 10.5% => 4.52% 
     - Th17 (IL17A) cells: (4.15+1.55+2.25+2.05)% / 2 = 5% => 2.15% 
CD4 IL-4 IFNg IL-4 
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B) ADV expanded cells 
Unfortunately ADV expanded cells died after stimulation with PMA and 
Ionomycin cocktail and no results could be obtained. 
 
Conclusion: 
 
As the ADV expanded cells died after stimulation, conclusion cannot be drawn. 
 
3.3 CHARACTERISATION OF REGULATORY T-CELLS (Tregs) by FoxP3 
STAINING 
FoxP3, a 49-55 kDa protein, is a member of the forkhead/winged-helix family of 
transcriptional regulators, and was identified as the gene defective in ‘scurfy’ (sf) 
mice. Constitutive high expression of FoxP3 mRNA has been shown in 
CD4+Cd25+ regulatory T cells (Treg cells), and ectopic expression of FoxP3 in 
CD4+CD25- cells imparts a Treg phenotype in these cells. The 236A/E7 
antibody reacts with human FoxP3 protein. 
 
Aim: 
To determine if there is regulatory T cells outgrowth in ADV expanded product. 
 
Methods:  
- The FoxP3 staining kit from eBiosceince (San Diego, USA) was used.   
- Thaw out cryopreserved ADV CTLs and unexpanded PBMCs in RPMI/10% 
HAS and count cells.  
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- Resuspend 1x106 cells in PBS and surface stain for CD4 (PerCP-CY5.5), 
CD25 (PE), and CD127 (FITC).  
- Add cold PBS into each FACs tube so that max volume is 200 µL each. 
- Wash cells at 1500rpm for 7 min. 
- Tip off supernatant and resuspend cell pellet in 1mL of freshly prepared 
Fixation/Permeabilisation solution; and mix well. 
- Incubate at 4 °C for 60 minutes in the dark. 
- Wash once by adding 2mL 1x Perm buffer then spin 350 x g for 5 min at 4°C. 
Tip off supernatant. 
- Block with 2% normal rat or mouse serum in 1x Perm buffer (20 µL serum in 
1mL buffer). Add 100µL into each FACs tube. 
- Incubate at 4°C in the dark for 15 minutes. 
- Without washing after blocking step add 20µL fluorochome conjugated anti-
human FoxP3 antibody or isotype control in 1x Perm Buffer and incubate at 4°C 
for at least 30 minutes in the dark. 
- Wash cells with 2mL 1x permeabilisation buffer. Spin at 350 x g for 5 minutes. 
- Repeat above step. 
- Resuspend in 500 µL Flow Cytometry staining Buffer or PBS and analyse by 
flow cytometry on BDTM LSR II System. Acquire at least 50,000 lymphocytes and 
at least 5000 CD4+CD2+CD127low cells. 
 
Reagents: 
 
1. FoxP3 staining Buffer set eBioscience (cat 17-4777) 
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2. Antibodies: 
 -CD4 PerCp Cy5.5 (BD Pharmingen cat 560650) 
 -CD25 PE (BD Pharmingen cat 555432) 
 -CD127 FITC (eBioscience cat 11-1278-73) 
 -FoxP3 APC (clone 236A/E7 eBioscience cat 17-4777) 
 
Preparing solutions: 
 
1. Dilute Fixation/permeabilisation concentrate (1 part) into the 
Fixation/Permeabilisation Diluent (3 parts). 
 
2. Permeabilisation buffer 10x stock dilute to 1x with DI water. 
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Results: 
Figure 3.4 Representative plot of FoxP3 phenotyping from one donor 
Unexpanded 
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Results from all donors 
 
Donor 
CD4+CD25+CD127lowFoxP3+ (%) 
Unexpanded T cells ADV expanded T cells 
1 0.9 0.4 
2 0.9 0.3 
3 1.6 0.3 
4 1.3 0.1 
5 6.4 0.9 
6 2 0.8 
7 1 0.4 
8 2.4 0.7 
9 0.4 0.3 
10 0.2 0.5 
 
Figure 3.5 Proportion of Regulatory T cells (CD4+CD25+CD127lowFoxP3+) in all 
donors 
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Conclusion: 
 
There is no outgrowth of regulatory T cells in ADV expanded T cells. 
 
 
3.4 CHARACTERISATION OF T-CELL SUBPOPULATIONS 
Aim:  
 
To characterise the T cell subpopulations in the virus-expanded cells compared 
to unexpanded T cells, in particular T memory stem cell population. 
 
Methods: 
 
Cryopreserved unexpanded T cells and ADV specific T cells from 8 donors were 
thawed in RPMI/10% HAS. Cells were washed, counted and resuspended in 
phosphate-buffered saline (PBS; Invitrogen Paisley, UK) and incubated for 10 
min at room temperature with saturating amounts of antibody (5 μL), then 
washed and resuspended in PBS before going through flow cytometric analysis 
on Becton Dickinson LSRII using BD FACSDIVA software. Cells were stained 
for CD4 (PerCP-Cy5.5), CD8 (PE), CD45RA (PE Cy7), CCR7 (Alexa Flour 647), 
CD62L (FITC), CD27 (Violet 525), CD95 (Violet 450). 
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Results: 
 
Figure 3.6 Representative dot plot of T cell phenotyping from one donor 
 Unexpanded 
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ADV expanded 
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Figure 3.7 Proportion of Tscm (CD4+ and CD8+) in unexpanded vs ADV 
expanded cells 
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Conclusion: 
There is a general trend for decrease in proportion of cells expressing stem cell 
memory markers (CD45RA+CD27+CD62L+CD95+) in the ADV-expanded T 
cells compared to unexpanded cells. 
 
3.5 DIVERSITY OF T-CELL RESPONSES 
 
Aim: 
 
To assess diversity of T cell responses of ADV specific T cells by spectratyping 
by PCR. 
 
Method: 
 
CDR3 TCR molecular spectratyping was performed for unexpanded and ADV-
expanded T cells. Template cDNA corresponding to rearranged transcripts with 
different CDR3 lengths from specific TCR variable region genes was amplified 
by PCR and the products run on AB3130 Genetic Analyzer (Applied 
Biosystems) and analyzed with SpA Web-based software. This was performed 
by Dr Stuart Adam at Bone Marrow Lab, Camellia Botnar Laboratories, Great 
Ormond Street Hospital.  
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Results: 
 
Representative result from one donor showing normal spectratype in 
unexpanded cells compared to the skewed spectratype with some clonal 
expansions in the ADV expanded cells. 
 
Figure 3.8 Representative spectratyping plot from one donor (unexpanded vs 
ADV  
                  expanded cells) 
 
 
 
Conclusion: 
As expected the ADV expanded cells showed antigen-driven oligoclonal T cell 
expansions in response to ADV stimulation.  
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3.6 SPECIFIC CYTOKINE (IFNγ) PRODUCTION BY ADV-SPECIFIC T-CELLS 
 
Aim:  
 
To confirm that expanded CD8+ and CD4+ T cells are antigen specific and 
produce effector cytokines (IFN-γ) upon stimulation. 
 
Method: 
 
Antigen-specific T cells are analysed using the IFN-γ secretion Assay (Miltenyi 
Biotec, Bergisch Gladbach, Germany) starting from thawed cryopreserved 
PBMCs. Cells were plated at density of 5x106 /cm2 to ensure optimum 
stimulation. 
Total cell number (cell 
number after 
suspension) 
Medium volume to add 
per well 
Culture plate Well diameter 
0.15x107 0.15mL 96 0.64cm 
0.50x107 0.50mL 48 1.13cm 
1.00x107 1.00mL 24 1.6cm 
2.00x107 2.00mL 12 2.26cm 
5.00x107 5.00mL 6 3.5cm 
 
Cells were stimulated for 4 hours with AdV5 Hexon PepTivator (Miltenyi Biotec), 
Staphylococcal enterotoxin B (Sigma-Aldrich, Dorset, UK) as positive control, or 
unstimulated as negative control; and incubated at 37ᵒC, 5-7% CO2, in moist 
chamber. 
 
After incubation an IFN-γ specific Catch Reagent was attached to the cell 
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surface of leukocytes. The cells were then incubated for a short time at 37ᵒC to 
allow cytokine secretion. The secreted IFN-γ binds to the IFN-γ Catch Reagent 
on the positive, secreting cells. These cells were subsequently labelled with a 
second IFN-γ-specific antibody, the IFN-γ Detection Antibody conjugated to R-
phycoerythrin (PE) for sensitive detection by flow cytometry. Non-specific 
background was minimised by dead cell exclusion staining with DAPI viability 
dye just before flow cytometry analysis and gating on viable cells.  
Statistical analysis by paired T test. 
 
Reagents: 
 
SEB – 1mg powder reconstituted in 1mL sterile water for injection to make stock 
solution of 1mg/mL. Concentration used - 10μg/mL (1μL per test). 
 
Results: 
Representative plot from one donor (PE = IFNγ, APC = CD4, FITC = CD8). 
Gated on lymphocytes (forward/side scatter) and Live cells (using DAPI 
antibody). 
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Figure 3.9 Representative IFNγ plot for ADV specificity (unexpanded vs ADV  
                  expanded) 
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Results from all donors 
 Unexpanded Expanded (fold increase from 
unexpanded) 
Donor CD4+ CD8+ CD4+ CD8+ 
1 0.25 0.22 16.2 (64.8) 3.78 (17.2) 
2 0.04 0.16 10.8 (270) 0.98 (6.1) 
3 0.11 1.02 23.1 (210) 5.45 (5.3) 
4 1.62 1.22 2.77 (1.7) 1.94 (1.6) 
5 0.06 0.03 8.91 (148.5) 1.11 (37) 
6 0.02 0.05 0.47 (23.5) 0.05 (1) 
7 0.03 0.06 17.8 (593) 7.22 (120.3) 
8 0.19 0.61 1.75 (9.2) 0.37 (0.6) 
9 0 0 10.1 (10.1)  2.36( 2.36) 
Fold increase 
(average) 
   147.9 
SD: 193.3 
P<0.02 
21.3 
SD: 38.95 
p<0.1 
 
 
Conclusion: 
Both CD4+ and CD8+ T cells in the expanded cell line were antigen-specific and 
produced effector cytokines (IFNγ) at a much higher level compared to 
unexpanded T cells.  
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3.7 BYSTANDER ACTIVATION BY CFSE PROLIFERATION 
Aim:  
To determine if ADV specific T cells can cause bystander activation and 
contribute to inflammatory complications in immunotherapy. 
 
Methods: 
Fresh PBMCs are obtained from the original donor and labeled with CFSE using 
CellTrace CFSE Cell Proliferation Kit (Life Technologies, Paisley, UK). 
Peripheral blood mononuclear cells (PBMCs) are derived from fresh blood by 
Ficoll/Paque (Pharmacia, Uppsala, Sweden) density gradient separation and 
resuspended at a cell density of 1x106 cells/mL in culture medium X-vivo 10 
(Lonza, Basel, Switzerland) supplemented with 10% human AB serum (Lonza, 
Walkersville, USA).  
 
CFSE was dissolved in DMSO to a stock concentration of 5 mM and stored in 
single aliquots at -20°C.  2μL of 5mM stock CFSE solution is added to each 
millilitre of cells for a final working concentration of 10 μM. After thorough mixing, 
the cell suspension was incubated at 37°C for 10 mins. The labeling reaction 
was then quenched with addition of 5 volumes of ice-cold culture media to the 
cells, and the mixture was centrifuged at 1500 rpm for 5 min. CFSE-labeled 
PBMC were then plated out at 1x105 in 96-well round bottom plate in different 
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conditions: 1) culture medium alone as negative control; 2) CD3/28 beads (1:1 
ratio i.e. 2μL of 108 in 1mL) and IL2 (200u/mL) as positive control; 3) ADV 
expanded cells (from the same donor, 1x105 ); 4) ADV expanded cells + OKT3 
(10μg/mL); 5) supernatant collected at the end of incubation period from ADV 
expanded T cells; 6) supernatant + OKT3 (10μg/mL). Cells were incubated at 
37°C, 5% CO2 for 4 days; after which cells were harvested and resuspended in 
PBS and analysed on LSRII flow cytometer using FACSDIVA software (Becton 
Dickinson). 
Supernatant was not collected from donors 1, 2 and 4. 
Statistical analysis by paired T test.
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Results: 
Figure 3.10 Representative CFSE proliferation result from one donor 
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Results from all donors 
Percentage of proliferation (above baseline [CM]) 
Donor CM CD3/28 
beads+IL2 
ADV CTLs 
(fold increase 
above 
baseline) 
ADV 
CTLs+OKT3 
Supernatant 
(fold increase 
above 
baseline) 
Supern
atant 
+OKT3 
1 3.38 26.92 81.62 (24) 84.12 - - 
2 6.98 9.22 31.72 (4.5) 65.32 - - 
4 0.89 55.21 20.61 (23.2) 58.31 - - 
5 1.6 81.7 47.4 (29.6) 83.6 1.62 (1) - 
6 0.85 75.95 31.75 (4.4) 33.15 1.11 (1.3) 1.15 
7 0.19 71.71 22.81 (120) 48.01 0.04        
(0.2) 
23.41 
8 0.46 81.44 23.84 (51.8) 26.54 0.05 (0.1) 5.44 
9 1.09 90.41 30.01 (27.5) 48.81 1.67 (1.5) 0.57 
10 0.45 90.75 49.15 (2.2) 76.95 0.66 (1.5) 0.33 
Fold 
increas
e from 
baselin
e 
(averag
e) 
  31.9 
SD: 36.59 
P<0.01 
 0.9 
SD: 0.63 
P<0.002 
 
 
Conclusion: 
ADV CTLs were able to induce proliferation of fresh PBMCs but not 
supernatant collected from culture of ADV CTLs. This suggests proliferation 
by cell-to-cell contact rather than cytokine induced proliferation.  
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3.8 CYTOKINE PROFILE 
 
Aim: 
To determine cytokine profile in supernatant of ADV expanded T cells by 
sandwich immunoassays. 
 
Methods: 
Using MSD Multi-spot Assay system (Rockville, USA), 5 cytokines were 
measured using two different panels -  
Proinflammatory panel 1: IFNγ, IL2, TNF-a 
Cytokine panel 1: Il7, IL15 
A plate precoated with capture antibodies on independent and well-defined 
spots is provided for each panel. Supernatant of ADV expanded T cells were 
collected from six donors and each sample was run in duplicates and 2 different 
dilutions: 
6 donors x 2 samples = 12 wells x duplicate = 24 wells 
1. 2-fold dilution 30microL sample + 30 microL diluent 
2. 5-fold dilution 20microL sample + 80 microL diluent 
Calibrator dilutions were prepared as follows: 
- 1000microL of Diluent 2 to lyophilized calibrator vial (Pro); diluent 43 (cyto). 
- 300microL of diluent in 7 ependorfs 
- 100microL into above 
Samples were diluted with diluent in 2- and 5-fold, and 50microL of sample, 
calibrator and control are added to plates precoated with capture antibodies, 
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sealed and incubated at room temperature with shaking for 2 hours. Plates 
were then washed 3 times and read on MSD instrument.  
 
Results: 
 
Donor IFNγ (pg/mL 
5x dilution) 
IL2 (pg/mL  
2x dilution) 
TNF-a 
(pg/mL 5x 
dilution) 
IL7 (pg/mL  
5x dilution) 
IL15 (pg/mL 
2x dilution) 
D1 1800 0.07 36.98 162 1.3 
D2 4555 0.22 23.95 269 1.25 
D3 5196 0.3 76.04 1498 1.68 
D4 2938 0 37.77 237 1.44 
D5 2657 0.29 22.45 309 2.89 
D6 10495 0.15 27.44 315 1.04 
D7 5033 0.16 41.04 503 1.8 
Median  4555 0.16 37 309 1.44 
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Figure 3.11 Individual graphs for cytokine profiling (x-axis = donor; y-axis =  
                    cytokine level) 
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Figure 3.12 Combined graphs of cytokine production for each donor 
 
 
Conclusion: 
Supernatant of ADV-activated T cells contained mostly IFNγ and TNFα 
but not the other Th1 cytokine – IL2. IL7 is also present in high amounts 
as it is used in the culture along with IL4.  
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CHAPTER 4 
DISCUSSION 
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Since the start of the ASPIRE trial in Quarter 1 2013 at Great Ormond Street 
Hospital, 6 patients have been treated pre-emptively with donor-derived ADV-
specific CTLs (Cytovir ADV) for the treatment of adenoviraemia. All treated 
patients have experienced a reduction in ADV viral load in the blood. Serious 
adverse events were recorded in 3 patients. One patient died of astrovirus 
encephalitis and death was not deemed related to Cytovir ADV. One patient 
developed severe GvHD around 60 days after cell infusion and subsequently 
died 2 years later of infectious complications. One patient developed acute 
pancreatitis 9 days after cell infusion after experiencing a drop in ADV viral load 
in blood. The occurrence of pancreatitis co-incided with a rebound in ADV viral 
load; and patient made a full recovery. 
The other three treated patients did not experience any serious adverse events 
at 6 months follow-up from cell infusion and were able to demonstrate in-vivo 
ADV specific response by ELIspot or IFNγ cytokine release assay. 
Whether the reduction in viral load was due to endogenous reconstitution of 
immunity, effect of donor-derived CTLs or effect of antivirals cannot be 
ascertained. Unlike CMV immunity, ADV specific T cells tend to appear only 
during acute infection and tend not to be detected when disease is quiescent. 
The frequency of T cells reactive with adenoviral hexon epitope is usually many 
times lower than frequency of CMV reactive T cells (Leen et al., 2006). Also 
many patients were lymphopaenic at time of evaluation making flow cytometry 
assessment difficult. This is also a heterogeneous group of patients with both 
haematological as well as non-malignant genetic diseases as their underlying 
condition. Although all patients on the study received serotherapy, individual 
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conditioning regiments varied. This makes drawing any significant conclusion 
difficult. 
However it can be argued that the outcome of a contemporaneous group of 
patients who developed adenoviraemia and did not receive Cytovir ADV was 
worse. Of the 21 patients who became viraemic during the trial period, 15 
patients did not receive Cytovir ADV (7 patients were not registered on the study 
and did not have products made; 8 patients were registered but not eligible to 
receive Cytovir ADV at the time of reactivation). Of these 15 patients, mortality 
rate was 60% (n=9); compared to 33% (n=2) in the group of 6 patients who 
received Cytovir ADV. Of the 9 viraemic patients who died and did not receive 
ADV-specific CTLs, 6 had high adenoviral load in blood at the time of death that 
could have been contributory to their demise. It could be argued that in some 
patients where adenovirus was already causing significant disease, that 
administration with adenovirus CTLs would not have made a difference to the 
eventual outcome. However, in some patients, there was a window in which 
adenoviraemia was present but before virus had opportunity to cause significant 
organ damage. It is perhaps in these patients that treatment with ADV CTLs 
could have controlled viraemia and allowed more time for immune reconstitution 
to take place, thereby bringing about a more favourable clinical outcome. 
The next section will examine different aspects of T-cell immunotherapy for the 
treatment of viral infections post HSCT. 
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REGULATORY T CELLS (Tregs) 
Regulatory T cells (Tregs) encompass several distinct phenotypes of immune 
system cells (Maizels and Smith, 2011) that are suppressive in nature and 
regulate responses towards tumour, foreign and allo-antigens that constitutively 
express CD25 (Fehervari and Sakaguchi, 2004b; Sakaguchi, 2004). They have 
an important role during immune homeostasis through the maintenance of 
immune tolerance and prevention of inflammatory disease (Hori et al., 2003). 
Treg cells are essential for the tolerance of commensal microbiota in the gut, but 
an excessive Treg cell response may facilitate tumor growth and chronic 
infection by limiting anti-tumor or anti-pathogenic immune responses (Gao et al., 
2012; Workman et al., 2009). Tregs constitutively express a variety of molecular 
markers, most significantly CD25 (IL-2Rα chain), CD62L, CD103, CD152 
(CTLA4 – a molecule classically only expressed after T cell activation) and GITR 
(glucocorticoid-induced TNF receptor family-related protein, also known as 
TNFRSF18). None of these markers are uniquely associated with Tregs as they 
can also be upregulated upon activation of conventional T cells (Fehervari and 
Sakaguchi, 2004a; Fehervari and Sakaguchi, 2004b). However, the isolation of 
T cells that constitutively express CD25 has become a very useful functional 
definition for Treg cells and it is widely known that this population of cells is 
important in the maintenance of self-tolerance and control of immune response, 
as depletion of CD25+CD4+ cells induce autoimmunity or enhancement of 
immunity (Sakaguchi et al., 2001). Subsequent work had concentrated on 
finding molecular markers that are unique to this T cell lineage and breakthrough 
came about with studies on the Scurfy (sf) mutant mouse model. The Scurfy 
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mouse exhibits a fatal X-linked lymphoproliferative disease that is mediated by 
highly activated CD4+ T cells (Godfrey et al., 1991; Lyon et al., 1990). The sf 
mutation was subsequently mapped to a novel forkhead/winged-helix family 
transcriptional repressor termed Foxp3, which encodes the protein scurfin 
(Godfrey et al., 1991). A 2-bp frameshift insertion in the X chromosome gene 
Foxp3 results in a truncated gene product lacking the C-terminal forkhead 
domain. Male mice hemizygous for the X-linked Foxp3sf mutation succumb to a 
CD4+ T cell-mediated, lymphoproliferative disease characterised by wasting and 
multi-organ lymphocytic infiltrates (Fontenot et al., 2003; Lyon et al., 1990). 
Similarly multiple mutations have been identified in the human orthologue, 
FOXP3, as the underlying cause of the aggressive autoimmune syndrome IPEX 
(for Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked 
syndrome) (Bennett et al., 2001; Wildin et al., 2002). This finding led several 
independent groups to demonstrate that Foxp3 mRNA and the encoded protein 
were specifically expressed only in naturally arising CD25+CD4+ Treg cells and 
were never observed in normal T cells even after activation (Fehervari and 
Sakaguchi, 2004b; Fontenot et al., 2003; Hori et al., 2003). Fontenot and 
colleagues (Fontenot et al., 2003) demonstrated that retroviral-driven Foxp3 
expression in CD4+CD25- T cells resulted in complete protection from wasting 
disease with accompanying colitis and inhibition of homeostatic proliferation of 
CD8+ T cells. These observations led to the conclusion that Foxp3 plays a role 
in the development and function of Tregs and is also used as a phenotypic 
marker of Tregs (Fontenot et al., 2003; Fontenot et al., 2005; Fontenot and 
Rudensky, 2005). In addition to Foxp3-expressing Tregs are other functional 
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regulatory cells, which may produce IL-10 (termed Tr1) and IL-35 (Tr35) 
(Collison et al., 2010). The definition of the Tr1 subset is relatively fluid as IL-10 
can also be produced by both Th1 (IFNγ+) and Th2 (IL-4+) effectors (Jankovic 
et al., 2007). T cells producing TGF-β can also act in a regulatory capacity. And 
while Tregs are generally found to be CD4+, CD8+ T cells can also express 
Foxp3 and produce the same suppressive cytokines (Maizels and Smith, 2011; 
Nakagawa et al., 2010) 
Tregs are generated during the normal course of T cell development in the 
thymus and are termed thymic or natural (n)Tregs, but may also develop in the 
periphery in certain situations and are termed induced (i)Tregs (Shevach, 2011). 
Thymic Tregs are a CD4+CD25+Foxp3+ phenotype, and deficiency of these 
cells results in fatal autoimmune inflammation; this subset remains committed to 
this function over time (Maizels and Smith, 2011; Rubtsov et al., 2010). Naïve T 
cells differentiate into iTreg cells in the presence of IL-2, transforming growth 
factor (TGF)-β and stimulation through the T-cell receptor (TcR) (Chen et al., 
2003; Gao et al., 2012). TGF-β is also required for IL-6-dependent expression of 
the transcription factor RORγt and inhibition of FOXP3 expression during the 
generation of Th17 cells from naive T cells (Gao et al., 2012; Mangan et al., 
2006). Induced Tregs can convert from CD4+Foxp3- to CD4+Foxp3+, 
expanding the range of Treg specificities to exogenous antigens. However, 
iTregs are not irrevocably programmed and may revert to an effector phenotype, 
losing expression of CD25 and Foxp3 under certain situations (Maizels and 
Smith, 2011). In the peripheral Treg cell pool there are three further 
classifications: ‘central’, ‘effector’ and ‘tissue-resident’. Central Treg cells 
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constitute the majority of Treg cells in the circulation and secondary lymphoid 
organs. They express CC-chemokine receptor 7 (CCR7) and the adhesion 
receptor CD62L (also known as L-selectin), which direct their recirculation 
through lymphoid tissues. Effector Treg cells make up a minor fraction of Treg 
cells in the circulation and secondary lymphoid organs. They share phenotypic 
features with activated conventional T cells and are variously defined as 
CD62LlowCCR7lowCD44hiKLRG1+ (killer cell lectin-like receptor subfamily G 
member 1-positive) CD103+. Tissue-resident Treg cells are those that have 
long-term residence in non-lymphoid tissues, as opposed to the short-term 
migration through non-lymphoid tissues observed by effector Treg cells. 
Currently, the best examples of tissue-resident Treg cells are adipose tissue 
Treg cells, which are marked by the expression of peroxisome proliferator-
activated receptor-γ, and gut-resident Treg cells, which are marked by free fatty 
acid receptor 2 expression (Liston and Gray, 2014). Additional characteristics 
differentiate central and effector Tregs. Central Tregs are predominantly found in 
the T-cell zones within the spleen, whereas effector Tregs localise to the 
marginal zone, red pulp, and B-cell follicle within the spleen. Distinct signals 
required for their homeostasis and survival also differ: central Tregs depend on 
IL-2R signalling, whereas effector Tregs require ligation through the co-
stimulatory molecule inducible T cell co-stimulator (ICOS) (Rothstein and 
Camirand, 2015; Smigiel et al., 2014). Central Tregs arise in the thymus and 
serve as a longer-lived pool of recirculating Tregs in secondary lymphoid 
organs. They become effector Tregs upon activation which are required for the 
maintenance of self-tolerance in nonlymphoid tissues, as well as in secondary 
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lymphoid organs (Rothstein and Camirand, 2015). The transcription factor 
interferon regulatory factor 4 (IRF4) appears to be a key regulator in effector 
Treg differentiation. It also promotes the expression of B lymphocyte-induced 
maturation protein-1 (BLIMP1) in effector Tregs, which is required for their 
function (Cretney et al., 2011).  
CD4+ CD25high T-cell subset represents only 1-2% of circulating CD4+ T cells in 
humans (compared to situation in rodents where 6-10% of splenic CD4+ T cells 
demonstrate regulatory function). Upon TCR cross-linking, CD4+CD25high cells 
are anergic and totally inhibit the proliferation and cytokine secretion by 
activated CD4+CD25- responder T cells in a contact-dependent manner 
(Baecher-Allan and Hafler, 2005).  
* Tregs and infections 
Recent work has shed more light into the role of Tregs in response to both acute 
and chronic infections (Boer et al., 2015; Maizels and Smith, 2011; Richert-
Spuhler and Lund, 2015; Sanchez et al., 2012). Tregs are induced by a wide 
range of pathogens and can exert distinct effects for different pathogens and in 
different stages of infection. They may potentiate effector response by assisting 
in recruitment of T cells to the infection site to resolve infection, facilitate 
accelerated antigen-specific memory responses, limit pathology, and contribute 
to disease resolution and healing (Richert-Spuhler and Lund, 2015). On the 
other hand they may also facilitate chronic pathogen persistence by reducing 
effector immunity and clearance of infection (Boer et al., 2015).   
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Tregs utilise several mechanisms to suppress pro-inflammatory cells. These 
include secretion or generation of inhibitory soluble factors (e.g. TGF-β, IL-10, 
IL-35, and adenosine), modulation of antigen-presenting cells (APCs) and 
activity of certain Treg membrane expressed molecules (such as cytotoxic T-
lymphocyte-associated antigen 4 – CTLA-4), direct killing of targets (through 
granzyme A/B), or deprivation of IL-2 or the amino acid tryptophan (through high 
IL-2R or the amino acid tryptophan (through high IL-2R expression or induction 
of indoleamine 2,3-dioxygenase in dendritic cells, respectively) (Boer et al., 
2015; Rothstein and Camirand, 2015). Several Treg-expressed molecular 
markers have now been implicated directly in mediating suppression, such as 
CTLA-4, which modulates APCs via its ligands CD80 and CD86. Typically, APC 
at sites of infection upregulate CD80 and CD86 in response to signalling by TLR 
or other microbial pattern recognition receptors. As a result, APC increase both 
in number and level of costimulatory molecule expression, resulting in the 
initiation of T cell responses in a CD28-dependent manner. The inhibitory 
receptor CTLA-4 shares the same ligands with CD28 but opposes T cell 
responses via a cell-extrinsic pathway; it influences the cells around it rather 
than the cells expressing it (Walker and Sansom, 2011) (Hou et al., 2015). Tregs 
expressing CTLA-4 capture CD80 and CD86 ligands from APC via trans-
endocytosis and degrade them intracellularly, thereby relatively depleting the 
APC’s expression of essential co-stimulatory receptors for T-cell CD28 ligation 
(Qureshi et al., 2011). In addition, the ecto-enzyme CD39 (E-NTPDase1), a 
relatively newly discovered Treg marker, exerts its suppressive effects through 
breakdown of adenosine triphosphate (ATP) (Boer et al., 2015). It is now 
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apparent that in response to environmental cues, Treg responses adapt to the 
type of immune response [i.e. T helper 1 (Th1), Th2, Th17, and T follicular 
helper cell (Tfh)]. This allows Tregs to both gain access to inflamed peripheral 
tissues and to limit the immune response at hand. The specialisation of Treg 
function is accomplished by distinct Treg subsets. Treg also function within 
peripheral tissues where they contribute to tissue homeostasis and repair. 
Therefore complexity of Treg function now extends to the control of 
nonimmunological processes in nonlymphoid tissues (Rothstein and Camirand, 
2015).  
Using a murine model, Jost and colleagues (Jost et al., 2014) demonstrated that 
Foxp3+ Tregs as well as T-cell-derived IL-10 interfere with an effective anti-viral 
immune response during mCMV infection. Depletion of Fop3+ Tregs by using 
DEREG (depletion of T reg) mice resulted in elevated T-cell activation as 
measured by the expression of CD62L, granzyme B and IFN-γ, and was 
accompanied by a significant reduction in viral titers in salivary glands, the site 
of persistent mCMV replication and shedding. The group also identified CD4+ 
Foxp3- T cells to produce elevated levels of the immunosuppressive cytokine IL-
10 at early time points during mCMV infection. Thus the group’s data illustrated 
a crucial role for CD4+Foxp3+ nTregs as well as IL-10-producing CD4+Foxp3- 
iTregs in the regulation of appropriate T-cell responses and viral clearance 
during mCMV infection. 
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* Tregs and immunotherapy 
Because viral infections/reactivation and GvHD are two of the more common 
complications arising post HSCT, there has been interest in the concept of co-
infusing both Tregs and anti-viral T cells as form of immunotherapy that inhibits 
GvHD on one hand and promotes anti-viral immune reconstitution on the other 
(Litjens et al., 2012; Lugthart et al., 2012; Samuel et al., 2014). Litjens and 
colleagues (Litjens et al., 2012) were able to identify functional Ag-reactive 
natural Tregs (nTregs) cells for a range of different common viral and 
vaccination Ags, at a frequency similar to the frequency of Ag-reactive T effector 
cells within the CD4+ T cell population. Ag-reactive nTregs were identified by 
CD154 expression and showed a memory phenotype and shared all 
phenotypical and functional characteristics of nTregs. They could be expanded 
by specific antigenic stimulation, while their Ag-reactive suppressive activity was 
maintained. Previous mouse model data also suggest that the coinfusion of 
Tregs and conventional T cells enhances rather than abrogates recovery of 
virus-specific immune reconstitution through prevention of GvHD (Nguyen et al., 
2008). Samuel and colleagues (Samuel et al., 2014) investigated the phenotype 
and function of CMV-specific T cells isolated through CD25 expression from G-
CSF-mobilised PBMCs with regard to FoxP3 expression and suppressive 
capacity and explored the impact of removal of CD4+ CD25+ Tregs from starting 
populations to augment selectivity of antigen-specific T cells for adoptive 
immunotherapy. The group found that CD25 enrichment post CMV stimulation in 
G-CSF-mobilised PMBCs results in the simultaneous generation of both a 
functional population of anti-viral T cells and Tregs thus illustrating a potential 
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single therapeutic strategy for the treatment of both GvHD and CMV reactivation 
following allogeneic haematopoietic stem cell transplantation. It also circumvents 
the many problems incurred with successive donations and procurement of cells 
from unrelated donors, thereby simplifying the clinical application of adoptive 
immunotherapy and broaden the approach for manufacturing multi-functional T 
cells. 
MEMORY T CELLS 
There is increasing interest amongst research groups to determine which 
infused T cell population results in long-lasting viral immunity in patients. In 
earlier studies carried out by group in Baylor, trispecific T cells for EBV, CMV 
and ADV were given to patients (Gerdemann et al., 2013b). Although they were 
able to detect increase in frequency of T cells against latent viruses EBV and 
CMV, ADV specific T cells were only detected in those with recent or concurrent 
ADV infection. Looking more closely at CMV specific T cells and further into T 
cell subpopulation, Scheinberg’s group (Scheinberg et al., 2009) demonstrated 
that less differentiated CD27+ CD57- CMV-specific memory T cells were more 
likely to persist in recipient after HSCT, compared with more terminally 
differentiated CD27- CD57+ CMV- specific memory T cells. The group also 
demonstrated that greater numbers of less differentiated CD8+ CMV-specific T 
cells in the donor appears to confer protection against viral reactivation in the 
recipient after HSCT. Feuchtinger and colleagues (Feuchtinger et al., 2010)  
treated 18 patients with CMV-specific T cells generated by ex vivo stimulation 
with pp65 and isolation of interferon-γ-producing cells. The group identified a 
mixture of naïve, central memory, and effector memory stages in the INF-γ-
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selected T-cell population. The pp65-specific T-cell immunity could be detected 
for > 6 months in patients after adoptive T-cell transfer. 
More recently a subset of human T cells called stem cell-like memory T cells 
(Tscm) have been shown to be self-renewing and multipotent and can sustain 
generation of all memory and effector T cell subsets (Gattinoni et al., 2011). 
Tscm express naïve markers but also have increased CD95 expression and 
show attributes of memory T cells 
(CD45RA+CCR7+CD62+CD27+CD28+CD127+CD95+). They represent about 
2-3% of all circulating CD4+ and CD8+ T cells in healthy donors, and <1% in 
umbilical cord blood (Gattinoni et al., 2011). Similar to memory T cells, Tscm 
cells possess the memory capability of rapid acquisition of effector functions 
after TCR stimulation; and divide extensively in response to IL-15. In donors with 
detectable naïve-like CD8+ T cells specific to influenza or CMV epitopes, vast 
majority of tetramer-binding cells highly expressed CD95. By analysing TCR-β 
sequences of CMV-specific T cell subsets spanning a time period of 22 months, 
dominant persisting clonotypes in Tscm cells were found indicating that they 
represent a stable memory T cell population rather than merely recently 
activated cells transitioning from a naive to a conventional memory state 
(Gattinoni et al., 2011). Tscm have also shown enhanced proliferative and 
survival capacities compared with naïve and conventional memory subsets after 
adoptive transfer into NSG mice. By adoptively transferring CD8+ T cell subsets 
into immunodeficient mice, the group found that Tscm cells engrafted with 10- to 
100- fold more progeny than central memory T cells (Tcm) or naïve T cells (Tn). 
Effector memory T cells (Tem), representing cell populations currently used in 
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adoptive immunotherapy, had a poor proliferative and survival capability 
resulting in negligible engraftment 1 month after transfer.  
It is increasingly recognised that in the setting of haematopoietic stem cell 
transplant and adoptive T cell transfer, it is more desirable to have minimally 
differentiated cells with a high proliferative potential which can expand in the 
presence of virus in recipients and maintain effector functions. Adoptive transfer 
of long-lived, multipotent CD62L+ memory T cells might significantly improve 
persistence and potential therapeutic efficacy of adoptive immunotherapies 
(Gattinoni, 2014). To illustrate the stemness of CD8+ memory T cells, Graef’s 
group measured self-renewal and multipotency of a single Tcm cell throughout a 
series of in vivo clonogenic assays (Graef et al., 2014). The group showed that 
after pathogen stimulation, a single Tcm cell could propagate itself while giving 
rise to a diverse progeny of Tem and Teff cells. The group suggested that 
regenerative quality rather than the quantity of transplanted T cells determine 
long-term persistence and success of adoptive T cell transfer; and that large 
numbers of cells are not necessary for therapeutic success when memory stem 
cell populations are employed.  
It has also been demonstrated elsewhere that lowest numbers of ex vivo-
selected CD8+ memory T cells can reconstitute pathogen-specific immunity in 
immunocompromised hosts (Stemberger et al., 2014). Using murine Listeria 
monocytogenes infection model, the group was able to show that major 
histocompatibility complex-Streptamer-enriched antigen-specific CD62Lhi but not 
CD62Llo CD8+ memory T cells proliferated, differentiated, and protected against 
L.m. infections after prophylactic application. Two patients received low-dose 
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HLA-Streptamer-enriched CMV-specific CD8+ T cells (3750 cells and 5130 cells 
per kg body weight, respectively) and experienced decreasing viral load with 
demonstrable antigen-specific T cells. The expanding CMV A2-pp65-multimer-
positive cells showed development from a less differentiated phenotype initially 
containing CCR7+ CD45RA- central memory phenotype cells to a mature 
population with a high percentage of Tem cells (CCR7-CD45RA+). The authors 
are in agreement with others that relatively undifferentiated human CD62Lhi 
memory T cells are better candidates for long-term protection against viruses in 
adoptive T cell transfer (Berger et al., 2008; Gattinoni et al., 2011). 
Looking at plasticity of antigen-specific CD4+ T cells, CMV specific T cells that 
express  TNF-α only predominantly displayed an early-differentiated phenotype 
with proportion expressing stem cell memory markers, compared to CD4+ T 
cells that express both IFN-γ and TNF-α which express more terminally 
differentiated cell markers (Edwards et al., 2014). TNF-α expressing CD4+ T 
cells also displayed functional plasticity by switching from TNF-α only to both 
IFN-γ+ and TNF-α+ upon in vitro stimulation with IE-1 CMV protein, suggesting 
that presence of less-differentiated populations endows T cells with functional 
flexibility and can reinforce immune responses in the control of viral infection, 
upon exhaustion of more differentiated cells. 
In my own experiments looking at T-cell phenotypes of unexpanded cells 
compared to ADV-specific T cells, there was a general trend for decrease in 
proportion of cells expressing stem cell memory markers 
(CD45RA+CD27+CD62L+CD95+). Previous adoptive T-cell transfer based 
clinical trials suggest that the capability to persist in vivo is dependent on the 
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differentiation stage. The cells employed in these trials display terminal 
differentiation and, following transfer, fail to persist in the long term in vivo 
(Mahnke et al., 2013; Russo et al., 2012). If used in the prophylactic setting it is 
more desirable to transfer polyspecific Tcm cells that can survive until 
pathogens start to replicate and functionally differentiate after antigenic 
stimulation and prevent clinical manifestation. ADV-expanded cells in my 
experiments although showed a reduction in proportion of cells with Tscm 
phenotype markings, they were able to show antigen specificity and cytokine 
production upon stimulation with ADV peptides. This suggests that in the 
preemptive setting such as described in the ASPIRE trial, the more differentiated 
transferred antigen-specific T cells may still be able to provide antiviral killing 
properties until transplant recipient reconstitutes immunity.  
It has been suggested that cytokines used in in-vitro culture of VSTs may 
enhance proportion of Tscm population. In the ASPIRE trial, donor PBMCs are 
supplemented with IL4 and IL7 when stimulated with ADV peptide.  Several 
groups have reported on IL-7 and IL-15 preferentially expanding Tscm cells and 
not inducing excessive proliferation and acquisition of effector function (Cieri et 
al., 2013; Lugli et al., 2013). Effector cells expanded in vitro from early 
differentiated cells, such as from the Tcm cells, also correlate with improved 
persistence (Mahnke et al., 2013; Restifo et al., 2012).  
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BYSTANDER ACTIVATION 
One of the concerns with T-cell immunotherapy is alloreactivity or stimulation of 
bystander cells. A case of third-party (haploidentical) virus-specific T cells 
triggering bystander GvHD has previously been reported (Qasim et al., 2011). A 
7-year-old girl who had undergone a 1C mismatched unrelated donor stem cell 
transplant received a dose of 104/kg CD3+ ADV-specific T cells from a 
haploidentical family donor for adenoviraemia. This resulted in resolution of high 
level adenoviraemia along with appearance of ADV-specific lymphocytes when 
tested in vitro 6 weeks post infusion. However, skin and liver GvHD developed 
around the same time with presence of original donor cells only detected by 
FISH on liver biopsy. This suggested proliferation of a bystander T cell 
population stimulated by antigen-specific T cell responses.   As had been shown 
in mouse models bystander activation can be mediated by cytokines, 
independent of specific TCR stimulation (Tough et al., 1996). Similarly using a 
transgenic mouse model the experiments of Ehl and colleagues (Ehl et al., 
1997)  showed that CD8+ T cells from unimmunised ‘naïve” TCR transgenic 
mice can differentiate into LCMV-specific cytolytic effector CTL during infections 
with vaccinia virus or Listeria monocytoges. Interestingly the group also showed 
that the factor mediating the bystander activation was transferable in the 
supernatant of specifically activated T cells, suggesting presence of soluble 
signal generated by specific responder cells. In human subjects who had 
received tetanus toxoid (TT)-booster vaccination, the phenomenon of bystander 
activation and expansion of CD4+ memory T cells specific for two unrelated 
antigens, purified protein derivative of tuberculin and Candida albicans have 
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been described (Di Genova et al., 2006). More recently the same group used a 
mouse model to better understand the underlying mechanism.  Activated 
transgenic CD4+ T cells (OT-II) specific for a peptide from OVA were transferred 
to mice pre-vaccinated with tetanus toxoid (TT). When these mice were 
subsequently challenged with TT, not only was there cytokine production (IL2 
and IFNγ) by TT-specific memory CD4+ T cells, the preactivated OT-II T cells 
also underwent bystander proliferation. The authors also found the bystander 
proliferation of peptide-activated T cells was proportional to the strength of the 
secondary cellular immune response to TT; and suggested IL-2 and IL-7 as 
potential mediators for bystander stimulation. Interestingly, co-culture with 
inflammatory cytokines IFN-γ, IL-1β, Il-6 and TNF-α did not induce proliferation, 
arguing against direct involvement of inflammatory cytokines in bystander 
proliferation. The authors concluded that transfer of cytokines, possibly IL-2, 
from an antigen-specific CD4+ T-cell memory response of significant magnitude, 
occurs in vivo at a tissue site. Parallel CD4+ T cells activated by other antigens 
can express appropriate receptors and undergo proliferation which could 
contribute to immunopathology (Di Genova et al., 2010). 
Using an in vitro system within which to analyse bystander T cell activation in 
human Bangs and colleagues investigated specific characteristics of bystander-
activated T cells and confirmed that it occurs preferentially among CD4+ 
memory T cells and that the mechanism for their activation involves soluble 
factors and is not dependent upon cell-cell contact (Bangs et al., 2009). 
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RECENT CLINICAL EXPERIENCE 
Recently the Tubingen group in Germany published their experience using 
donor-derived ADV hexon-specific T cells to treat 30 patients with treatment 
refractory ADV infection (Feucht et al., 2015). VSTs were derived by stimulating 
donor PBMCs with ADV hexon protein for 16 hours followed by enrichment of 
IFN-γ secreting cells using CliniMACS (Miltenyi Biotec). Mean T-cell dose 
transferred was 4.1x103 CD3+ cells/kg (range 0.3-24x103), composed of a 
mixture of naïve, central memory, effector memory and effector T-cell 
populations with predominance of late effector stages. 14 out of 23 evaluable 
patients developed in vivo expansion of ADV-specific T cells with 86% clearing 
viraemia within the 6-month observation period. ADV-related mortality was 
100% in non-responders compared to 9.5% in responders.  
RECENT ADVANCES 
In the last few years there has been increasing interest in therapeutic application 
of T-cell engineering particularly in the treatment of haematological malignancy. 
One strategy to bypass immune tolerance in the treatment of malignancy is by 
modifying native T cells with a chimeric antigen receptor (CAR) which can then 
be targeted against any extracellular antigen. CAR T cells are reprogrammed 
using synthetic biology and gene transfer techniques to attack cells expressing 
the target extracellular antigen, independent of MHC presentation (Miller and 
Maus, 2015). CAR therapies were first conceived in the last 1980s, but there 
has been a recent breakthrough in the application of autologous CD19-directed 
 207 
 
CAR T cells for the treatment of adult and paediatric relapsed/refractory ALL 
(Humphries, 2013; Miller and Maus, 2015). However one difficulty with 
adoptively-transferred tumor-specific T cells is the requirement for extensive in 
vivo proliferation via stimulation through CAR or TCR, costimulatory receptors 
and cytokine, and most tumours do not present antigens in an 
immunostimulatory fashion and lack costimulatory molecules. Therefore infused 
tumor-specific T cells are unlikely to receive adequate stimulation after infusion. 
By contrast, most viral infections are highly immunostimulatory, especially in the 
case of EBV and CMV infection post-transplant (Sun et al., 2015). Therefore 
Cruz and colleagues (Cruz et al., 2013) explored the option of infusing donor-
derived virus-specific T cells that have been engineered to express CD19-CAR 
into 8 patients with residual B-cell malignancies after HSCT. No infusion-related 
toxicities were observed and VSTs persisted from 1 to 12 weeks after each 
infusion. Two of 6 patients with relapsed disease during the period of 
CD19.CAR-VST persistence had objective antitumor activity and 2 who received 
cells while in remission remained disease free. In 2 of 3 patients with viral 
reactivation, donor CD19.CAR-VSTs expanded concomitantly with VSTs. The 
authors concluded that the inherent virus specificity of the native TCRs in the 
allogeneic CD19-CAR-VSTs promoted the proliferation and persistence of these 
CAR-VSTs in vivo in response to endogenous viruses (CMV, ADV, EBV) and 
associated co-stimulatory molecules presented on antigen-presenting cells 
infected with virus or cross-presenting viral antigens. However there was little 
apparent expansion of these cells in patients. Therefore in a more recent study 
Sun and colleagues (Sun et al., 2015) developed and optimised a GMP 
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compliant method for the early transduction of VSTs (instead of transducing on 
day 19 of culture as in Cruz’s study which might have allowed enough T-cell 
differentiation to occur to limit subsequent proliferative capacity of transduced T-
cells). Using a CAR directed to the tumor-associated antigen disialoganglioside 
(GD2) the group transduced VSTs directed to EBV, ADV and CMV early on day 
3 of culture with prosurvival cytokines (IL-4 and IL-7) to allow rapid expansion 
and early cryopreservation of GD2.CAR-modified triVSTs for use in a clinical 
trial in patient who have received T-cell depleted HSCT for multiple relapsed 
neuroblastoma. The authors suggested that early-transduced T-cells should 
have a greater potential to proliferate, eliminate tumors and enter the memory 
compartment than VSTs transduced on day 19 at which time the majority of cells 
have lost expression of CCR7 and have an effector memory phenotype. These 
GD2.CAR-modified triVSTs have been used in a phase 1 clinical safety trial 
(NCT01460901). The primary aim of the trial is to investigate safety and 
persistence of the modified cells and evaluate the anti-viral and anti-tumor 
function of the infused GD2.CAR-modified triVSTs in patients with 
relapsed/refractory neuroblastoma post allogeneic stem cell transplant. 
SUMMARY 
In summary this thesis has demonstrated the safety and efficacy in adoptive T-
cell Immunotherapy in the treatment of adenoviraemia in a small number of 
high-risk paediatric transplant recipients. Although it is difficult to ascribe 
effectiveness solely to transferred virus-specific T cells in exclusion of drug 
therapy and immune reconstitution, the majority of patients who developed 
adenoviraemia and received Cytovir ADV survived compared to the non-
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survivors who developed adenoviraemia and did not receive VSTs. The results 
of the phase I/II2 clinical ASPIRE study support a further clinical trial enrolling a 
larger number of patients to further the understanding of patient and dose 
selection. Ultimately the wider application of virus-specific T cells beyond the 
realms of clinical trials, and progression from bespoke designer treatment to 
licenced medicinal products incorporated into standard clinical care is currently 
limited by manufacturing logistics. However there is increasing interest and 
investments from pharmaceutical companies in the field of T-cell therapy, and 
certainly the potential to reduce morbidity and mortality and possibility of 
reducing need for antivirals is an incentive for health care providers to 
accelerate the clinical application of virus-specific T cells beyond the super 
specialised centres. In the UK there are a number of transplant centres that 
perform paediatric allogeneic stem cell transplants. A collaboration between all 
these centres would be ideal in ensuring all high-risk paediatric patients will 
have access to virus-specific T cells. Due to the costs involved in the 
manufacturing process, it would be sensible to have one or two central 
production hub and a robust method of cell transfer out to required centres. In 
addition it would be helpful to develop harmonised end points and consensus 
between research groups on clinical trial design so to facilitate comparisons 
between studies. Given the explosion in the field of cell therapy, both in the 
treatment of viral infection and cancer, the development of a national and 
international consensus may ultimately make it easier for groups to obtain 
ethical approvals and facilitate development of harmonised cell therapy trials 
worldwide.  
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